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Abstract 
Methylation is an underpinning process of life and provides control for biological processes 
such as DNA synthesis, cell growth and apoptosis. Methionine Adenosyltransferases (MAT) 
produce the cellular methyl donor, S-Adenosylmethionine (SAMe). Dysregulation of SAMe 
levels is a relevant event in many diseases including cancers such as hepatocellular carcinoma 
and colon cancer. In addition, MAT deficiency causes isolated persistent hypermethioninemia 
(IPH), resulting from mutations in MAT1A gene encoding MATal (hepatic form). Most 
associated hypermethioninemic conditions are inherited as autosomal recessive traits, however 
dominant inheritance of hypermethioninemia is caused by Arg264His (R264H). Also, R264H 
mutation has been confirmed in a screening programme of newborns as the most common 
mutation in babies with IPH. Arg264 makes an inter-subunit salt bridge located at the dimer 
interface where the active site assembles.  In mammals, MATα1/α2 and MATβV1/V2 are the 
catalytic and the major form of regulatory subunits, respectively. A gating loop comprising 
residues 113-131 is located beside the active site of the catalytic subunits (MATα1/α2) and 
provides controlled access to the active site. The gating loop adopts conformational changes 
during enzyme catalysis facilitating SAMe formation and controlling the catalytic efficiency. 
Mutations of a number of residues including MATα1 (Arg264) and MATα2 (Gln113, Ser114 
and Arg264) led to partial or total loss of enzymatic activity demonstrating their critical role in 
SAMe formation. The enzymatic activity of the mutated enzymes is restored to varying degrees 
upon complex formation with MATβV1 or MATβV2 endorsing its role as an allosteric 
regulator of MATα2 in response to the levels of methionine or SAMe. The protein-protein 
interacting surface formed by the MATα1/2:MATβ complexes is explored to demonstrate that 
several quinolone-based compounds modulate the activity of MATα1/2 and its variants, 
providing a rational for chemical design/intervention responsive to the level of SAMe in the 
cellular environment.  
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Chapter I 
Introduction to methionine adenosyltransferase and X-ray crystallography 
 
1.1 Methionine adenosyltransferases  
Methionine adenosyltransferase (MAT) or S-adenosylmethionine synthetase (EC 2.5.1.6) 
catalyses S-adenosyl-L-methionine (SAMe, SAM or AdoMet) from methionine (Met) and 
adenosine triphosphate (ATP). This enzyme is found in all living organisms excepting some 
intracellular parasites gaining SAMe from their host [1]. Normal cellular function and survival 
requires SAMe as a versatile molecule ranging its roles from methylation, gene expression to 
membrane fluidity [2-4]. 
In mammalian cells, MAT1A, MAT2A and MAT2B genes encode MATα1, MATα2 and 
MATβ, respectively. MATα1 and MATα2 are the catalytic subunits of MAT enzymes [5, 6], 
while MATβ is the regulatory subunits co-expressing with MATα2 proteins in extrahepatic 
tissues [7]. MATβ has four variants (MATβV1, MATβV2, MATβV2a and MATβV2b), the 
major isoforms of which are MATβV1 and MATβV2 [8-10]. MATα1 forms two homo-
oligomeric states, a dimer or a tetramer, and it is mainly found in the adult liver [11, 12]. 
MATα2 functions as a hetero-oligomer forming the hetero-complex with the regulatory 
subunit, MATβ, in 2:1 ratio [10, 13]. One subunit of MATβV2 interacts with one MATα2 
dimer at the dimeric interface as reported in structural studies of MAT(α2)4(bV2)2 complexes 
(PDB: 4KTT, 4NDN and 4KTV) [13]. MATα1 can also interact with MATβ, but both of them 
are not co-expressed in the same tissue [13]. The oligomeric states of MAT isoforms are 
illustrated in Fig 1.1A. The catalytic subunits of MAT revealed by structural and phylogenetic 
study are shown to be conserved from eubacteria to mammal with 30 % sequence identity [1], 
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while about 20 % sequence similarity is found among archaeal bacteria, S. solfataricus, to E. 
coli and human [14]. In addition, the protein structures of MAT catalytic isoforms are found to 
be conserved though evolution at secondary (b-sheets, a-helices, etc.) and tertiary (protein 
folding) structural levels (Fig.1.1B). Three domains of b-sheets are folded at the interface 
necessary for dimer formation, while the a-helices are located at the solvent-exposed surface.  
 
Fig. 1.1 Catalytic and regulatory subunits of human MAT enzymes. (A) MATa1 is mainly 
localised in the adult liver as a homo-tetramer or a homo-dimer. MATa2 is found in 
extrahepatic tissues and it forms the hetero complex with the regulatory subunit, MATbV1 or 
MATbV2. (B) The structures of a S. solfataricus MAT (PDB: 4L7I), a human MATa2 (PDB: 
5A1I) and an E. coli MAT (PDB: 1RG9) monomer show the same pattern of three-dimensional 
protein folding. The conserved patterns are found at secondary and tertiary structures. SAMe 
molecules are represented as sticks (carbon, nitrogen and oxygen atoms are shown in orange, 
blue and red colour, respectively). The figure (1.1B) was modified from reference [14].  
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1.1.1 Expression and similarity of MATs  
MATa1 and MATa2 are encoded by MAT1A and MAT2A genes located in chromosome 10 
(cytoband, q22) [15] and chromosome 2 (cytoband, p11.2) [16], respectively. They encode 395 
amino acids in length for both isoforms. MATa1 has 84 % similarity to MATa2 [17], despite 
their distinct kinetic properties and tissues of gene expression.  
MATa2 is expressed in several organs including heart, brain, kidney and fetal liver, while 
MATa1 is highly expressed in the adult liver (mainly in hepatocytes) where MATa2 is 
expressed at very low levels [18]. Liver and colon tumour cells show the increase in MATa2 
expression, whilst MATa1 expression is down-regulated [19-22]. Under normal condition, 
methionine metabolism in liver mainly depends on MATa1 function. Methylation reactions 
(84 %) and methionine metabolism (48 %) take place in the liver, suggesting its role in 
regulation of blood methionine levels [23, 24]. MATa1 and MATa2 tissue-specific 
expressions are shown in Fig.1.2 [25]. 
The MAT2B gene encoding the regulatory subunit, MATb, is located on chromosome 5 
(cytoband, q34) [8]. Among the four variants of the regulatory subunits (MATbV1, MATbV2, 
MATbV2a and MATbV2b), MATbV1 and MATbV2 are the two predominant isoforms which 
have 334 and 323 amino acids, respectively. MATb proteins are expressed ubiquitously in 
extrahepatic tissues including kidney, lymph node, heart, brain and thyroid [10]. The pattern 
of MAT2B gene expression is shown in Fig. 1.3 [25]. MATbV1 and MATbV2 differ in their 
first 20 amino acids residues of the N-terminus as a result of differences in a transcriptional 
initiation site. Regarding the expression levels of the other two MATb variants (MATbV2a 
and 2b), their expressions are very low in comparison with MATβV2 [10]. Available functional 
data have been studied mainly on the V1 and the V2 isoform. Therefore, the information on 
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V2a and V2b variants associating with the catalytic MATα2 subunits and how they regulate 
MATα2 is still lacking to date. The detail of MATb expressions in different human tissues and 
hepatocellular carcinoma (HCC) was studied by Yang H et al., (2008) [10]. The difference in 
gene expression pattern of these two main variants (V1 and V2) was found in human healthy 
tissues (Fig. 1.4A). The MATbV1 isoform was highly expressed in thyroid, lung, prostate and 
brain, while MATbV2 was mainly expressed in heart and kidney (Fig. 1.4A). In human HCC, 
the mRNA levels of MAT2A and the two major variants of MAT2B (V1 and V2) were 
elevated, while MAT1A gene expression was silenced (Fig. 1.4B). 
 
Fig. 1.2 MAT1A and MAT2A gene tissue-specific expressions. MAT1A gene encoding 
MATa1 protein is highly expressed in an adult liver and a small amount is found in the 
pancreas. MAT2A gene encoding MATa2 protein is expressed in several tissues and a small 
amount is found in the liver. The raw data used to reproduce this figure were taken from the 
supplementary Data Set S1 of reference [25] with permission (License ID: 1010272-1).  
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Fig. 1.3 MAT2B gene expressions in different tissues. The high levels of MAT2B gene 
expression were found in lymph node, thyroid gland, urinary bladder, spleen and kidney. The 
raw data used to reproduce this figure were taken from the supplementary Data Set S1 of 
reference [25] with permission (License ID: 1010272-1).  
 
Fig. 1.4 Northern blot analysis of MAT2B gene expressions. (A) Normal tissue expression 
patterns of MAT2B genes (V1 and V2 variants) (B) MAT gene expressions (MAT2B, MAT1A 
and MAT2A) in normal liver were compared with HCC samples. The figure was taken from 
reference [10] with permission (License Number: 4734280795189). 
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1.1.2 SAMe synthesis reaction 
MAT catalyses SAMe synthesis from two-step reactions [26].(i) The sulphur atom of Met 
attacks C-5’ atom of ATP, known as the nucleophilic substitution SN2 reaction, to produce 
SAMe (Fig. 1.5). Tripolyphosphate (PPPi) is an intermediate of ATP cleavage as SAMe is 
formed [27, 28].; (ii) MAT subsequently hydrolyses the PPPi to pyrophosphate (PPi) and 
orthophosphate (Pi) by its tripolyphosphatase activity [29]. The PPPi hydrolysis is believed to 
facilitate the product release from MAT enzymes as PPi and Pi interactions to the active site 
are less stable in comparison with the PPPi binding. Human MATa2 structure with the PPPi 
bound in the active site showed an open conformation of the gating loop, indicating that SAMe 
could be released prior to the hydrolysis of PPPi [30].  
Divalent cations are essential for the phosphatase activity of MAT, similar to other reported 
phosphatases. The phosphatase activity needs Mg2+ ions and can be stimulated by K+ ions. Two 
types of cations, the monovalent (K+) and the divalent (Mg2+, Mn2+ or Ca2+) ions which bound 
to the active site of MAT enzymes were confirmed in E. coli MAT studies [31-34]. At least 
three Mg2+ ions were present in MAT crystal structures from rat liver [35]. AMP-PNP (non-
hydrolysable analogue of ATP) producing non-hydrolysable PPNP as an intermediate during 
SAMe formation was used in the study of E. coli MAT by Komoto J et al., (2004) [36]. The 
stable ternary complex forms of crystals were obtained and revealed that Mg2+ ions interacted 
with PPNP at its O atoms and these interactions stabilised the negative charges of PPNP [36]. 
The K+ ion was suggested to indirectly relate to the SAMe formation, as it was in the distant 
position to the catalytic site. For the half maximal activation of MAT, more than 5 mM of K+ 
ions was required [34]. However, the human MATa2 structure in a complex with 
SAMe+Met+Adenosine+PPNP later showed that PPNP directly interacted with two Mg2+ ions 
and one K+ ion via its phosphate oxygen atoms. The conformations of the triple phosphate and 
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the metal ion binding sites were preserved in AMP-PNP from E. coli MAT (PDB: 1P7L) to 
human MAT structure (PDB: 5A1I) as shown in Fig. 1.6A. The two Mg2+ ions and one K+ ion 
coordinating with PPNP, water molecules and four residues in the active site (Asp31, Glu57, 
Asp258 and Ala259) are illustrated in Fig. 1.6B. The first Mg2+ ion interacted with two oxygen 
atoms (O1G and O2A) of PPNP and four oxygen atoms of water molecules. The second Mg2+ 
ion interacted with four oxygen atoms of Asp31 (OD2), PPNP (O2G, O1A and O1B) and also 
two oxygen atoms of water molecules. The K+ ion interacted with one water and four oxygen 
atoms of PPNP (O1B), Glu57 (OE2), Asp258 (OD1) and Ala259 (O).  
 
 
Fig.1.5 MAT catalytic reaction. SAMe is synthesized by the MAT enzyme from ATP and L- 
methionine in two consecutive reactions. The first step is involved in the synthesis of SAMe 
and tripolyphosphate (PPPi) from ATP and methionine. Orthophosphate (Pi) and 
pyrophosphate (PPi) are generated during the second step, PPPi hydrolysis. The figure was 
modified from [36].  
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Fig.1.6 AMP-PNP and metal ion binding sites in E. coli and human MAT structures. (A) 
An alignment of the AMP-PNP molecule from an eMAT structure (PDB: 1P7L, green sticks) 
and the PPNP molecule from a human SAMe+Adenosine+Met+PPNP structure (PDB: 5A1I, 
pink sticks) is illustrated. Mg2+ and K+ ions are shown in green and purple spheres of dark and 
light colour corresponding to E. coli and human MAT, respectively. (B) Two Mg2+ ions and 
one K+ ion interact with PPNP and water molecules in the active site. Water molecules are 
represented by red spheres. All H-bonds are shown in black dots. Asterisks (*) indicate the 
residue from the dimeric subunit.  
1.2 S-adenosylmethionine (SAMe) 
SAMe is the sulfonium compound containing a very reactive methyl group which makes SAMe 
become the principle methyl donor for methylation reactions. The electrophilic structure of 
SAMe carbon centre is adjacent to the positively charged sulphur atom that brings SAMe into 
a contact with the nucleophilic groups in a variety of substrates (Fig. 1.7). SAMe metabolism 
is involved with many metabolic pathways (Fig.1.8). Once SAMe donates its methyl group, it 
becomes S-adenosylhomocysteine (SAH), the transmethylation inhibitor. SAH is subsequently 
hydrolysed to adenosine (ADO) and homocysteine (Hcy). Hcy can be remethylated to 
methionine or it can participate in the trans-sulfuration pathway. In this pathway, Hcy is the 
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precursor of several compound biosynthesis including glutathione (a major cellular 
antioxidant), cysteine, taurine, etc. Alternatively, SAMe can enter a polyamine biosynthesis 
pathway after it has been decarboxylated and becomes the propylamine donor for spermidine 
or spermine biosynthesis [37]. 
SAMe serves as the methyl group donor for a number of biomolecules including nucleotide 
bases of DNA and RNA, histones, sugars and amino acids [38]. SAMe is important for the 
methylation reactions which are involved in many cellular processes ranging from fetal 
development to brain function in all living organisms. Gene expressions are regulated by DNA 
methylation and the actions of hormones or neurotransmitters are also regulated by 
methylation. The methylation of phospholipids maintains the fluidity and the mobility of 
membranes and receptors [39]. SAMe is found to regulate cellular proliferation, differentiation, 
and death in the liver [2, 40, 41] and is also involved in cellular antioxidant capacity [42]. 
Strongly electrophilic properties of a SAMe methyl group allow it to react with the nucleophilic 
groups of a variety of substrates. SAMe participates in a large number of trans-methylation 
processes compared to other methyl donors (e.g. folate), indicating that it is more favourable 
for thermodynamic reactions than other compounds [39]. 
 
Fig. 1.7 The electrophilic structure of SAMe. Methyltransferases catalyse the transfer of the 
methyl group of SAMe to nucleophilic substrates. Nu and MTs represent a nucleophilic 
molecule and methyltransferases, respectively. The figure was modified from reference [39]. 
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Fig.1.8 SAMe synthesis and related metabolic pathways. SAMe can donate its methyl group 
to a number of acceptors by the enzyme, methyltransferases (MTs). After decarboxylation by 
SAMe decarboxylase, SAMe becomes the precursor of polyamines synthesis (e.g. spermine), 
or it can be converted to SAH after transferring its methyl group to the acceptors. SAH is 
catalysed by SAH hydrolase to produce Hcy and ADO. Hcy can be remethylated for 
methionine regeneration by either methionine synthase (MS) or betaine-homocysteine 
methyltransferase (BHMT) in the reaction that requires 5-MTHF or betaine. In addition, Hcy 
is the precursor of an amino acid cysteine, the substrate for glutathione synthesis. 5-MTHF and 
THF stand for 5-methyltetrahydrofolate and tetrahydrofolate, respectively. The figure was 
modified from reference [4]. 
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1.3 Enzyme structures of catalytic subunit MATa1/2  
To date several MAT X-ray crystal structures have been identified from bacteria to mammals 
in a native state (apo-form) or in a substrate/ product-bound form. The crystal structures of 
MAT from various species show the conserved secondary structure and the similar order of 
domain arrangements, in agreement with amino acid sequences that are conserved through 
evolution. The two functional active sites of MAT assemble between a dimer where both 
subunits contribute their residues to form the active sites. The α-helices of a monomer 
distributes along a solvent exposed surface, while each MAT subunit contacts to its partner 
inversely by hydrophobic interaction using b-sheet domains to form the dimer (e.g. Fig. 1.9A, 
an archaeal MAT structure).   
Several reported MAT structures have a common feature containing a flexible gating loop 
located at the entrance of the active site. The gating loop contains residues 113-131 in a human 
MATa1 and a human MATα2 [30], residues 98-108 in an E. coli MAT [36] and residues 141-
155 in an archaeal MAT [14]. The gating loop is suggested to function as a flexible loop that 
controls the entry to the active site. The gating loop closes and obstructs the active site entrance 
when it is occupied by SAMe, but when the active site is empty, the loop orients in the open 
conformation (disordered and invisible in most reported crystal structures). This allows access 
to the active site. The ordered gating loops in their closed conformation are reported in 
numerous MAT structures e.g. archaeal MATs (PDB: 4L7I, 4L2Z and 4K0B), eMATs (PDB: 
1P7L and 1RG9), and human MAT structures: MATα1 (PDB: 2OBV) and MATα2 (PDB: 
2P02 and 5A1I) [14, 30, 36, 43]. 
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1.3.1 Archaeal MAT structures (S. solfataricus and T. kodakarensis) 
The first archaeal MAT was structurally characterised from Sulfolobus solfataricus MAT 
(SsMAT) [44]. The SsMAT has about 20 % amino acid sequence similarity to E. coli and 
human MATs. Methanococccus jannaschii MAT contains 22 % and 23 % sequence identity to 
E. coli and human MATs, respectively, while E. coli and human sequences are about 59 % 
identical.  [45, 46]. Wang F et al., 2014 reported the structures of the thermostable SsMAT in 
three different forms: an apo, a SAMe-bound and a S-adenosylethionine (SAE)-bound form 
[14]. The gating loop of SsMAT (residues 141-151) showed full electron density representing 
the a-helix when the active site was occupied by SAMe, Pi and PPi (Fig. 1.9A), while residues 
141-155 were mostly invisible when the active site was unbound (Fig. 1.9B, an apo form). In 
various structures of E. coli MAT [36] and human MAT [13, 30, 43, 47], the active site ligand 
occupation and the ordered gating loop are synchronised, consistent with these observations 
found in SsMAT structures (Fig. 1.9A-B). Interestingly, Schlesier J et al., 2013 [48] firstly 
reported the archaeal Thermococcus kodakarensis MAT (TkMAT) structure with the complete 
gating loop organisation in the open conformation (Fig. 1.9C). The observation of the ordered 
gating loop in the open conformation supports a mechanism proposed in E. coli MAT study 
that upon the substrate binding the interactions of the gating loop and the substrate in the active 
site facilitate the rearrangement of the flexible gating loop into its closed conformation [36]. 
The ligand orientations reported in the E. coli MAT studies by Komoto J et al., 2004 and human 
MAT studies by Murray B et al., 2014, 2016 and Shafqat N et al., 2013 are similar to those of 
the SsMAT structure (Fig.1.9A). However, different ligand orientations with the disordered 
gating loop had been reported in E. coli MAT structures reported by Takusagawa F et al., 1996 
[49] and in rat MAT structures proposed by Gonzalez B et al., 2003 [35]. The high temperature 
factors (B-factors) of ligands in the active site were in excess of 70 Å2 in the rat MAT and more 
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than 100 Å2 in the E. coli MAT structure. This indicated the uncertainty of atomic positions 
causing by the temperature-dependent atomic movement and the displacement of atomic 
positions in different unit cells [50]. Moreover, the flexible gating loops were undefined despite 
the fact that the active sites were occupied. The rat and the E. coli MAT share about 59 % of 
the amino acid sequence similarity and all active site residues are conserved, but they present 
with the entirely distinct ligand orientations in the active site. In contrast to these rat and E. coli 
MAT structures reported by Gonzalez B et al., 2003 and Takusagawa F et al., 1996, all ligands 
in the active site of human, E. coli (reported by Komoto J et al., 2004) and SsMAT MAT 
structures showed reasonable B-factors. 
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Fig 1.9 Archaeal MAT Structures in the SAMe-bound and the apo form.  (A) The structure 
shows asymmetrical binding of SAMe, PPi and Pi in one active site with the ordered, closed 
conformation of the gating loop (red), while the other half active site is empty with the 
disordered gating loop (mostly invisible in the model). (B) Apo structures of SsMAT and (C) 
TkMAT contain no ligand in the active sites. Apo structures show the open conformation of 
the gating loop. The SsMAT structure shows mostly disordered (invisible) gating loop, while 
the TkMAT structure shows the full open conformation of the gating loop (red). a-Helix, b-
sheet and connecting loop are shown in blue, pink and wheat colour, respectively.  
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1.3.2 E. coli MAT structure 
The first crystal structure of E. coli MAT (eMAT) containing two PO43- (Pi) molecules and 4 
cations (two Mg2+ ions and two K+ ions) was reported by Takusagawa F et al., 1996a at 3 Å 
(PDB: 1XRA) [51]. This structure showed the open conformation of the flexible loop (gating 
loop, residues 98-108) [51] (Fig.1.10A). The crystal structure of eMAT obtained by ATP co-
crystallisation showed adenosine diphosphate (ADP) and Pi in the active site at 2.8 Å  provided 
by Takusagawa F et al., 1996b (PDB: 1MXB, Fig. 1.10B) [49]. However, the binding position 
of the ADP (adenosine moiety) was different to adenosine binding site of the eMAT structure 
that was later proposed by Komoto J et al., 2004 (Fig. 1.10C). The eMAT structures containing 
AMP-PNP+Met (PDB: 1P7L, 2.5 Å) and SAMe+PPNP in the active sites (PDB: 1RG9, 2.5 Å) 
showed the closed conformation of the ordered gating loop [36]. AMP-PNP and Met were used 
as the substrates in Komoto J et al., 2004 studies when the formation of SAMe could occur but 
the tripolyphosphate hydrolysis was inhibited. This resulted in the formation of a stable crystal 
form (SAMe+PPNP bound crystals). Fu Z et al., 1996 obtained the apo eMAT structure (1FUG, 
3.2 Å) and suggested that the flexible gating loop, which is poorly conserved among species, 
was involved in the determination of the substrates in the active site [52].  
The difference in position of adenosine moiety found in the ADP+Pi bound structure of eMAT 
also showed the high B factor of ADP (90.21 Å2). In contrast, the AMP-PNP+Met or the 
SAMe+PPNP bound eMAT structure showed good electron density of SAMe with B-factor of 
13.5 Å2 for adenosine moiety and B-factor of 14.2 Å2 for the entire molecule of SAMe. The 
adenosine ring of SAMe and Met are likely to reside in their correct positions as no empty 
space was observed in the active site of this structure (Fig. 1.10C). The eMAT structures with 
different ADP binding sites compared with the human MATa2 structure (PDB 5A1I, 1.1 Å) 
are shown in Fig. 1.10D-E. The eMAT structure in complex with AMP-PNP+Met or 
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SAMe+PPNP showing the similar positions of adenine binding sites compared to the human 
MATa2 structure is shown in Fig. 1.10F. 
 
Fig.1.10 Structures of eMAT in comparison with human MATa2 (A) The eMAT structure 
shows two inorganic phosphates (PDB: 1XRA) (B) The eMAT structure shows ADP+Pi in the 
active site (PDB: 1MXB) (C) The eMAT structure contains AMP-PNP+Met in the active site 
(PDB: 1P7L) (D) The human MATa2 structure is bound with SAMe+PPNP+Met+ADO in the 
active site (PDB: 5A1I) (E) The human MAT structure (5A1I, wheat) is aligned with the eMAT 
structure (1MXB, green) (F) The human MAT structure (5A1I, wheat) is compared with the 
eMAT structure (1P7L, blue) by structural alignment. The gating loop is shown in red. Mg2+ 
and K+ ions are represented by green and purple spheres, respectively. Ligands in active sites 
are shown as sticks. 
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1.3.3 Eukaryotic MAT structures (R. norvegicus, H. sapiens) 
1.3.3.1 R. norvegicus MAT structure (rMAT) 
Several rMAT structures in complex with substrates or their analogues were reported by 
Gonzalez B et al., 2000, 2003 [35, 53]. Met and its analogue, L-2-amino-4-methoxy-cis-but-3-
enoic acid (AMB), were found to bind to the active site of rMAT at the similar position of the 
ATP (adenine moiety) of eMAT and human MAT which were later reported by Komoto J et 
al., 2004 and Murray B et al., 2016 (Fig.1.11) [30, 36]. The AMB showed to stack against 
Phe251 aromatic ring in the AMB bound structure of rMAT (Fig.1.11A). This is in contrast to 
the usual p-p stacking of ATP adenine ring against Phe251. Also, ATP and ADP positions 
found in rMAT structures showed the different orientations in both adenine moieties and 
tripolyphosphate chains (Fig.1.11 B-C and F). The substrate binding positions reported in the 
eMAT structure (by Komoto J et al., 2004) and the human MAT structure are consistent and 
almost identical (Fig.1.11D-E). The high-resolution structure of the human MATa2 reported 
at 1.1 Å (PDB: 5A1I) showed that the adenine moiety of ATP is in the similar conformation 
after the formation of SAMe (Fig. 1.11E). In addition, the average B-factors of ligands and 
ions in the active site from these reported rMAT structures were much higher than those of the 
proteins (Table 1.1), indicating the low occupancy of the substrate or the analogue binding to 
the active site. There are no X-ray data available in PDB server, therefore the calculation of 
ligand real space correlation coefficients cannot be performed because of this limitation. 
Regarding these unavailable data, the unusual features of the ligand binding modes in the active 
site of rMAT structures should be treated with caution. In addition, this ATP+Met bound 
structure of rMAT was obtained by soaking ATP into the crystal of Met+2Pi bound structure, 
while the gating loop remained disordered, suggesting that this structure may not represent the 
functional states of the enzyme.  
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Fig. 1.11 The comparison of substrate binding sites in rMAT, eMAT and human MAT 
structures. The structure of rMAT was in complex with AMB in the active site (PDB: 1QM4) 
(A), ATP+Met (PDB: 1O9T) (B), and ADP+AMP (PDB: 1O92) (C). (D) The eMAT structure 
shows AMP-PNP+Met in the active site (PDB: 1P7L). (E) The human MATa2 structure was 
bound with SAMe+Met+ADO+PPNP (PDB: 5A1I). (F) The structural alignment of the 
ATP+Met bound structure and the ADP+AMB bound structure of rMAT is shown in yellow 
(PDB: 1O9T) and peach (PDB: 1O92), respectively. MAT substrates or their analogues are 
shown as sticks.  
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Table 1.1. The average B-factors of proteins and molecules in the active site. All rMAT 
structures showed the relative higher B-factors of ligands in the active site compared to those 
reported in the eMAT structure. The lower B-factors (less than 30 Å2) indicate the higher 
confidence in the ligand atomic positions. 
Complex PDB 
 
Resolution 
(Å) 
B-factor 
of protein 
(Å2) 
B-factors of ligands 
in the active site (Å2) 
Ref 
eMAT 
(SAMe+PPNP) 
1P7L 2.5 19.6 14.2 (SAMe), 15.1 
(PPNP) 
[36] 
rMAT (ATP+Met) 1O9T 2.9 37.0 82.3 (ATP), 75.2 (Met) [35] 
rMAT (ADP+AMB) 1O92 3.19 24.6 76.0 (AMP), 73.4(ADP) [35] 
rMAT (AMB) 1QM4 2.66 31.4 43.0 [53] 
 
1.3.3.2 H. sapiens MAT structure (hMAT) 
Numerous structures of hMAT that have been reported to date are summarised in Table 1.2. 
Structures of hMATa1 and hMATa2 in complex with SAMe in the active site were firstly 
reported by Shafqat N et al., 2013 [43]. The crystals were obtained by co-crystallisation of 
proteins with SAMe that showed two molecules of SAMe in the two equivalent active sites 
(Fig. 1.12A). Structures of hMATa1 and hMATa2 are almost supposable with the root mean 
square deviation (RMSD) of 0.41 Å and they show the similar SAMe binding site [43]. SAMe 
directly interacts to Ser247 and Asp258 with its ADO and ribose moieties, while Met 
mainchain is partly stabilised by Gln113 of the neighbouring gating loop and Glu70 (Fig. 
1.12A). A number of hMATa2 structures with different ligands have been studied by Murray 
B et al., 2016 [30]. The structure of hMATa2 in complex with SAMe+Met+ADO+PPNP 
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obtained at 1.09 Å showed the atomic details of substrate binding leading to SAMe formation 
with partial occupancies of ligands in the active site [30]. The structural alignment of hMATa2 
(SAMe-bound structure, PDB: 2P02) and hMATa2 (SAMe+Met+ADO+PPNP-bound 
structure, PDB: 5A1I) reveals RMSD of 0.094 Å and SAMe binding sites of these two 
structures are identical (Fig. 1.12B). The SAMe-bound crystal of hMATa2 (PDB: 2P02) was 
obtained by soaking SAMe into the crystal, while the SAMe-bound form of hMATa2 structure 
(PDB: 5A1I) was produced by co-crystallisation of enzyme substrates (AMP-PNP and 
methionine), suggesting the functional relevance of enzyme reactions. In the hMATa2 
(SAMe+Met+ADO+PPNP) structure, the cleavage of AMP-PNP to ADO and PPNP occurred 
before SAMe formation, as the reaction is initiated by the nucleophilic attack of the sulphur 
atom of Met to the C5 atom of ATP. At the transition state of SAMe formation, the enzyme 
intermediates (ADO and PPNP) including Met were captured in the hMATa2 
(SAMe+Met+ADO+PPNP) crystal structure (Fig. 1.13A). Also, Murray B et al., 2016 reported 
the PPNP-bound structure of hMATa2 (PDB: 5A19) which revealed the open conformation of 
the gating loop without PPPi hydrolysis taking place (Fig 1.13B-C) [30].  
Three crystal structures of MAT(a2)4MATb(V2)2 complexes were reported with SAMe+Pi, 
SAMe+PPNP and ADO+PPi+Pi bound in the active sites [13]. The C-terminal tail of MATβ 
(residues 316-321) interacted with MATα2 at the dimeric pocket of MATα2 dimers (Fig. 
1.14A-B). Forming the complex with MATβV1 and MATβV2 showed an increase in SAMe 
formation by 4- and 3-fold, respectively, when compared to the activity of MATα2 alone [13]. 
However, the binding of the regulatory subunit did not alter the positions of residues in the 
active sites of MATa2, suggesting that MATβ modulated the activity of MATa2 by an 
allosteric mechanism. The structure of MAT(a2)4MATb(V2)2 complex (SAMe+PPNP) have 
four active sites, two of those showing the closed gating loops with SAMe and PPNP bound to 
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and the two empty active sites showing the disordered mostly invisible gating loops (Fig. 
1.14C-D). 
Table 1.2. The structures of hMATa1, hMATa2 and MAT(a2)4MATb(V2)2 reported to 
date  
Name 
 
PDB 
 
Resolution 
(Å) 
Ligands in the active site References 
MATa1 2OBV 2.05 SAMe [43] 
MATa2 2P02 1.21 SAMe [43] 
MATa2 5A1I 1.09 SAMe+Met+ADO+PPNP  [30] 
MATa2 5A19 2.34 PPNP [30] 
MATa2 5A1G 1.83 SAE+PPNP [30] 
MAT(a2)4MATb(V2)2 4KTT 2.59 SAMe+Pi [13] 
MAT(a2)4MATb(V2)2 4NDN 2.34 SAMe+PPNP [13] 
MAT(a2)4MATb(V2)2 4KTV 3.30 ADO+PPi+Pi [13] 
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Fig. 1.12 The structure of hMATa2 in complex with SAMe and SAMe+Met+ADO+PPNP 
in the active site. (A) The SAMe-bound structure of MATa2 (PDB: 2P02) is shown in green 
and blue ribbons. Carbon atoms of SAMe in each active site are represented by green and blue 
sticks. The ordered gating loop is shown in red. (B) The SAMe-bound structure of MATa2 
(PDB: 2P02, green) is aligned with the SAMe+Met+ADO+PPNP-bound structure (PDB: 5A1I, 
pink). Carbon atoms of SAMe in each active site are represented by green (PDB: 2P02) and 
pink sticks (PDB: 5A1I). The ordered gating loop is shown in red. 
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Fig. 1.13 The SAMe+Met+ADO+PPNP structure and PPNP-bound structure of human 
MATa2 (A) The active site ligands (SAMe, Met, ADO and PPNP) of the human MATα2 
structure (PDB: 5A1I) show occupancies of 0.5, 0.3, 0.5 and 0.7, respectively. The gating loop 
in closed conformation blocks the entrance to the active site. (B) The PPNP bound structure 
(PDB: 5A19) shows the open conformation of the gating loop, the main part of which is not 
observed in the structure representing its flexibility. (C) The alignment of the PPNP bound 
structure and the SAMe+Met+ADO+PPNP bound structure is shown. The open loop is 
disordered and invisible in the structure, while the loop in its closed conformation is clearly 
visible in the structure of the SAMe+Met+ADO+PPNP bound crystal. 
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Fig. 1.14 The SAMe+PPNP-bound structure of the human MAT(a2)4MAT(bV2)2 
complex (A) The MAT(a2)4MAT(bV2)2 complex (PDB: 4NDN) contains 4 subunits of 
MATa2 and 2 subunits of MATbV2. The tetramer of MATa2 is shown in pale yellow. One 
subunit of MATbV2 interacts with a dimer of MATa2 with its C-terminus (red) at the MATa2 
dimer interface. The N-terminus of MATbV2 is shown in blue. (B) The complex is rotated by 
180o along the x-axis to show the empty active site. (C) SAMe and PPNP (orange sticks) were 
captured in one active site of the MATa2 dimer. (D) The dimer of MATa2 contains one 
occupied and one empty active site which was flanked by the closed and open gating loop 
(pink), respectively.  
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1.3.4 SAMe binding sites based on human MATa1 and MATa2 crystal structures 
SAMe binding sites are reported in human MATa1 and MATa2 at 2.05 and 1.09 Å resolution, 
respectively. All residues that interact with SAMe are conserved in both MAT isoforms. The 
SAMe interacting residues in the active site are described by using MATa2 as the model 
regarding to its higher resolution. Methionine moieties of SAMe are maintained by Glu70 (OE1 
atom), Asp258 (OD1 atom), Gln113 (NE2 atom) and two water molecules (Fig. 1.15A). 
Adenosine aromatic ring of SAMe forms p-p stacking with Phe250 and three of SAMe’s N 
atoms are coordinated with Ser247 (O atom), Arg249 (O atom) and two water oxygen atoms, 
while its ribose moiety (O atom) forms the H-bond with Asp179 (OD1 atom), Fig 1.15A.  
There are three water molecules interacting with SAMe as observed by the structural 
comparison of MATa1 and MATa2 (Fig. 1.15B-C). The first water molecule is coordinated 
by N6 and N7 atoms of SAMe and an OG atom of Ser114 (gating loop). The second water 
forms H-bond with N3 and O4 atoms of SAMe and an OD1 atom of Asp134. The third water 
molecule is coordinated with an O atom of SAMe and Ser114 main chain (N atom). For the 
MATa2 structure, there is one more water molecule which interacts to SAMe at an O atom of 
methionine moiety. This water molecule (number 4, Fig. 1.15B) is coordinated by the O atom 
of SAMe and Gly133 main chain (O atom).  
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Fig. 1.15 SAMe binding sites from the crystal structures of human MATa1 and MATa2. 
(A) The SAMe binding site is illustrated using the structure of MATa2 as the model (PDB: 
5A1I). Carbon atoms of SAMe are shown in orange sticks and waters are shown in blue 
spheres. (B) Waters interacting with SAMe are shown in red spheres of the MATa1 model 
(PDB: 2OBV). (C) Waters interacting with SAMe are shown in blue spheres of the MATa2 
model (PDB: 5A1I). Carbon, nitrogen and oxygen atoms of SAMe are represented by orange, 
blue and red colours, respectively. All residues from the partner subunit are marked with 
asterisks. 
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1.4 MAT transcriptional and post-translational regulation 
1.4.1 MAT transcriptional and epigenetic regulation 
MAT1A and MAT2A gene expressions are mainly regulated by epigenetic controls via DNA 
methylation and histone (H4) acetylation [54]. The MAT1A gene of the adult liver is 
unmethylated and actively expresses, while the MAT1A gene of the developing liver and the 
extrahepatic tissues is suppressed by being hypermethylated at CpG sites on MAT1A gene 
promoter regions and vice versa for MAT2A expressing tissues. Histone acetylation levels have 
been found to increase in both MAT1A and MAT2A expressing tissues (2 and 3.5-fold for 
hepatic MAT1A and kidney MAT2A genes, respectively), suggesting that these epigenetic 
modifications are crucial for the tissue-specific expression of both MAT1A and MAT2A genes 
[55]. Moreover, HepG2 cells (human hepatocellular carcinoma cell line) showed an 
undetectable level of the MAT1A gene expression due to hypermethylation, while treatment 
of HepG2 cells with the demethylating agent (5-aza-2’-deoxycytidine) or the histone 
deacetylase inhibitor (trichostatin) could regain the cell’s ability to express the MAT1A gene 
[22, 55].  
The promoters of MAT1A [56-58], MAT2A [59, 60] and MAT2B [9] genes have been cloned 
and sequenced. The consensus binding sites for transcription factors including activator protein 
1 (AP-1), cyclic AMP response element binding protein (CREBP), CCAAT enhancer binding 
protein (C/EBP), Transcription factor family including E2F- and DP-like subunits (E2F), 
glucocorticoid response elements (GRE), hepatocyte-enriched nuclear factor (HNF), 
interleukin-6 (IL-6), signal transducers and activators of transcription (STAT), avian 
myeloblastosis viral oncogene homologue (v-Myb) and myelocytomatosis viral oncogene 
homologue (c-Myc) were characterised in the MAT1A gene [58] and some of them were 
studied in detail. The combined actions of HNF and C/EBF as the transcriptional activator are 
important for liver-specific gene expression. The transcriptional activity of hepatic MAT 
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promoters is positively regulated by the binding of a nuclear factor 1 (NF1) family, a NF1-like 
protein or a liver-enriched transcription factor (HNF3 family) [56]. Glucocorticoid (GC) could 
bind to GRE on the MAT1A promoter, and this elevated MAT1A expression and promoter 
activity in rat hepatoma H35 cells and primary cultures of hepatocytes in both dose- and time-
dependent manners [61]. Healthy hepatocytes and bile duct epithelial cells expressed high 
levels of the MAT1A gene. These two cell types showed the increased levels of c-Myc and c-
Maf (cellular muscular aponeurotic fibrosarcoma) during cholangiocarcinoma (CCA) 
development. The MAT1A gene expression was found to decrease in developing CCA, while 
overexpression of MAT1A gene could inhibit c-Myc induction and CCA proliferation [62]. 
H69 cells (Cholangiocytes: benign bile duct epithelial cells) treated with IL-6 showed the 
reduction of MAT1A mRNA levels by 20 %, while this elevated c-Myc and c-Maf about 40 % 
[63]. Also, overexpression of c-Myc was found to lower the MAT1A promoter activity by 75 
% in KMCH cells (human cholangiocarcinoma cell lines) [62]. The active rat MAT1A 
promoter was reported in non-hepatic cell types (e.g. Chinese hamster ovary cells), suggesting 
that the liver-specific expression maybe not specifically controlled by these transcriptional 
factors, but it is rather regulated by epigenetic modifications (i.e. methylation of CpG islands 
as mentioned above or compaction of chromatin). The summary of MAT1A gene regulators is 
shown in Fig. 1.16. 
The promoter of MAT2A contains NF-κB (nuclear factor kappa B) and AP-1 response 
elements. NF-κB and AP-1 could bind to the MAT2A promoters after they were activated by 
TNF-α (tumour necrosis factor-α). NF-κB and AP-1 binding to MAT2A promoter was found 
to increase in hepatocellular carcinoma of HepG2 cells and this promoted MAT2A 
transcription [64]. Transcription factors including Sp1 (specificity protein 1), c-Myb and E2F 
also up-regulated the activity of the MAT2A promoter [65, 66]. The MAT2A gene was 
overexpressed in the CCl4-induced fibrosis mice, while the administration of the NPLC0393 
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(the inhibitor of transforming growth factor beta-1 (TGF-β1) signalling pathway) could inhibit 
the upregulation of the MAT2A gene [67]. This underlying mechanism was studied in hepatic 
stellate cells. When TGF-β1 activated the phosphorylation of p65 (nuclear factor kappa B p65), 
the phosphorylated p65 entered the nucleus and promoted MAT2A transcription and protein 
expression. In addition, the hypoxic environment of hepatoma cells could trigger MAT2A 
expression via the binding of a HIF-1a (hypoxia-inducible factor-1α) on the MAT2A promoter 
[68]. Upstream regulatory regions of the MAT2A promoter contains several peroxisome-
proliferator activated receptor (PPAR) response elements (PPREs). Nuclear receptors 
including the PPAR of rat activated hepatic stellate cells were found to bind on PPREs. PPARγ 
and PPARβ share the similar binding site on the MAT2A promoter [69]. PPARγ was 
predominant in silent hepatic stellate cells, while PPARβ was activated during the liver 
fibrogenesis [70, 71]. In quiescent hepatic stellate cells, binding of the PPARγ to PPREs 
negatively regulated MAT2A transcriptions. During hepatic stellate cell activation, the PPARγ 
expression and activity significantly decreased and this promoted the binding of the PPARβ to 
PPREs on the MAT2A promoter, resulting in MAT2A expressions [69]. A summary of 
MAT2A gene regulators is described in Fig. 1.17.  
The switch of MAT1A to MAT2A gene expressions and lower SAMe levels were found to be 
related with CpG hypermethylation and deacetylation of histone H4 of the MAT1A promoter. 
CpG hypomethylation and histone H4 acetylation of MAT2A were reported in F344 rats ( 
genetically predispose to HCC) and human liver cancer cells [72]. The methylation of MAT1A 
genes at +10 and +88 sites (relative to the transcriptional start site) down-regulated MAT1A 
gene transcriptions [73]. In addition, the MAT1A gene hypermethylation and low levels of 
mRNA expressions were also reported in patients with the advanced non-alcoholic fatty liver 
disease [74].  
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Fig. 1.16 Transcriptional regulations of the MAT1A gene. MAT1A expression can be 
regulated by several transcriptional factors that contain their response elements on the MAT1A 
promoter. Positive and negative regulators are represented by plus and minus, respectively. 
Glucocorticoid (GC); glucocorticoid receptor (GR); hepatocyte-enriched nuclear factor (HNF); 
nuclear factor 1 (NF1); glucocorticoid response element (GRE); interleukin-6 (IL-6); CCAAT 
enhancer binding protein (C/EBP); activator protein 1 (AP-1); cyclic AMP response element 
binding protein (CREBP); transcription factor family including E2F- and DP-like subunits 
(E2F); signal transducers and activators of transcription (STAT), myelocytomatosis viral 
oncogene homologue (c-Myc); avian myeloblastosis viral oncogene homologue (v-Myb).  
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Fig. 1.17 Transcriptional regulation of the MAT2A gene. Positive and negative regulators 
are represented by plus and minus, respectively. Tumour necrosis factor alpha-1 (TNF-a1); 
transforming growth factor beta-1 (TGF-β1); nuclear factor kappa B (NF-kB); activator protein 
1 (AP-1); transcription factor family including E2F- and DP-like subunits (E2F); specificity 
protein 1 (sp1), hypoxia-inducible factor-1α (HIF-1α); peroxisome-proliferator activated 
receptors (PPAR) response elements (PPRE); myeloblastosis viral oncogene homologue (c-
Myb); nuclear factor kappa B p65 (p65). 
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1.4.2 MAT post-translational modification 
Post-translational modification (e.g. phosphorylation, nitrosylation, sumoylation, 
ubiquitylation and acetylation) can regulate MAT enzyme activity and stability (Fig. 1.18). 
Treatments of the rat liver MAT with nitric oxide (NO) donors (e.g. linsidomine, S-nitroso-N-
acetylpenicillamine or S-nitrosoglutathione monoethyl ester) showed the decrease in an 
enzyme activity in a dose-dependent manner. Removal of the NO donors or the administration 
of some reducing agents (e.g. b-ME or glutathione) could reverse the effect of these NO 
releasing agents. The NO binding site was determined in the rat liver MAT showing that 
Cys121 (equivalent to Cys120 in human MATa1) was involved in the inhibition effect of the 
NO on MAT enzymes [75]. Cys121 is only found in MATa1 (Gly121 in MATa2) and it is a 
part of the enzyme gating loop. The serine substitution of acidic or basic amino acids (e.g. 
Asp335, Arg357 and Arg363) around Cys121 could inhibit the effect of NO on MATa1 
activity, suggesting that these Cys121 surrounding residues were involved in the inhibition of 
MATa1 activity by S-nitrosylation [76]. 
The regulation of the rat liver MAT by protein kinase C (PKC) phosphorylation was studied 
and Thr342 was identified as the phosphorylation site. The phosphorylated Thr342 in a hepatic 
MAT dimer caused enzyme dissociation to a monomeric form [77]. Tyr371/Tyr374 and 
Thr257/Tyr259 were determined as the phosphorylation sites of MATα2 and MATβ proteins, 
respectively. They were phosphorylated by mitogen-activated protein kinase (MAPK) family 
members (Ras/Raf/MEK/ERK cascade reaction) [78]. Only the MATb subunit showed the 
decrease in phosphorylation and enzyme stability when B-Raf or ERK1/2 were silenced, while 
MEK inhibition had effect on both MATb and MATα2 proteins.  
Sumoylation is the SUMOs (small ubiquitin-like modifiers) addition process to the target 
protein which can affect the protein structure (stability), and subcellular localisation [79]. In 
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human colon and liver cancer cell lines (e.g. HepG2 and RKO), MATα2 required Ubc9 
(Ubiquitin-conjugating enzyme 9) for sumoylation at Lys340, Lys372 and Lys394 to increase 
their stability. Colon cancer showed greater levels of MATa2 sumoylation, total MATa2 and 
Ubc9 levels which in turn facilitated tumour cell growth by maintaining Bcl-2 (B-cell 
lymphoma 2) expression [80].  
P300 (E1A binding protein p300) acetylated MATa2 at Lys81 and destabilised MATa2 by the 
activation of ubiquitylation processes which resulted in proteasomal degradation [81]. In 
contrast, MATa2 was deacetylated and stabilised by a histone deacetylase-3 by inhibiting the 
proteasomal degradation process. Acetylation of MATa2 at Lys81 was also found to decrease 
in human hepatocellular cancer.  
 
Fig. 1.18 Post-translational modification of MAT enzymes. MATa1 and MATa2 can be 
regulated by post-translational modification processes e.g. phosphorylation, acetylation, 
sumoylation, etc. These processes result in enzyme activity and stability alteration. Nitric oxide 
(NO); protein kinase C (PKC); Ubc9 (Ubiquitin-conjugating enzyme 9); P300 (E1A binding 
protein p300).  
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1.5 Introduction to X-ray crystallography   
1.5.1 Structural biology through X-ray crystallography 
The origin of X-ray diffraction of macromolecule crystals can be traced back to the finding of 
X-ray in 1895 by Wilhelm Conrad Röntgen whose scattering and polarisation nature was 
illustrated by Charles Glover Barkla [82-85]. This finding gave rise to the first diffraction 
experiments by Max von Laue. Those Röntgen rays (X-rays) were generated by the impact of 
cathode rays on a solid object. The X-rays can penetrate the solid material and cast the shadow 
on pieces of film. Max von Laue showed X-ray diffraction patterns of a salt crystal in 1912, 
demonstrating that X-rays are electromagnetic waves that can produce a diffraction pattern 
when they travel through a crystal [86, 87]. In 1913 William Henry Bragg (father) and William 
Lawrence Bragg (son), introduced the Bragg’s equation (Bragg’s Law) to explain  the 
interference pattern of X-rays scattered by crystals [88]. In 1953, the double-helix model of 
DNA was proposed by James Watson and Francis Crick using X-ray diffraction images 
obtained from Rosalind Franklin [89]. In 1959, Max Perutz and John Kendrew firstly 
elucidated the myoglobin structure and just a few months later the haemoglobin structure was 
successfully obtained (about 64 years after X-rays were discovered) [90, 91]. Since then 
numerous structures of important biochemical substances have been discovered by X-ray 
crystallography techniques including vitamin B12 and insulin by Dorothy Hodgkin [92-94], 
the photosynthetic reaction centre, which is the first membrane protein structure, by Johann 
Deisenhofer, Robert Huber and Hartmut Michel [95], the ATP synthase structure by John E 
Walker [96] and the G-protein-coupled receptor (GPCR) structure by Brian Kobilka and Robert 
Lefkowitz [97]. 
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1.5.2 Protein crystallisation 
Protein crystallisation is a trial-and-error experiment in which the presence of impurities, 
crystallisation nuclei and other unknown factors can affect crystallisation processes either 
interfering with or promoting crystal growth.  Contaminants should be at the least amount and 
all protein molecules should retain their surface charge distribution, as these factors have an 
effect on the packing of the molecules in the crystal. Crystallisation depends on many 
parameters including the purity and homogeneity of proteins. In order to obtain starting 
crystallisation conditions, many reservoir conditions are tested using commercial screens and 
robotics. Over the last 50 years, requirements for large crystals have diminished going from 
mm to micron when synchrotron radiation [98, 99] and cryo-crystallography [100-102] are 
used for data collection. Cryo-crystallography is a technique used to decrease the effect of 
radiation damage on protein crystals by soaking the crystals with cryoprotectants and freezing 
them with liquid nitrogen before being exposed to X-ray beams (the crystals will be in cold 
stream during data collection).    
When the achievable highest purity of protein is obtained, the purified protein is mixed with a 
suitable buffer combined with a precipitant solution for crystallisation. The initiation of 
crystallisation nuclei is induced by the supersaturation of the protein solution that promotes the 
formation of small aggregates (Fig.1.19). The surface tension energy is needed for spontaneous 
crystal nucleation. Crystal growth can begin once the energy barrier of nucleation is overcome. 
The successful formation of crystal nuclei usually occurs at high levels of supersaturation (the 
state that the energy barrier is easy to overcome) [103]. Protein solubility depends upon a 
number of factors (e.g. protein concentrations, types of salt in the buffer, the pH of the buffer, 
etc.). Different crystallisation methods can be used to drive the solution into the supersaturated 
state and the easiest way to adjust protein concentrations is to vary temperatures or precipitant 
concentrations. The protein solubility should be gradually decreased to the point where 
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spontaneous precipitation can occur. Addition of precipitants is the most prevalent procedure 
to lower protein solubility for protein crystallisation. Polyethylene glycols (PEGs) and 
inorganic salts (e.g. ammonium sulphate, (NH4)2SO4), are commonly used as the protein 
precipitant reagents.  
 
 
Fig. 1.19 The crystallisation phase diagram of macromolecules. The supersaturation zones 
contain two phases (metastable and labile regions). Nucleation can be formed in the labile 
region, while the metastable region is where nuclei develop into crystals (no new nuclei occur 
in this zone). A precipitation occurs when protein drops are highly supersaturated. Growth of 
crystals during crystallisation is shown in diagram via a vapour diffusion (a to c) technique. 
Crystals stop growing once the concentration of proteins is at the equilibrium between the 
solution and the solid state.  
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1.5.2.1 Crystallisation solutions 
A salt usually acts by salting out proteins from solutions once high salt concentrations increase 
ionic strengths in the system. Proteins and salt ions will compete for water to keep their 
solubility at high ionic strength [104]. At this point, when the concentrations of ions become 
adequately high, the proteins are forced to neutralise their surface charges (to fulfil their 
electrostatic requirements) by interacting with one another [105, 106]. This interaction may 
create an ordered arrangement of the proteins in a crystalline lattice [107]. The advantages of 
using salts as the precipitating agent are their nontoxic and soluble properties.  
Some polymers (PEGs are mostly used) [108, 109], create volume exclusion effects that 
promote the separation of proteins from solutions [108, 110]. PEGs are the effective 
precipitating agent at low cost and contain different sizes that can be used for crystallisation 
screening. PEG molecules move randomly in solution and occupy much larger space than their 
molecular weights due to the flexibility and the water-soluble property. This volume exclusion 
effect limits free space for proteins and induces protein molecules to segregate and nucleate, 
transitioning to form a solid state (either amorphous or crystalline). In addition, PEGs are very 
hydrophilic and can immobilise water molecules (the same property as found in salt solutions) 
[111]. PEGs compete with proteins to bind to water molecules, and the water will be less 
available in the solution, mimicking higher protein concentration.  
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1.5.2.2 Crystallisation methods 
To adjust protein solutions to the supersaturated state, several crystallisation techniques can be 
used [112, 113], while the basic principles of these methods (e.g. micro-batch, vapour-diffusion 
and micro-dialysis) are different. 
The micro-batch method has been developed by Chayen N et al., 1992 [114]. Protein crystals 
can be grown in 1–2 µL protein drops mixed with the precipitant. The drops are kept in an oil 
(e.g. paraffin oil) to prevent evaporation (Fig. 1.20A). This technique is not suitable for using 
organic compounds that can be dissolved in the oil as precipitating agents [115, 116]. The 
volume of the drop and the concentration of precipitants do not change during the incubation 
time because of the limited evaporation rate. The protein concentration will instantly change 
once crystals or amorphous precipitants are formed. If the starting point of protein 
concentrations is in the under-saturated or supersaturated state (too low or too high 
concentrations), only a small chance of crystal formation can take place. The protein solution 
will rapidly precipitate if its starting concentration is in the precipitation zone (Fig. 1.19). 
Therefore, only protein concentrations that are high enough, but not too high to cause 
precipitations will favour crystal growth. For this technique, the equilibration develops very 
rapidly, therefore it influences the crystal growth rate and the crystal quality. The optimal 
starting concentration of proteins is needed to avoid too rapid growth of crystals which is 
generally not good for producing high quality crystals. 
The vapour-diffusion technique is done by mixing proteins and reservoir solutions (e.g. 1:1 
or 1:2 ratio) on a cover slip. The cover slip containing the protein drop will be hung upside 
down against the reservoir (well) solutions that contain precipitating agents (Fig. 1.20B). 
Alternatively, the vapour-diffusion technique can be performed by the sitting drop method 
which protein drops are set on micro-bridges to prevent the protein from falling down the cover 
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slip (Fig. 1.20C). The ratios of proteins and reservoir solutions can be varied in order to adjust 
the protein concentrations during screening. Water from reservoir solutions normally 
evaporates from protein drops (lower precipitating agent concentration) and this will bring the 
protein solution into the supersaturated state.   
Dialysis technique is based on the diffusion rate of the precipitating solution through the 
dialysis selective membrane that contains protein solutions (Fig. 1.20D). The protein 
concentration will slowly approach the equilibrium concentration at which it can be 
crystallised.   
 
Fig. 1.20 Protein crystallisation techniques. (A) Micro-batch (B) Vapor diffusion (hanging 
drop) and (C) Vapour diffusion (sitting drop) and (D) Micro-dialysis. Protein crystals are 
shown in red.  
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1.5.3 X-ray diffraction 
1.5.3.1 Overview 
X-rays have very short wavelength (about 1 Å) compared to other electromagnetic waves (e.g. 
infrared, 100-1 µm and visible light, 720-400 nm) and they can interact with matters differently 
[117]. There are four principal phenomena when X-rays interact with matters including two 
scattering (Rayleigh scattering and Compton scattering) and two absorption processes 
(photoelectric effect and pair production). The energy applied for X-ray crystallographic 
experiments is usually about 10 keV which can interact with atoms of the crystal by three major 
ways [118, 119]. Firstly, the X-rays (photons) that collide with atoms and scatter coherently 
resulting in an observed diffraction pattern are called Thomson or Rayleigh scattering (Fig. 
1.21A). Secondly, Compton scattering (Fig.1.21B) may occur if photons inelastically scatter 
and transfer their energies to electrons in atoms which finally emit the lower energy 
incoherently. A background on diffraction images is generally generated by the Compton 
scattering. The third way is photoelectric interaction (Fig.1.21C) that occurs when the incident 
X-rays are completely absorbed, and photoelectrons are ejected. The entire energy of photons 
is often deposited into the crystal. 
X-ray diffraction is a phenomenon happening when X-rays are scattered by electrons inside the 
atom of crystalline materials (e.g. salt or protein crystals). The atom hit by X-rays becomes a 
small secondary X-ray source that emits scattered waves. These waves either coherently or 
incoherently interfere to each other (Fig. 1.22). If the scattered waves coherently interact with 
each other (in phase), the phenomenon called a constructive interference will occur (Fig. 
1.22A). If the scattered waves cancel out each other (out of phase), a destructive interference 
will take place (Fig. 1.22B). Only the certain condition that satisfies Bragg’s Law will produce 
constructive interferences and can give diffraction reflections (see below, section 1.5.3.2).  
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Fig 1.21 Illustration of main phenomena of X-ray interactions with matters. (A) Rayleigh 
scattering (B) Compton scattering (C) Photoelectric effect.  
 
Fig. 1.22 Addition of two waves of the same wavelength. This phenomenon yields a third 
wave of the same wavelength, while the phase and amplitude of this resulting wave can either 
be the same or different from those of the two summed waves. In fact, the relative phase of the 
two summed waves critically affects the appearance of the third wave. (A) The two waves to 
be added are perfectly in phase, and the resulting wave contains an amplitude twice that of the 
wave1 and wave2, with the same phase. (B) The two added waves are 180o out of phase and 
cancel each other so that the resulting wave has zero amplitude.  
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1.5.3.2 Single-crystal X-ray diffraction (XRD) and electron density distribution 
The interaction of X-rays and crystal lattices giving to diffractions is ruled by Bragg's law 
which states that the constructive interference is only observed when Bragg’s equation [1] is 
satisfied. 
 nl = 2dsinq       [1] 
where n is an integer (a whole number of wavelength), λ is the wavelength of X-ray, d is the 
distance between parallel planes in the crystal lattice, and θ is the angle of incidence between 
the X-ray beam and the diffracting planes (Fig. 1.23).  
 
Fig. 1.23 Bragg diffraction in a crystal. The resulting waves will be in phase at the certain 
angle of the X-ray beam hitting the crystal lattice plane, resulting in diffraction intensities 
(i.e. Bragg's Law is fulfilled when the total path difference (nl) is equal to 2dsinq). 
The electron density r(xyz) is constructed by the equation [2] and the structure factors (Fhkl) 
can be obtained experimentally from the measured reflection hkl (hkl indices corresponding 
lattice planes of the reflection hkl).   
r(xyz) = ∑Fhkl exp[2πi (hxj + kyj + lzj)]     [2] 
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where Fhkl is the structure factor,  xjyjzj is the fractional coordinates (atomic position in the unit 
cell) of the atom j and i is the imaginary number (-1)1/2. 
In the experiment, the Bragg reflection intensities (Ihkl) are measured and they represent the 
amplitudes of the resulting waves (diffraction patterns). Ihkl is related to Fhkl by the equations 
listed below. 
                                                          I(hkl) = |F(hkl)|2                                                             [3] 
                                                     F(hkl) = |F(hkl)|exp(ifhkl)                                                    [4] 
                                       F(hkl) = ∑ fj exp[2πi (hxj + kyj + lzj)]                                               [5] 
where Fhkl is the structure factor of a reflection hkl, fhkl is the phase angle, i is the imaginary 
number (-1)1/2, fj is the scattering factor which contains information of the crystal structure and 
xjyjzj is the fractional coordinates of the atom j. 
Only an absolute structure factor |Fhkl| is obtained from the experiment, but in order to calculate 
the electron density r(xyz), Fhkl is necessary (require both phase and amplitude). However, the 
phase (fhkl) cannot be obtained directly by experiments (known as phase problem), while it 
needs to be solved for electron density calculation (see section 1.5.5.2).   
1.5.4 Data collection  
1.5.4.1 X-ray sources (Synchrotron) 
An enormous improvement in X-ray generation techniques took place in the mid-1970s, when 
the application of synchrotron radiation was developed [120, 121]. A synchrotron facility is 
constructed with a gigantic storage ring, where electrons move at a very high speed (nearly the 
speed of light) in the straight channel that forces electrons to slow down intermittently when 
they meet the bending magnet and change their direction to meet the curvature of the ring 
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(Fig.1.24). At this moment, when electrons change their direction, they emit a high intensity 
radiation known as the synchrotron radiation covering the whole electromagnetic spectrum 
from far-infrared to X-rays [122]. X-rays are selected by the use of a combination of X-ray 
mirrors with monochromators. A single wavelength of X-rays is selected for crystallographic 
experiments. The storage ring used to generate X-rays at a synchrotron is shown in Fig. 1.24.  
 
Fig. 1.24 The layout of the synchrotron storage ring. Accelerated electrons are injected into 
the storage ring which contains several dipole bending magnets (BMs). BMs produce the 
magnetic field which is perpendicular to the direction of electron movement. Lorentz 
(electromagnetic) force controls electrons to move around the storage ring. Electrons emit 
electromagnetic radiation when they reach the curve of the BMs, while RF (radiofrequency) 
system provides the accelerating field for an electron beam to compensate the energy loss 
during radiation emission. ID (insertion device) is a linear periodic magnetic array which can 
enhance the radiation intensity emitted by electrons. The figure was modified from reference 
[122].  
1.5.4.2 Mounting, aligning the crystals and data collection  
The protein crystal is picked from crystallisation drops using nylon loops and is soaked with 
appropriate cryoprotectants (e.g. glycerol, ethylene glycol, PEGs, etc) under a light microscope 
before being frozen with liquid nitrogen. The crystal is then aligned on the goniometer head 
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and positioned to the centre of the X-ray beam using the video screen (Fig. 1.25). During data 
collection, the crystal will be treated with the cold stream at all times to decrease radiation 
damage when being exposed to X-ray beams. The diffraction quality of the crystal can be tested 
at a few different angles for optimising some parameters (detector distance, exposure time and 
beam intensity). When the data collection parameters are optimised, the crystal will be exposed 
to X-ray beams repeatedly by rotating the crystal about 0.1-0.2o  at a time (oscillation). The 
crystal can diffract and give diffraction spots only when the Bragg’s condition is fulfilled. 
Therefore, the crystal needs to be rotated to increase the set of crystal planes that satisfy Bragg’s 
law, and this will increase the completeness of the data. If the protein crystal used in the 
experiment has never been determined before, full data collection of 360o is recommended. For 
most protein crystals, 180o of data collection should be adequate as the low symmetry crystals 
(i.e. 2-fold symmetry) need 180o collection. The higher symmetry crystals will require less than 
180o of data collection. The intensity of diffraction spots will be used for the structure 
determination following a series of data processing and model building (e.g. indexing, 
integration, scaling, phasing, model building and refinement).     
 
Fig. 1.25 The alignment of the MAT crystal to X-ray beams. The MAT crystal was mounted 
onto the nylon loop and kept in liquid nitrogen before being exposed to X-ray beams. 
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1.5.5 Data analysis for structure determination  
1.5.5.1 Data processing  
Data processing contains four key steps including (i) crystal evaluation and indexing from 
initial images, (ii) integration of reflection intensities of the full set of oscillation images (iii) 
scaling/ merging and (iv) truncation. The output file provides information of space group, cell 
dimension, hkl intensity and sigma (background or noise) for all of the unique reflections that 
were measured. 
Indexing is the process to determine the lattice plane indicated by Miller (hkl) index that gives 
each reflection spot. When the specific lattice plane of each spot (hkl) is indexed, the unit cell 
dimension (a, b, c and α, β, γ), lattice type and crystal orientation can be identified. Each hkl 
reflection will be measured its intensity (I) by the process called integration. All detected spots 
on diffraction images will be determined, and the background around the spots will be 
calculated and determined as the sigma value (s). After integration, the reflection data will be 
subjected to a common scale (scaling) which minimises the inconsistency causing by various 
factors (e.g. detector, incident X-ray beam, etc.) between the individual data and average data 
of the equivalent symmetry-related spots. However, the overall intensities of hkl reflections 
may be extracted in several thousands, they usually contain the symmetry-related spots 
representing the redundancy or multiplicity of the data (redundancy of 3.5 or above is 
considered acceptable). The unique set of data will be obtained after the data are scaled and 
merged the symmetry-related spots (merging). Finally, the intensities (Ihkl or |Fhkl|2) will be 
truncated to |Fhkl| by the truncation process.  
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 1.5.5.2 Phasing by molecular replacement (MR) 
To calculation the electron density r(xyz), the structure factor F(hkl) is needed as shown in 
equation [2]. Fhkl contains both amplitude and phase (as shown earlier in equation [4]). Only 
Ihkl or |Fhkl|2 obtained from experiments by measuring the diffraction intensities is not enough 
to calculate the structure factor Fhkl [123]. The missing information of phases is known as phase 
problem and it needs to be solved to construct the electron density of the crystal structure.  
The Patterson map provides the distribution of the interatomic distance that is directly 
computable from the data. MR [124] compares the Patterson map of the homology known 
structure (search model) with the unknown structure [125]. Rotation of the search model in 
three dimensions will give different calculated structure factor values, |Fcalc|(hkl), which will 
be matched to the |Fobs|(hkl) of the experimental diffraction data. The orientation that gives 
the best match of |Fcalc|(hkl) to |Fobs|(hkl) will be used to define the correct translation of the 
model in the unit cell of the crystal. When the correct orientation and translation of the search 
model can be determined, the phases (fhklcalc) of the search model can be calculated and 
applied to the experimental structure factor calculation (equation [4]) by using |Fobs|(hkl) 
derived from the measured intensity and fhklcalc as shown below.  
Fobs(hkl) = |Fobs(hkl)|exp(ifhklcalc) 
Therefore, the electron density which is the Fourier transform of Fobs(hkl) can be calculated 
as shown earlier in equation [2]. 
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1.5.6 Structure refinement and validation  
Once the initial model is obtained, refinements of the model against the data by varying x,y,z 
coordinates (atomic positions) and B-factors (thermal motions) will be performed to find the 
best agreement of the experimental |Fobs|(hkl) from diffraction intensities and the calculated 
|Fcalc|(hkl) from the initial model (R-factor, equation [6]). This R-value is the measurement of 
an atomic model quality derived from the crystallographic data. Refinement incorporates 
restraints on an atomic position relied on the known chemical properties of the protein structure 
(e.g. bond lengths, angles, side chain rotation) and the R value less than 20 % indicates that the 
model is in reasonable agreement to the experimental data.  
																																				" − $%&'() = 	∑ ||-(./(ℎ23)| − |-&%3&(ℎ23)||567 ∑ |-(./(ℎ23)|567 																																		[6] 
The quality of models will be better through the process of structural refinements. The model 
will fit better to the electron density (experimental data). However, too many cycles of 
refinement normally introduce bias to the system as the refined model is used to calculate the 
electron density. The R-free value is the parameter to be used along with the R-factor value to 
prevent this bias. About 5 % of the experimental data will be excluded from the original data 
and will not be refined to calculate the R-free value. For a good refined model, R-free and R-
factor values should be very similar to each other. Typically, R-free will have about 3-5 % 
higher than the R-factor value and it is considered acceptable for the model validation [126].   
The Ramachandran plot is used to evaluate the Φ (phi) and Ψ (psi) angles of amino acids in 
peptide bonds. The irregular or inappropriate rotations of amino acid main chains can be 
identified from this plot. Other molecules (e.g. waters, ions, chemical reagents, cryoprotectants, 
etc.) which are contained in purification buffers or crystallisation reagents might be existing in 
the electron density and are needed to be built in the model. Interatomic distances are 
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investigated for preventing adjacent atomic clashes. Bond lengths, bond angles and other 
parameters (e.g. clash score, Ramachandran outliers) of the model can be calculated and 
compared to the expected value using Protein Data Bank (PDB) validation report server 
(https://www.wwpdb.org/validation/validation-reports) or MolProbity server 
(http://molprobity.biochem.duke.edu). These online servers allow users to validate the quality 
of models before performing structural deposition on PDB.  
1.6 Research aim of my project 
My project can be divided into three main objectives. The first part is to investigate the 
functional role of a gating loop on MAT activity both SAMe formation and PPPi hydrolysis. 
The gating loop is located above an active site entrance undergoing structural changes during 
substrate binding and product release. The direct evidence of the gating loop’s functional 
relevance on SAMe formation is still elusive. The consequences caused by mutations of some 
key residues of the gating loop that are directly or indirectly involved in substrate (methionine) 
or product (SAMe) binding will be accomplished by site-directed mutagenesis, activity assay 
and crystallographic structure with a variety of ligands. 
The second objective is to investigate the effect of Arg264 mutations on MAT function and 
structure. Arg264 is located at the dimer interface where the active sites assemble. Arg264His 
mutations of MATa1 have been reported to be the most common cause of isolated persistent 
hypermethioninemia (i.e. high levels of the methionine in blood plasma). Arg264Ala and 
Arg264His mutants will be generated in MATa1 as well as Arg264Ala mutant in MATa2. The 
mutants will be characterised for the enzyme activity and the oligomeric form in solution and 
crystal structures.  
The last objective is to investigate the effect of quinolone-based compounds on MAT activity. 
The compound binding positions on MAT are preliminarily predicted by molecular docking 
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and are shown to interact with MAT catalytic subunits at the same binding interface where the 
regulatory subunit, MATb, has been reported to bind at. The effects of these compounds on 
MAT activity will be studied in comparison with MATb subunits. The compound bound 
crystals will be produced by co-crystallisation method using commercial screens.   
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Chapter II 
Materials and Methods 
2.1 Plasmid DNA and bacterial culture 
MATa1 and MATa2 (pNIC28-Bsa4 vector, with a kanamycin-resistance gene) constructs 
were kindly provided by structural genomic consortium (University of Oxford, UK) and 
MATbV1 and MATbV2 constructs were generously provided from Dr. Shelly Lu (University 
of California Los Angeles). MATbV1 and MATbV2 genes were sub-cloned into pET-28M-
SUMO3 vector, with a kanamycin-resistance gene.  
For protein expression of MATα1, MATα2 and MATβ (V1/V2 variants), BL21 (DE3) cells 
were used, while StellarTM (Clontech) cells were used for site-directed mutagenesis and DNA 
amplification. Bacterial cells were cultured in LB (Lysogeny or Luria broth, Miller) containing 
yeast extract (5.0 g/L), peptone from casein (10.0 g/L) and NaCl (10.0 g/L). 12.5 g of LB Broth 
was dissolved in 500 mL RO (reverse osmosis) water and was autoclaved for 15 min at 121 
°C. Kanamycin or ampicillin was added at a final concentration of 50 µg/mL or 100 µg/mL, 
respectively. 
2.2 Site-directed mutagenesis 
Primers for site-directed mutagenesis were designed by using SnapGene software (from GSL 
Biotech; available at snapgene.com). Primer sequences used in this study are shown in Table 
2.1. The desired plasmids of mutants were generated by using a CloneAmp HiFi Polymerase 
Chain Reaction (PCR) Premix (Clontech). 12.5 µL of the CloneAmp HiFi PCR Premix was 
mixed with 7.5 pmol of each primer and 100 ng of the wild-type plasmid DNA. Autoclaved 
water was added at a final volume of 25 µL and the reaction was centrifuged shortly. A thermal 
cycler was programmed with the following cycling conditions: 10 min 98 °C (1); 10 sec 98 °C 
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(2); 15 sec 55-60 °C (3); 45 sec 72 °C (4); 10 min 72 °C (5). Steps 2 to 4 were repeated for 34 
times. DpnI (NEB) was added at a final concentration of 800 units/mL to remove DNA 
templates, and the PCR product was incubated at 37 oC for 2 h. The plasmids were then 
transformed to StellarTM competent cells. Transformed cells were plated on selective agar plates 
and incubated at 37 °C overnight. A single colony was picked and inoculated to 5 mL of 
selective media and incubated at 250 rpm, 37 °C overnight. Plasmid DNA was purified and 
sent for DNA sequencing at GATC biotech or DNA Sequencing and Services (University of 
Dundee, UK). The desired mutated plasmids were collected and stored at -20 °C until use. 
Table 2.1 Primers used for site-directed mutagenesis 
Primers Primer Sequences (5’-3’) 
Q113A MAT2A F CTGGTAGCCTTGGAGCAAGCGTCACCAGATATTGCTCAA 
Q113A MAT2A R TTGAGCAATATCTGGTGACGCTTGCTCCAAGGCTACCAG 
S114A MAT2A F GTAGCCTTGGAGCAACAGGCACCAGATATTGCTCAAGGT 
S114A MAT2A R ACCTTGAGCAATATCTGGTGCCTGTTGCTCCAAGGCTAC 
P115G MAT2A F GTAGCCTTGGAGCAACAGGGACCAGATATTGCTCAAGGT 
P115G MAT2A R ACCTTGAGCAATATCTGGTCCCTGTTGCTCCAAGGCTAC 
R264A MAT2A F GATGCTGGTTTGACTGGAGCGAAAATCATTGTGGACACT 
R264A MAT2A R AGTGTCCACAATGATTTTCGCTCCAGTCAAACCAGCATC 
R264H MAT1A F GATGCGGGTGTCACTGGCCATAAGATTATTGTGGACACC 
R264H MAT1A R GGTGTCCACAATAATCTTATGGCCAGTGACACCCGCATC  
R264A MAT1A F GATGCGGGTGTCACTGGCGCTAAGATTATTGTGGACACC 
R264A MAT1A R GGTGTCCACAATAATCTTAGCGCCAGTGACACCCGCATC 
R299H MAT1A F TCAGCCGCTTATGCTGCCCACTGGGTGGCCAAGTCTCTG 
R299H MAT1A R CAGAGACTTGGCCACCCAGTGGGCAGCATAAGCGGCTGA 
R356W MAT1A F CATAAGAACTTCGACCTCTGGCCGGGCGTCATTGTCAGG 
R356W MAT1A R CCTGACAATGACGCCCGGCCAGAGGTCGAAGTTCTTATG 
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2.3 Plasmid transformation 
BL21 (DE3) or StellarTM cells were thawed on ice. Each tube containing 50 µL of cells was 
mixed with 1 µL of a plasmid DNA (50-100 ng/µL) in 1.5 mL tubes. All tubes were rested on 
ice for 30 min in cold room (4 oC). The cells were incubated at 42 oC using water bath for 45 
sec and placed on ice for 10 min. 200 µL of LB broth or S.O.C medium (Thermo Fisher 
Scientific) without the antibiotics was added to the cells and followed by incubation for 1 h at 
250 rpm, 37 oC. 150 µL of transformed cells were plated on LB agar supplemented with 
appropriate antibiotics and incubated overnight at 37 oC. All plates were kept at 4 oC until use. 
2.4 Plasmid purification 
The transformed bacterial cells were grown overnight (16-18 h) at 250 rpm, 37 °C. An 
overnight culture was then centrifuged at 5000 g to collect cell pellets. DNA purification was 
performed using Wizard Plus SV Minipreps DNA Purification System (Promega)’s 
centrifugation protocol. Briefly, cell pellets were resuspended with 250 µL of Cell 
Resuspension Solution and 250 µL of Cell Lysis Solution was added to each sample. 350 µL 
of Neutralisation Solution was added and all tubes were centrifuged at 13000 rpm at room 
temperature by using a bench top centrifuge (Eppendorf). The clear lysate was transferred to a 
Spin Column (provided by the kit) and centrifuged at 13000 rpm for 1 min. The collected flow-
through was discarded and 750 µL of Wash Solution was added. All tubes were centrifuged at 
13000 rpm for 1 min. The flow-through was discarded and the centrifugation with 250 µL of 
Wash Buffer was repeated for 5 min. The Spin Column was transfer to a 1.5 mL 
microcentrifuge tube and 100 µL of warm nuclease-free water was added. All tubes were 
centrifuged at 13000 rpm for 1 min and DNA concentrations were measured (concentration 
ranges: 40-60 ng/µL) before being stored at -20 oC. 
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2.5 Bacterial glycerol stock 
For long term storage of plasmid-transformed bacterial cells, an overnight culture was mixed 
with sterile glycerol at a final concentration of 25 %. The cells’ glycerol stocks were then flash 
frozen by liquid nitrogen and being stored at -80 oC until use. The cells could be regrown by 
streaking onto LB agar plates and incubated at 37 oC overnight.  
2.6 Protein expression 
A single colony of transformed cells was taken from the LB plate using a sterile pipette tip. 
The tip was dropped into a 5 mL starter culture tube. All tubes were incubated at 250 rpm, 37 
oC for 12-18 h. The growth of bacteria was inspected by a cloudy haze in the media. 5 mL of a 
freshly grown starter culture was added to a flask containing 500 mL of LB media 
supplemented with appropriate antibiotics. All flasks were shaken at 250 rpm, 37 oC for 3-4 h 
until OD600 reached 0.6-0.8 (optimum number of bacterial cells for induction). Protein 
expression was induced by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG). Then, the culture was incubated overnight at 250 rpm, 20 oC (for all proteins used in 
this work). The culture was then centrifuged at 6000 x g for 20 min at 4 oC. Pellets were 
harvested and flash frozen in liquid nitrogen before being stored at -80 oC until use. 
2.7 Purification of MATα1 and MATα2 (pNIC vector) 
All buffers used in protein purification are indicated in Table 2.2. Cell pellets were resuspended 
with ice-cold Lysis Buffer in 1:4 ratio (pellet, g: buffer, mL). All tubes were placed on ice and 
PMSF (phenylmethylsulfonyl fluoride) was added at a final concentration of 1 mM. Cell 
suspensions were sonicated for 15 cycles at 8 Amp for 30 sec (on/ off). Sonication was carried 
out on ice to avoid an increasing temperature from the sonication. Cell suspensions were 
centrifuged at 20,000 x g for 40 min to remove cell debris. Clear supernatant was collected and 
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loaded into a His-trap HP column (GE Healthcare) pre-equilibrated with 10 times (10X) 
column volumes (CV) of Lysis Buffer. The column was washed with Lysis Buffer (10X) 
followed by Wash Buffer (5X). Proteins were eluted with the Elution Buffer and fractions 
containing proteins were confirmed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). To cleave the His-tag from MATα2, eluted proteins were 
incubated with tobacco etch virus (TEV) protease in 100: 1 (protein, mg: TEV, mg) ratio by 
dialysis against Dialysis Buffer (2L) overnight at 4 oC, using a 10k cut off dialysis membrane 
(SnakeSkin™ Dialysis Tubing, Thermo Fisher Scientific). The cleavage of His tag was 
checked by Western Blot analysis (Fig. 2.1). 
Proteins were then centrifuged at 4000 x g for 30 min and clear supernatants were loaded into 
an anion-exchange chromatography column (HiTrap Q HP, GE Healthcare) pre-equilibrated 
with Buffer A (5X). Proteins were eluted by using isocratic gradient from 0.05 M to 1 M NaCl 
containing Buffer A. Selected fractions of proteins were then concentrated using a 30K cut-off 
centrifugal concentrator and loaded into a HiLoad 16/600 or a 10/300 Superdex 200 gel 
filtration column (GE healthcare) pre-equilibrated with 25 mM HEPES pH 7.5 (2X). Fractions 
containing proteins were pooled and stored in 500 mM NaCl, 0.5 mM TCEP (Tris(2-
carboxyethyl)phosphine) and 5 % glycerol. Proteins were flash frozen using liquid nitrogen 
and kept at -80 oC. MAT activity was measured in comparison of fresh, 1-day and 30-day 
frozen samples which were stored at -80 oC to confirm the activity intact after storage (Fig. 
2.2). 
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Table 2.2 The buffers used in the purification of MATα1, MATα2, MATβV1 and 
MATβV2 
Buffer Compositions 
Lysis Buffer 500 mM NaCl, 5 % (v/v) glycerol, 5 mM Imidazole and 10 mM β-ME 
(β-mercaptoethanol) 
Wash Buffer 500 mM NaCl, 5 % (v/v) glycerol, 30 mM Imidazole and 10 mM β-ME 
Elution Buffer 500 mM NaCl, 250 mM Imidazol and 10 mM β-ME 
Dialysis Buffer 25 mM HEPES pH 7.5, 50 mM NaCl and 10 mM β-ME 
Buffer A 25 mM HEPES pH 7.5, 25 mM NaCl and 5 mM β-ME 
 
 
Fig. 2.1 Western blot analysis of His-tag removal in MATα2. Anti His-tag antibody was 
used to detect His-tag removal of MATα2 after incubation with TEV protease overnight at 4 
oC.  
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Fig. 2.2 A measurement of the MATa2 activity from the fresh and frozen enzyme. MAT 
activity was measured in comparison of fresh, 1-day and 30-day frozen enzymes at -80 oC. 
2.8 Purification of MATβV1 and MATβV2 (pET_SUMO vector) 
The buffers used in the purification were shown in Table 2.2. Cell pellets were resuspended 
with ice-cold Lysis Buffer in 1:4 ratio. All tubes were placed on ice and PMSF was added at a 
final concentration of 1 mM. Cell suspensions were sonicated for 15 cycles at 8 Amp for 30 
sec and stopped 30 sec and cell suspensions were centrifuged at 20,000 x g for 40 min to 
remove cell debris. The clear supernatant was collected and loaded into a pre-equilibrated His-
trap HP column in Lysis Buffer (10X). The column was washed with Lysis Buffer (10X) 
followed by Wash Buffer (5X). Then, proteins were eluted with Elution Buffer and fractions 
containing proteins were pooled. To cleave a SUMO (small ubiquitin-like modifier) tag from 
MATβV1 and MATβV2, the proteins were incubated with Sentrin-specific protease 2 (SENP2) 
in 1500 (protein, mg):1 (SENP2, mg) ratio. The proteins were incubated at room temperature 
for 1 hour on an orbital shaker and then dialysed against 2L Dialysis Buffer at 4 oC overnight. 
The cleavage of the SUMO tag could be analysed by SDS-PAGE as the target protein had 
about 12 kDa lower molecular weight. The cleaved SUMO tag bands could be detected at about 
10 kDa of the standard marker (Fig 2.3). 
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Proteins were then centrifuged at 4000 x g for 30 min and loaded into an anion-exchange 
chromatography column pre-equilibrated with Buffer A (5X). Proteins were eluted by using 
isocratic gradient from 0.05 M to 1 M NaCl (the buffer containing Buffer A and NaCl). The 
selected fractions of proteins were then concentrated and loaded into a HiLoad 16/600 or a 
10/300 Superdex 75 gel filtration column (GE healthcare) pre-equilibrated with 25 mM HEPES 
pH 7.5 (2X). The fractions containing proteins were pooled and stored in 500 mM NaCl, 0.5 
mM TCEP and 5 % glycerol. Proteins were flash frozen by liquid nitrogen and stored at -80 
oC.  
 
Fig. 2.3 SDS-PAGE gel showing a removed SUMO-tag of MATb proteins. MATb 
proteins before and after SUMO-tag cleavage by SENP2 were analysed by SDS-PAGE. 
SUMO (small ubiquitin-like modifier); SENP2 (Sentrin-specific protease 2). 
2.9 Production of TEV protease 
Cell pellets were resuspended and sonicated in the same manner as described in MAT protein 
purification (section 2.7). Cell suspensions were centrifuged at 20,000 x g for 40 min to get rid 
of cell debris. The clear supernatant was loaded into a His-trap HP column pre-equilibrated 
with Lysis Buffer (10X). The column was washed with Wash Buffer (5X). Then, proteins were 
eluted with Elution Buffer. The eluted proteins were dialysed against Dialysis Buffer (2L) 
 59 
overnight at 4 oC. Proteins were then centrifuged at 4000 x g for 30 min and the collected 
supernatant was loaded into an anion-exchange chromatography column pre-equilibrated with 
Dialysis Buffer (5X). TEV protease was eluted in the flow-through and concentrated using a 
10K cut-off centrifugal concentrator. The samples were dialysed against Storage Buffer (1L) 
overnight. The proteins were flash frozen in liquid nitrogen and stored at -80 oC until use. The 
buffers used in the purification were modified from Alsarraf HM et al., 2011 [127] and shown 
in Table 2.3. 
Table 2.3. The buffers used for the purification of TEV protease 
Buffer Compositions 
Lysis Buffer  50 mM Tris–HCl pH 8, 400 mM NaCl, 20 mM imidazole, 5 mM β-ME 
and 1 mM PMSF 
Wash Buffer  50 mM Tris–HCl pH 8, 1 M NaCl, 50 mM imidazole, 5 mM β-ME and 1 
mM PMSF 
Elution Buffer  50 mM Tris–HCl pH 8, 400 mM NaCl, 500 mM imidazole and 5 mM β-
ME  
Dialysis Buffer 50 mM Tris–HCl pH 8 and 5 mM β-ME 
Storage Buffer 50 mM Tris–HCl pH 8, 5 mM β-ME and 50 % glycerol 
  
 60 
2.10 Production of SENP2 protease  
Cell pellets were resuspended and sonicated in the same manner as described in MAT protein 
purification (section 2.7). Cell suspension was centrifuged at 20,000 x g for 40 min and cell 
debris was discarded. Clear supernatant was collected and loaded into the His-trap HP column 
pre-equilibrated with Lysis Buffer (10X). The column was washed with Wash Buffer (5X). 
Then, proteins were eluted with Elution Buffer and fractions containing proteins were pooled. 
The eluted proteins were dialysed against Dialysis Buffer (2L) overnight at 4 oC. The proteins 
were then centrifuged at 4000 x g for 30 min and the collected supernatant was loaded into the 
anion-exchange chromatography column pre-equilibrated with Buffer A (5X). Proteins were 
eluted by using isocratic gradient from 0.05 M to 1 M NaCl (buffer containing Buffer A and 
NaCl). Eluted proteins were concentrated and stored in 10 % glycerol. SENP2 protease was 
flash frozen in liquid nitrogen and stored at -80 oC. The buffers used for the purification were 
indicated in Table 2.4. 
Table 2.4. The buffers used in the purification of SENP2 protease 
Buffer Compositions 
Lysis Buffer  20 mM Tris-HCl pH 8.0, 1 mM β-ME, 350 mM NaCl and 10 mM 
imidazole 
Wash Buffer  20 mM Tris-HCl pH 8.0, 350 mM NaCl, 1 mM β-ME and 20 mM 
imidazole 
Elution Buffer  20 mM Tris-HCl pH 8.0, 350 mM NaCl, 1 mM β-ME and 400 mM 
imidazole 
Dialysis Buffer 20 mM Tris-HCl pH 8.0, 100 mM NaCl and 1 mM β-ME 
Buffer A 20 mM Tris-HCl pH 8.0, 50 mM NaCl and 1 mM β-ME 
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2.11 Activity assay 
The enzyme activity assay was performed by following the procedure described in Murray B 
et al., 2014 [13]. SAMe synthetic activity was measured using methionine and ATP at final 
concentrations of 200 µM and 1 mM, respectively. The phosphatase activity of MAT enzymes 
was measured under various concentrations of ATP (0.1-4.0 mM) by detecting inorganic 
phosphate (Pi) production. Briefly, the reaction was prepared in a final volume of 100 µL. All 
enzymes (50 nM) were preincubated with 200 µM methionine in the reaction buffer (50 mM 
HEPES pH 7.5, 25 mM MgCl2 and 25 mM KCl) for 15 min. ATP was added to initiate the 
reactions and all mixtures were agitated at 1400 rpm using Titramax 100 (Heidolph 
Instruments) for 10 min at 37 °C. All enzymes and substrates were diluted in the dilution buffer 
containing 10 mM HEPES pH 7.5, 500 mM NaCl, 5 % glycerol and 0.5 mM TCEP. The 
reactions were stopped by adding 50 µL of 100 mM EDTA pH 8.0 before measuring SAMe 
and Pi production.  
2.12 SAMe formation detection 
SAMe formation was analysed by S-adenosylmethionine enzyme-linked immunosorbent assay 
(ELISA) kit (Cell biolabs) following the manufacturer’s protocol. Data are the mean of three 
independent experiments ± Standard Error of Mean (SEM). All experiments were performed 
using protein samples from the same batch of protein purification (different aliquots). 
Significance was assessed using a one-way analysis of variance (ANOVA), followed by 
Tukey–Kramer tests using GraphPad Prism version 5. P-values less than 0.05 were considered 
significant.  
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2.13 Phosphatase activity  
The detection of inorganic phosphates was modified from the protocol described by Baginski 
ES et al., 1967 [128]. 50 µL of samples were mixed with 150 µL of 2 % Ascorbic acid in 10 % 
trichloroacetic acid (A-TCA). 50 µL of ultrapure water (Milli-Q® Type 1 Ultrapure Water 
Systems) was added in each sample followed by addition of 75 µL of 2 % ammonium 
molybdate, and 150 µL of 2 % (w/v) Arsenite-citrate in 10 % TCA. All samples were mixed 
thoroughly (vortex) and incubated at room temperature for 20 min. Phosphate ions react with 
ammonium molybdate to produce a phospho-molybdenum blue complex, which can be 
measured by the absorbance at 750 nm using SpectraMax® Plus 384 Microplate Reader 
(Molecular Devices). Pi quantification was obtained by using the calibration curve of various 
standard KH2PO4 solutions (0.125-2.0 µg/ mL). Pi standard curve is shown in Fig. 2.4. 
 
Fig. 2.4 Standard curve of Pi measurement. All reactions of enzyme assays were measured 
by the absorbance at 750 nm. The Pi quantification of an unknown sample was obtained by 
using the calibration curve of various standard KH2PO4 solutions (0.125-2.0 µL/ mL). 
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2.14 Quinolone-based compounds 
All quinolone-based compounds were kindly provided by Prof. Paul M. O’Neill (Department 
of Chemistry, School of Physical Sciences, University of Liverpool, UK). The synthesis of 
quinolone-based compounds has been described by Charoensutthivarakul S et al., 2015 [129]. 
Structures of the compounds are shown in Fig. 2.5. Stock solutions were made in DMSO 
(Dimethyl sulfoxide) before being diluted to a final concentration using dilution buffer 
containing 10 mM HEPES pH 7.5, 500 mM NaCl, 5 % glycerol and 0.5 mM TCEP. 
2.15 Differential scanning fluorimetry (DSF) 
All samples were prepared in a Fast Optical 96-well reaction plate (Life Technologies) using a 
StepOnePlusTM Real-Time PCR instrument (Applied Biosystems). Each well (20 μL) 
contained 10 µL of 0.5 mg/mL proteins and 10 µL of SYPROTM Orange protein gel stain (Life 
Technologies) at a final concentration of 10X. For the quinolone-based compound study, the 
protein was incubated with or without the compound. All enzyme and compounds were diluted 
in 10 mM HEPES pH 7.5 buffer containing 500 mM NaCl, 5 glycerol and 0.5 mM TCEP and 
the final concentration of DMSO in the protein sample was less than 1 %. Fluorescence 
intensities were measured from 25 °C to 99 °C with a ramp rate of 1° C/min. Data were 
analysed using MATLAB® executable TmToolTM following TmToolTM Quick Set-Up Guide 
(Life technologies). Data are represented as the mean of Tm (melting temperature) of three 
independent experiments using protein samples from the same batch of protein purification ± 
SEM.  
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Fig. 2.5 Quinolone-based compounds used in this study. The synthesis of quinolone-based 
compounds has been described in reference [129]. 
2.16 Complex formation of MATa1/a2 and MATb  
The complex formation was performed using the protocol described by Murray B et al., 2014 
[13]. Briefly, MATα1/2 was incubated with MATβV1 or MATβV2 at 1:2 ratio for 1 h, at 4 °C 
in the buffer containing 50 mM HEPES pH 7.5, 10 mM MgCl2 and 50 mM KCl. The complex 
was then loaded into a Superdex 200 10/300 column and eluted with 25 mM HEPES pH 7.5 
buffer containing 200 mM NaCl, 1 mM MgCl2, 5 mM KCl and 1 mM TCEP. The complex 
formation was confirmed by SDS and Native-PAGE analysis. 
2.17 SDS-PAGE analysis 
SDS-PAGE analysis for protein purity determination was performed using 12 % (w/v) 
acrylamide gels. Samples were mixed with loading buffer (4X) containing 100 mM Tris-Cl pH 
6.8, 4 % (w/v) SDS, 0.2 % (w/v) bromophenol blue, 20 % (v/v) glycerol and 200 mM DTT 
(Dithiothreitol) in 1:4 ratio. All samples were heated in an aluminium heating block at 90 °C 
for 5 min. PageRuler™ Plus Prestained Protein Ladder (Thermo Fisher Scientific) was used as 
the molecular weight markers (10 to 250 kDa). Electrophoresis was carried out using fixed 
 65 
voltage (200 Volt) in running buffer (0.025 M Tris, 0.192 M glycine and 0.1 % (w/v) SDS, pH 
8.5) for 50 min using a Mini Gel Tank (Thermo Fisher Scientific) and a power supply apparatus 
from Biorad. The gel was stained in Coomassie brilliant blue solution (see section 2.19). 
2.18 Native-PAGE analysis 
Native-PAGE analysis for complex assessment was carried out using 8 % (w/v) acrylamide 
gels. The gels and electrophoresis solutions were prepared without SDS and a reducing agent 
(DTT). Samples were mixed with loading buffer (4X, 100 mM Tris-Cl pH 6.8, 0.2 % (w/v) 
bromophenol blue and 20 % (v/v) glycerol). All samples were prepared on ice and loaded 
immediately onto acrylamide gel. NativeMark™ Unstained Protein Standard (Thermo Fisher 
Scientific) was used as the molecular weight markers (20 to 1200 kDa). Electrophoresis was 
carried out at 200 Volt in running buffer (0.025 M Tris and 0.192 M glycine pH 8.5) for 45 
min using a Mini Gel Tank and a power supply apparatus from Biorad. The gel was stained in 
Coomassie brilliant blue solution (see section 2.19). 
2.19 Protein gel staining 
Gels were stained for 30 min in staining solution containing 0.1 % (w/v) Coomassie Brilliant 
Blue R-250, 40 % (v/v) methanol and 10 % (v/v) glacial acetic acid. De-staining solution (40 
% (v/v) methanol and 10 % (v/v) glacial acid) was used to visualise protein bands. Stained gels 
were incubated with de-staining solution until the background colour faded out and protein 
bands were clearly visible. 
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2.20 Size exclusion chromatography-small-angle X-ray scattering (SEC-SAXS) 
SEC-SAXS experiments were carried out at beam-line SWING at Synchrotron SOLEIL using 
a1.79 sample detector distance and 12 keV incident beam energy. An Agilent BioSEC Advance 
300Å, 4.6 x 300 mm column equilibrated with 25 mM HEPES pH 7.5 and used for size 
exclusion chromatography instantly prior to exposure to X-rays. 20 µL of protein at 10 mg/mL 
was loaded into an Agilent 1200 High Performance Liquid Chromatography (HPLC) system 
at a flow rate of 0.3 mL/min and column temperature of 15 oC. Exposures were collected prior 
to the column void volume, for the purposes of buffer scattering subtraction, and over the 
course of protein elution. Exposures were 1 sec interspersed with 0.5 sec dead-time. Frames 
were inspected and averaged in Foxtrot [130] and analysed in with Primus [131]. 
The scattering data obtained by SEC-SAXS were analysed using FoXS Server [132] in which 
the scattering profile of the input crystallographic structure could be calculated and fitted onto 
the experimental data. 
2.21 Crystallisation and data collection 
All purified MAT proteins were stored at -80 οC in storage buffer containing 500 mM NaCl, 5 
% glycerol and 0.5 mM TCEP. Prior to crystallisation, aliquots containing stored proteins were 
quickly thawed using cold tap water and were immediately kept on ice. MATα2 proteins and 
their variants were then concentrated to 5.8 mg/mL and pre-equilibrated with substrates (10 
mM Met and 150 µM AMP-PNP) in 50 mM HEPES buffer pH 7.5 containing 10 mM MgCl2, 
50 mM KCl and 10 mM DTT before crystallisation. Crystal drops containing 1 µL of the 
protein and 1 µL of the precipitation agent (100 mM HEPES pH 6.5 and 30 % PEG 600) were 
equilibrated against a reservoir solution (100 mM HEPES pH 6.5 and 30 % PEG 600). Crystals 
appeared at 25 οC within 1-2 days. Prior to data collection, crystals were soaked in reservoir 
solution with additional 20 % ethylene glycol and were flash frozen in liquid nitrogen. Different 
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crystallographic datasets were collected at the I24, I03 and I04-1 beamlines at Diamond Light 
Source (Oxford, England) and the PROXIMA-1 beamline at SOLEIL synchrotron (Saint-
Aubin, France). 
The MATa1 (R264H) mutant protein was concentrated to 5 mg/mL and pre-equilibrated with 
substrates (10 mM Met and 150 µM AMP-PNP) in 50 mM HEPES buffer pH 7.5 containing 
10 mM MgCl2, 50 mM KCl and 10 mM DTT before crystallisation. Wild-type protein 
(MATa1) was concentrated to 5 mg/mL in 50 mM HEPES buffer pH 7.5 containing 10 mM 
MgCl2, 50 mM KCl and 10 mM DTT before crystallisation to produce crystals of apo forms. 
Crystal drops containing 1 µL of the protein and 1 µL of the precipitation agent (200 mM NaF, 
20 % PEG 3350 and 15 % ethylene glycol) were equilibrated against a reservoir solution (200 
mM NaF, 20 % PEG 3350 and 15 % ethylene glycol). Crystals appeared at room temperature 
within 3-7 days. Prior to data collection, crystals were soaked and frozen in the same manner 
to MATa2 proteins. Different datasets were collected at the I03 (R264H crystals) and I04 
(wild-type crystals) beamlines at Diamond Light Source (Oxford, England).  
Data were integrated by iMosflm [133] and scaled using Aimless [134]. The crystal structures 
were solved by MOLREP [135] using human MATα1 (PDB: 2OBV) and MATα2 (PDB: 5A1I) 
as search models. The model building and restrained refinement were carried out using Coot 
[136] and REFMAC [137]. Crystallographic data collection and refinement statistics are given 
in Table 3.4.3a, 3.4.3b (Chapter III, section 3.4.2) and Table 4.4 (Chapter IV, section 4.4.2). 
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2.22 Molecular docking 
Autodock Vina [138] and SwissDock  [139] were used to perform a local and blind docking, 
respectively. Ligand binding modes by the local docking were determined in the defined box, 
while the binding modes generated by the blind docking were performed in the vicinity of all 
target cavities. SCR0911 and SCR0915 molecules in Tripos Mol2 File Format (.mol2) were 
created using a Marvinsketch tool (https://chemaxon.com/products/marvin). The ligand-free 
crystal structures of wtMATα2 (PDB: 5A1I) and MATα2 (R264A) mutant (PDB: 6FCD) were 
generated by the UCSF Chimera suite [140]and used as the target protein models. 
For Autodock Vina docking, the docking box was defined (box centre: x,y,z = -2.43, 11.29, -
29.28 Å: box size: x,y,z = 29.08, 67.52, 59.57 Å) and used for both wtMATα2 and MATα2 
(R264A) mutant docking. Ligand binding modes were predicted in the determined box with a 
number of all possible clusters. The most favourable energy binding site was selected based on 
its binding energy (∆Gbinding: kcal/mol).  
For Swissdock docking, the target model in a PDB file format and a compound in .mol2 format 
were uploaded on web browser interface (http://www.swissdock.ch/docking). A number of 
ligands binding modes were predicted in the vicinity of all target cavities. After docking 
process termination, all predicted binding clusters were available to download on the server. 
The results could be visualised by the Viewdock tool in UCSF Chimera. The best binding pose 
was chosen by the lowest Gibbs free energy (∆G) and FullFitness scores. 
The best binding poses of SCR0911 or SCR0915 were selected and combined with the protein 
model. A protein-ligand complex structure in PDB file format was written by using the UCSF 
Chimera tool. The protein-ligand interaction profiles were determined and visualised by DS 
visualiser (Dassault Systèmes BIOVIA, Discovery Studio Modelling Environment, Release 
2017, San Diego: Dassault Systèmes, 2016). 
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2.23 Western blot  
Samples were loaded onto a 12 % polyacrylamide gel and electrophoretically transferred to a 
polyvinylidene difluoride (PVDF) membrane. The membrane was blocked with 5 % non-fat 
dry milk in Tris-buffered saline containing 0.1 % Tween-20 for 1 h and then incubated 
overnight at 4 °C with mouse anti-His-tag (ab18184, Abcam) in 1:5,000 dilution. The 
membrane was then incubated with a horseradish-conjugated anti-mouse IgG (1:10,000) for 2 
h at room temperature and was visualised by enhanced chemiluminescence using ECL reagents 
(GE Healthcare). The protein bands were assessed by automated gel imaging system (Biorad).  
2.24 MAT sequence analysis 
A multiple sequence alignment analysis of the human MATa1 protein was performed by using 
2,963 sequences of MAT protein family by GREMLIN Co-evolution Analysis [141]. A 
sequence conservation analysis was generated by using WebLogo 3 [142]. 
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Chapter III 
A structural and functional analysis of the gating loop in human MAT enzymes 
The results of this chapter were largely derived from the published paper which I mainly wrote 
the manuscript, performed experiments, analysed data and deposited all reported structures to 
the PDB server. 
The apo wtMATa2 crystal was crystallised by J. Bradley-Clarke and this structure was 
processed and refined by me (PDB: 6FAJ). Prof. J.M. Mato reviewed the manuscript. Prof. 
P.M. O’Neill provided the quinolone compounds. Dr. S.V. Antonyuk and Prof. S.S. Hasnain 
conceptualised the study and supervised the project for J. Bradley-Clarke and me.   
Paper detail: 
“Panmanee, J., J. Bradley-Clarke, J. M. Mato, P. M. O'Neill, S. V. Antonyuk and S. S. Hasnain 
(2019). "Control and regulation of S-Adenosylmethionine biosynthesis by the regulatory beta 
subunit and quinolone-based compounds." FEBS J 286(11): 2135-2154” 
3.1 Background and objective 
The crystallographic structures of MAT enzymes suggest that the gating loop (residue 113-
131) is required for substrate entry and product release [13, 30, 36]. It is a flexible polypeptide 
loop located near the active site. When the active sites of MATα1 and MATα2 are occupied by 
SAMe, the gating loop is shut (well-ordered) [30, 43]. A recent study has found that the gating 
loop is opened (disordered) when PPNP is bound in the active site, indicating that the opening 
of the gating loop is not driven by the breakdown of the tripolyphosphate (PPNP). In addition, 
only few interactions between residues of the gating loop (Gln113 and Ser114) and SAMe were 
reported. The mechanism that opens up the gating loop and releases SAMe remains unclear 
despite a number of high-resolution structures of the enzyme in different ligated forms. 
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Mutation of the E. coli gating loop showed the decrease in SAMe formation more than two 
hundred-fold compared with the wild type, while these mutations had only little effect on the 
hydrolysis rate of the tripolyphosphate [143]. 
Previously, the study of the wild-type MATa2 was found that Gln113 is the only residue of 
the gating loop that interacts with SAMe directly through its NE2 atom by forming a hydrogen 
bond with the O atom of SAMe, while Ser114 indirectly interacts with SAMe via a water 
molecule (Fig. 3.1.1). MAT gating loop sequences are quite variable among species, whereas 
these two amino acids are conserved in all species from bacteria to mammals (Fig. 3.1.2). 
Therefore, both of these residues (Gln113 and Ser114) as well as their neighbouring residue 
(Pro115) were further investigated by site-directed mutagenesis, activity assay and 
crystallographic study with a variety of ligands.  
 
Fig. 3.1.1 Interactions between the gating loop and the substrate (Met+ADO)/ product 
(SAMe). Gln113 and Ser114 are highlighted in green boxes. Two MATα2 subunits forming a 
dimer represented by different colours (blue and slate). Carbon, nitrogen and oxygen atoms of 
substrates are coloured in orange, blue and red, respectively. H-bonds are shown in black dots 
and water oxygens are shown in red spheres. The figure was depicted from the reported MATα2 
structure at 1.09 Å (PDB: 5A1I) [30]. 
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Fig. 3.1.2 Sequence alignment of E. coli, human MATa2 and rat MATa1 enzyme. An 
amino acid residue is numbered according to the human MAT. The gating loop amino acid 
sequences are indicated in blue boxes (residues 113-131). The first five residues are conserved 
from E. coli to mammal (rat and human). The conserved residues of the gating loop are 
highlighted in blue colour. An asterisk (*) indicates fully conserved residues. A colon (:) shows 
residues that are conserved between groups and share similar properties. A period (.) period 
shows amino acid conservation between groups of weakly similar properties. 
3.2 Production of MATα2 and its mutants: Gln113Ala, Ser114Ala and Pro115Gly 
The mutants produced by site-directed mutagenesis were confirmed by DNA sequencing (Fig. 
3.2.1) and full DNA sequence results obtained from DNA sequencing for each mutant are 
shown in Table 3.2. The suitable annealing temperature for mutant generation was at 55-60 oC. 
All mutant plasmids were transformed into E. coli cells, BL21 (DE3), for protein expression 
and purification. The wild-type and mutant proteins were purified in the same manner using 
three different chromatography columns (section 2.7, chapter 2), including immobilised metal 
affinity chromatography (IMAC), anion exchange chromatography and size-exclusion 
chromatography. As all proteins were histidine-tagged, purification by IMAC was the obvious 
choice for crude purification. For the second step the anion exchange chromatography, a Q-
column was used. Due to the negative charges of MATα2 (pI 6.0) in the buffer solution of pH 
7.5, NaCl gradient (0.05-1.0 M) was applied for the second purification step. MATα2 was 
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eluted with 0.05-0.4 M NaCl. The last step of purification, size-exclusion chromatography was 
used for separating protein oligomeric forms. 
Each step of purification was checked by SDS-PAGE and estimated molecular weight of 
MATα2 subunit is about 45 kDa. Protein purity of all mutants was assessed by SDS-PAGE gel 
staining (Fig. 3.2.2-3.2.5). The high purity was observed after proteins had been purified by 
anion-exchange chromatography. The major problem of mutant production was the protein 
precipitation during the dialysis and the concentrating procedure which caused a reduction in 
protein yield. Any aggregated protein was removed by centrifugation and soluble aggregates 
were separated in the final step of purification, gel filtration chromatography. The soluble 
aggregated protein was eluted firstly at the void volume of the gel filtration column and was 
discarded. Protein yields of MATα2 and its mutants ranged from 2-5 mg/L. This amount was 
sufficient to grow protein crystals and for other related experiments. The purity of the proteins 
was high enough to produce good quality protein crystals. 
 
Fig. 3.2.1 The alignment of wild-type and mutant DNA sequences. DNA sequences of 
MATa2 mutants (Gln113Ala, Ser114Ala and Pro115Gly) were aligned to the wild-type DNA 
using SnapGene. Gln (CAG) and Ser (TCA) were mutated to Ala (GCG and GCA, 
respectively). Pro (CCA) was mutated to Gly (GGA). 
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Table 3.2 DNA sequencing results for Gln113Ala, Ser114Ala and Pro115Gly mutants 
Mutant Sequences 
Gln113Ala 
(MAT2A) 
CATGAACGGACAGCTCAACGGCTTCCATGAGGCGTTCATCGAGG
AGGGCACATTCCTTTTCACCTCAGAGTCGGTCGGGGAAGGCCACC
CAGATAAGATTTGTGACCAAATCAGTGATGCTGTCCTTGATGCCC
ACCTTCAGCAGGATCCTGATGCCAAAGTAGCTTGTGAAACTGTTG
CTAAAACTGGAATGATCCTTCTTGCTGGGGAAATTACATCCAGAG
CTGCTGTTGACTACCAGAAAGTGGTTCGTGAAGCTGTTAAACACA
TTGGATATGATGATTCTTCCAAAGGTTTTGACTACAAGACTTGTA
ACGTGCTGGTAGCCTTGGAGCAAGCGTCACCAGATATTGCTCACT
GGTAGCCTTGGAGCAAGCGTCACCAGATATTGCTCACTGGTAGCC
TTGGAGCAAGCGTCACCAGATATTGCTCCTGGTAGCCTTGGAGCA
AGCGCCACCAGATATTGCTCAAGGTGTTCATCTTGACAGAAATGA
AGAAGACATTGGTGCTGGAGACCAGGGCTTAATGTTTGGCTATGC
CACTGATGAAACTGAGGAGTGTATGCCTTTAACCATTGTCTTGGC
ACACAAGCTAAATGCCAAACTGGCAGAACTACGCCGTAATGGCA
CTTTGCCTTGGTTACGCCCTGATTCTAAAACTCAAGTTACTGTGCA
GTATATGCAGGATCGAGGTGCTGTGCTTCCCATCAGAGTCCACAC
AATTGTTATATCTGTTCAGCATGATGAAGAGGTTTGTCTTGATgAA
ATGAGGGATGCCCTAAnGGAGAAnGTCATCAAAGCAGTTGTGCCT
GCgAAaTAccTTGATGAGGATaCAATctaCCACCTACAGCCAAGTGG
CAGATttgttaTTGgtGGgCCTCAaGgTGATGCTggtttgActg 
Ser114Ala 
(MAT2A) 
CATGAACGGACAGCTCAACGGCTTCCATGAGGCGTTCATCGAGG
AGGGCACATTCCTTTTCACCTCAGAGTCGGTCGGGGAAGGCCACC
CAGATAAGATTTGTGACCAAATCAGTGATGCTGTCCTTGATGCCC
ACCTTCAGCAGGATCCTGATGCCAAAGTAGCTTGTGAAACTGTTG
CTAAAACTGGAATGATCCTTCTTGCTGGGGAAATTACATCCAGAG
CTGCTGTTGACTACCAGAAAGTGGTTCGTGAAGCTGTTAAACACA
TTGGATATGATGATTCTTCCAAAGGTTTTGACTACAAGACTTGTA
ACGTGCTGGTAGCCTTGGAGCAACAGGCACCAGATATTGCTCAA
GGTGTTCATCTTGACAGAAATGAAGAAGACATTGGTGCTGGAGA
CCAGGGCTTAATGTTTGGCTATGCCACTGATGAAACTGAGGAGTG
TATGCCTTTAACCATTGTCTTGGCACACAAGCTAAATGCCAAACT
GGCAGAACTACGCCGTAATGGCACTTTGCCTTGGTTACGCCCTGA
TTCTAAAACTCAAGTTACTGTGCAGTATATGCAGGATCGAGGTGC
TGTGCTTCCCATCAGAGTCCACACAATTGTTATATCTGTTCAGCAT
GATGAAGAGGTTTGTCTTGATGAAATGAGGGATGCCCTAAnGGA
GAAAGTCATCAAAGCAGTTGTGCCTGCGAAATACCTTGATGAGG
ATACAATCTACCACCTACAGCCAAGTGGCAGATTTGTTATTGGTG
GGCCTCAGGGTGATGCTGGTTTGACTGGACGCAAAATCATTGTGG
ACACTTATGGCGGTTGGGgTGCTCATGGaggAGGTGCCTTTTCAGG
AAAGGATTATACCAAGGTCGACCGTTCAGCTGCTTATGCTGCTCG
TTGGGTGGCAAAATCCCTTGTTAAaGGaggTCTGTGCCGGaaGgTTC
TTgttCAGGTCtCTTATGctATTGgaaTtnctcATCCATTATCTATcnCcATT
TtCCATTnngnnnCctcTCanaaga 
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Mutants Sequences 
Pro115Gly 
(MAT2A) 
CATGAACGGACAGCTCAACGGCTTCCATGAGGCGTTCATCGAG
GAGGGCACATTCCTTTTCACCTCagagTCGGTCGGGGAAGGCCAC
CCAGATAAGATTTGTGACCAAATCAGTGATGCTGTCCTTGATGC
CCACCTTCAGCAGGATCCTGATGCCAAAGTAGCTTGTGAAACTG
TTGCTAAAACTGGAATGATCCTTCTTGCTGGGGAAATTACATCC
AGAGCTGCTGTTGACTACCAGAAAGTGGTTCGTGAAGCTGTTAA
ACACATTGGATATGATGATTCTTCCAAAGGTTTTGACTACAAGA
CTTGTAACGTGCTGGTAGCCTTGGAGCAACAGTCAGGAGATATT
GCTCAAGGTGTTCATCTTGACAGAAATGAAGAAGACATTGGTGC
TGGAGACCAGGGCTTAATGTTTGGCTATGCCACTGATGAAACTG
AGGAGTGTATGCCTTTAACCATTGTCTTGGCACACAAGCTAAAT
GCCAAACTGGCAGAACTACGCCGTAATGGCACTTTGCCTTGGTT
ACGCCCTGATTCTAAAACTCAAGTTACTGTGCAGTATATGCAGG
ATCGAGGTGCTGTGCTTCCcATCAGAGTCCACACAATTGTTATAT
CTGTTCAGCATGATGAAGAGGTTTGTCTTGATGAAnTGAGGGAT
GCCCTAAAGGAnAanGTCATCAAAGCAGTTGTGCCTGcgAanTACC
TTGATGAGGATACAATCTACCACCTACAGCcAAGTGGCAGaTTtG
TTATTGGTGGGCCTCagntnGATGC 
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Fig. 3.2.2 wtMATα2 purification. (A) SDS-PAGE of the wtMATα2 protein from the Ni-
affinity purification is shown (lane 1 = flow-through; lane 2 = Wash buffer; lane 3-6 = Elution 
fractions from the Ni-affinity column). The eluted fraction containing proteins was collected 
and loaded into the Q column (lane 7 = flow-through; 8 = Elution of 0.05 M NaCl; 9 = Elution 
of 0.2 M NaCl; 10 = Elution of 0.4 M NaCl; 11 = Elution of 0.6 M NaCl; 12 = Elution of 0.8 
M NaCl; 13 = Elution of 1.0 M NaCl). The fractions containing proteins were pooled and 
followed by size-exclusion chromatography. (B) The size-exclusion chromatography profile is 
shown by the absorbance at 280 nm (indicating a protein peak). The first peak is protein 
aggregation, and the second peak is the protein in a tetrameric state (65.0-70.0 mL). The third 
peak is a dimeric form of wtMATα2 (72.5-82.8 mL). The SDS-PAGE of the fractions 
containing the tetrameric wtMATα2 eluted at 65.0- 70.0 mL is shown. 
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Fig. 3.2.3 MATα2 Gln113Ala mutant purification. (A) SDS-PAGE of the Gln113Ala 
protein from the Ni-affinity purification is shown (lane 1-4 = Pre-induction; 5-6 = Post-
induction; 7 = flow-through; 8 = Wash buffer; 9-12 = Elution fraction 1-4). (B) SDS-PAGE of 
the proteins from the anion-exchange purification is exhibited (lane 1 = protein sample; 2 = 
flow-through; 3 = Elution of 0.05 M NaCl; 4 = Elution of 0.2 M NaCl; 5 = Elution of 0.4 M 
NaCl; 6 = Elution of 0.6 M NaCl; 7 = Elution of 0.8 M NaCl; 8 = Elution of 1.0 M NaCl). (C) 
The size-exclusion chromatography profile is shown by the absorbance at 280 nm. The main 
peak indicated that the majority of protein was eluted at 70.0-80.5 mL. The SDS-PAGE of the 
fractions eluted at 40.5-80.5 mL is shown. The mutant crystals were obtained from the pooled 
fractions of 70.5-80.5 mL fractions. 
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Fig. 3.2.4 MATα2 Ser114Ala mutant purification. (A) SDS-PAGE of the Ser114Ala protein 
from the Ni-affinity purification is shown (lane 1, 2 = Pre-induction; 3 = lysate of protein 
sample; 4 = flow-through; 5 = Wash buffer; 6-11 = Elution fraction 1-6). (B) SDS-PAGE of 
the protein from the anion-exchange purification is exhibited (lane 1 = flow-through; 2 = 
Elution of 0.05 M NaCl; 3 = Elution of 0.2 M NaCl; 4 = Elution of 0.4 M NaCl; 5 = Elution of 
0.6 M NaCl; 6 = Elution of 0.8 M NaCl; 7 = Elution of 1.0 M NaCl). (C) The size-exclusion 
chromatography profile is shown by the absorbance at 280 nm. The first peak indicated the 
protein aggregation and the second peak was eluted at 70.0-80.5 mL fractions. The SDS-PAGE 
of fractions containing Ser114Ala is shown. The mutant crystals were obtained from the pooled 
fractions of 70.0-85.0 mL fractions.  
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Fig. 3.2.5 MATα2 Pro115Gly mutant purification. SDS-PAGE of the Pro115Gly protein 
from Ni-affinity purification is shown (lane 1-4 = Elution fraction 1-4). (B) SDS-PAGE of the 
protein from the anion-exchange purification is shown (lane 1 = flow-through; 2 = Elution of 
0.05 M NaCl; 3 = Elution of 0.2 M NaCl; 4 = Elution of 0.4 M NaCl; 5 = Elution of 0.6 M 
NaCl; 6 = Elution of 0.8 M NaCl; 7 = Elution of 1.0 M NaCl). (C) The size-exclusion 
chromatography profile is shown by the absorbance at 280 nm. The first peak indicated the 
protein aggregation and the second peak was eluted at 11.5-12.5 mL. The SDS-PAGE of 
fractions containing Pro115Gly is displayed. The crystals were obtained from the pooled 
fractions containing proteins (11.5-12.5 mL). 
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3.3 Production of MATβV1 and MATβV2 
MATβV1 and MATβV2 variants were purified using Ni-affinity, anion exchange and gel 
filtration chromatography (section 2.8, chapter 2). MATβ has an estimated isoelectric point 
(pI) around 6.9, while the pH of the buffer solution is 7.5. At pH 7.5, MATβ proteins containing 
negative charges bound to a positively charged anion exchange resin and could be eluted by 
0.05-0.4 M NaCl gradient. At lower ionic strength, proteins with pI values closer to 7.5 are 
eluted before proteins with lower pI. Size-exclusion chromatography using a gel filtration 
column was used as a polishing step in purification. The SUMO tag was cleaved from MATβ 
proteins using SENP2 protease and the tag could be removed from the protein sample by size-
exclusion chromatography. SDS-PAGE analysis was performed for each step of purification 
to check protein purity (Fig. 3.3.1-3.3.2). No protein aggregation was observed in MATβ 
purification as shown by the gel filtration profiles. Protein yield was about 3-5 mg/L for each 
batch of purification.  
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Fig. 3.3.1 MATβV1 purification. (A) SDS-PAGE of MATβV1 proteins from Ni-affinity 
purification is displayed (1 = Pre-induction; 2= Sample; 3 = Flow-through; 4 = lysis buffer, 5 
= wash buffer, 6-10 = Elution 1-6). (B) SDS-PAGE of the protein from anion-exchange 
purification with 0.05-0.8 M NaCl gradient is shown. (C) The gel filtration profile is shown by 
the absorbance at 280 nm. The main peak indicated that the majority of protein was eluted at 
11.0-12.0 mL. (D) SDS-PAGE of fractions containing MATβV1 is exhibited. 
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Fig. 3.3.2 MATβV2 purification. (A) SDS-PAGE of MATβV2 proteins from Ni-affinity 
purification is shown (1 = Pre-induction; 2 = Flow-through; 3 = lysis buffer, 4 = wash buffer, 
5-9 = Elution 1-5). (B) SDS-PAGE of the protein from anion-exchange purification with 0.05-
0.8 M NaCl gradient is displayed. (C) The gel filtration profile is shown by the absorbance at 
280 nm. The main peak was eluted at 47.5-57.5 mL. (D) SDS-PAGE of fractions containing 
MATβV2 is shown at 47.5-57.5 mL.   
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3.4 A structural and functional analysis of the gating loop’s role in human MAT 
enzymes 
3.4.1 The enzymatic and phosphatase activity of MATa2 
The functional significance of the active site gating loop was explored using various mutants 
of the human MATα2. The mutants were designed based on the well-characterised residues of 
the gating loop that showed to interact with SAMe. The conserved residues (Gln113, Ser114 
and Pro115) of the gating loop were mutated to Gln113Ala, Ser114Ala and Pro115Gly by site 
directed mutagenesis. Proline (Pro115) is the only amino acid that connects its side chain to 
backbone, therefore it is mutated to Gly which has no side chain at all. Glutamine (Gln113) 
and serine (Ser114) contain polar side chains (amide group (-NH2) of Gln and hydroxyl group 
(-OH) of Ser) that were reported to interact with Met and SAMe [30]. Thus, these two amino 
acids (Gln and Ser) are mutated to alanine (Ala) that contains only the nonpolar -CH3 group to 
investigate the functional role of their side chains.  
A recent study has shown that Gln113 and Ser114 residues interact with both Met and SAMe 
in the active site of the enzyme on its own and when it complexes with MATb subunits [13, 
30]. Gln113Ala mutation results in a decrease in SAMe production to 75.6 ± 4.5 %, while 
Ser114Ala mutation shows only 2.5 ± 0.8 % (p < 0.05) of SAMe formation when compared to 
wtMATα2 (Fig. 3.4.1A). In contrast, Pro115Gly mutation has no effect on enzymatic activity 
(Fig. 3.4.1A). Remarkably, the SAMe production is recovered in Gln113Ala and Ser114Ala 
mutants when they complex with either MATbV1 or MATbV2 to the extent that the production 
of SAMe by Gln113Ala/Ser114Ala MATα2:MATb complexes is the same as for the 
wtMATα2:MATb complex (Fig. 3.4.1A). The concentrations of substrates used for measuring 
SAMe formation (200 µM Met and 1 mM ATP) were likely to be insufficient to allow 
Ser114Ala mutant’s activity reaching its Vmax without forming complexes with the regulatory 
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subunits (MATbV1/V2). This indicates a reduction in enzyme-substrate affinity leading to the 
decrease in SAMe formation of the mutant.  
Surprisingly, none of the mutants show any change in the phosphatase activity compared to the 
wtMATα2 (Fig. 3.4.1B), suggesting that structural elements which involve in SAMe formation 
are different from those responsible for PPPi hydrolysis. ATPase activity of MAT enzymes 
was suggested to be independent from SAMe synthesis [49, 53]. The ADP-bound MATα1 
crystal structure was derived from the co-crystallisation of ATP and methionine analogue 
(LcisAMB) confirming that the hydrolysis of ATP could take place without SAMe formation 
[35]. Complexation with MATbV1 generally results in higher activity than when wtMATα2 or 
its mutants complex with MATbV2. These observations suggest that MATb binding has a 
profound effect on MAT enzymes where the length of the MATb protein has a significant 
impact on MATα2 activity (Fig. 3.4.1A) [13]. 
There is limited published work concerning the phosphatase activity of MAT enzymes. The 
findings in the current study are consistent with the two reported studies which had shown that 
MAT activity decreased in the mutants associated with the gating loop or the active site 
mutations, while the phosphatase activity was unaffected. The first study in E. coli MAT 
showed that kcat of SAMe formation decreased by more than two hundred fold caused by 
mutations at the enzyme’s gating loop without effecting the PPPi hydrolysis rate [143]. This 
study suggested that the mutations caused the unorganised active site and decreased the 
enzymes’ ability to catalyse SAMe formation, while the hydrolysis of the tripolyphosphate 
took place in different parts of the protein and is less affected by these mutations. A study of 
MATα1 variants (18 mutations) identified in patients with persistent hypermethioninemia 
[144] found that seven of these variants (Arg249Trp, Ile252Thr, Gly257Arg, Asp258Gly, 
Ala259Val, Lys289Asn, and Gly381Arg) showed a reduction in MAT activity (SAMe 
formation), while their phosphatase activity was unaffected. The structural study of MATα2 
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by Murray B et al., 2016 [30] provided structural elements to explain a loss of activity for these 
reported mutants based on their residues’ roles. Arg249 is found to stabilise the binding of 
adenosine to the active site prior to SAMe formation, while Asp258 and Ala259 are observed 
to coordinate with the K+ ion. In addition, Asp258 also interacts with substrate methionine and 
is involved in SAMe formation. Taken together, it is likely that the phosphatase activity is 
independent to SAMe formation and the gating loop has an important role in SAMe production 
which does not affect the PPPi hydrolysis rate upon its mutations.  
 
Fig. 3.4.1 The enzymatic activity of wild-type and mutant MATα2 (A) SAMe formation of 
wtMATα2 and complexes compared to its mutants. (B) Phosphatase activity of the wild-type 
enzyme and the complexes compared to the mutants. ‘*’ ‘**’ and ‘***’ denote statistical 
significance at p < 0.05, p < 0.1 and p <0.001 compared with wtMATα2, respectively. ‘###’ 
and ‘&&&’ indicate statistical significance at p < 0.001 compared to Q113A and S114A 
mutants, respectively. Data are the mean of three independent experiments ± SEM (n =3). All 
experiments were performed using protein samples from the same batch of protein purification 
(different tubes). 
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MATβ subunits interact with the active site residues that recognise the PPPi of the catalytic 
subunits [13] via the helical loop (Fig. 3.4.2A). The complex structure of MATαβ shows that 
His323 (NE2 atom) of MATβV2 interacts with Gly273 (O atom) which constitutes the 
tripolyphosphate recognition loop (Arg264-Gly273) of MATα2, where the NE atom of Arg264 
(MATα2) interacts with the O1G and O3G atom of PPNP (Fig. 3.4.2A). The current study has 
found that the phosphatase activity of MAT complexes is significantly higher than that of the 
catalytic subunit alone (Fig. 3.4.2B). The Vmax and Km values of MATα2, MATα2βV1and 
MATα2βV2 are reported in Table 3.4.1. 
Triphosphate is an intermediate generated during ATP cleavage when SAMe is formed. It 
needs to be hydrolysed to PPi and Pi before being released from the active site. The PPPi 
hydrolysis allows enzymes for proceeding to the next reaction cycle. The activity of the mutants 
which are recovered by complex formation may be in part facilitated by an increase in the 
phosphatase activity of enzyme complexes. This observation is in agreement with the protein 
dynamics study showing that the ATP binding region of MATα2 undergoes allosteric 
modifications upon binding of MATβ [145]. The structural alignment of the wtMATα2 and the 
MATα2β complex revealed that the conformation of residues in the active site of wtMATα2 
were similar compared to those with or without MATβ binding, however several movements 
of the solvent-exposed α-helices are observed in MATα2β complexes. The increase in the 
solvent exposed area along the MAT(α2)4 surface is found in MATα2β complexes when 
compared to the homo-oligomer of the wild type (Fig. 3.4.2C). Additionally, the complex 
thermal stability of both MATα2βV1 (Tm = 55.2 ± 0.1 οC, p < 0.001) and MATα2βV2 (Tm = 
48.4 ± 0.1 οC, p < 0.001) are higher than that of the catalytic subunit alone (Tm = 47.2 ± 0.2 
οC). The normalised fluorescence curves of MATα2, MATα2βV1 and MATα2βV2 are shown 
in Fig. 3.4.2D.   
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Table 3.4.1. The effect of regulatory subunits on kinetic properties of MATa2 
phosphatase activity. 
Protein Vmax (x103 Pi, pmol/s/nmol of protein) Km (ATP, 
mM) 
MATa2 5.2 ± 0.4 0.3 ± 0.1 
MATα2βV1 27.2 ± 2.4 0.5 ± 0.2 
MATα2βV2 17.8 ± 1.3 0.6 ± 0.1 
 
 
Fig. 3.4.2 Structural comparison and phosphatase activity of MATαβ complexes and 
homo-oligomeric wtMATα2 (A) The structural alignment of MATα2 (pale green) with 
MATαβ complex (pink) shows the helical PPPi recognition loop (yellow, residues 264-273) 
that interacts with the MATβ subunit. (B) Michaelis-Menten plots of phosphatase activity of 
the wild-type enzyme and complexes using various ATP concentrations. Curve fitting by 
nonlinear regression was performed using GraphPad Prism 5 software. (C) An overview of 
MATα2 (upper) and MATα2βV2 complex (lower, PDB ID: 4NDN) shows the overall enzyme 
surface. The gating loop is displayed in red. The α-helices, β-sheets and connecting loops are 
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shown in cyan, purple and pink, respectively. (D) Thermal shift assay was used to determine 
the wtMATα2 stability with or without MATβV1 and MATβV2 complex formation. 
 
3.4.2 Crystallographic structures of the gating loop mutants  
Ser114Ala (S114A) mutant structures have been obtained in two different crystallographic 
space groups (I222 and P22121), while the structure of Pro115Gly (P115G) has only been 
obtained in the I222 symmetry. The Gln113Ala (Q113A) mutant also crystallised in the space 
group P22121. All mutants were incubated with the same ligands (Met and AMP-PNP) prior to 
crystallisation. SAMe is observed in wtMATα2, Q113A and P115G, all of which show similar 
enzymatic activity (75-110 % of wtMATα2). However, SAMe is absent in the structure of 
S114A mutant which has less than 4 % enzymatic activity, consistent with the inability of this 
mutant to convert methionine into SAMe. Only enzyme intermediates (PPNP and ADO) are 
found in S114A active sites and it is consistent in both crystallographic forms (I222 and 
P22121). The enzyme product and intermediate found in the active site of each mutant are 
summarised in Table 3.4.2. Data collection and refinement statistics of the gating loop mutants 
(Q113A, S114A and P115G) are shown in Tables 3.4.3a and 3.4.3b. 
Table 3.4.2 Summary of the enzymatic activity and ligands found in the active site of 
MATα2 mutants and wtMATα2. 
Mutant* Resolution (Å) Space 
group 
Active site ligands SAMe synthesis (%)  
Q113A 2.70 P22121 PPNP, SAMe 75.6 ± 4.5 
S114A 1.65 P22121 PPNP, ADO 2.5 ± 0.7 
S114A 1.80 I222 PPNP, ADO 2.5 ± 0.7 
P115G 2.70 I222 PPNP, SAMe 111.4 ± 2.8 
wtMATα2 1.35 I222 PPNP, SAMe 100.0 
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The crystal structure of S114A in the I222 space group contains one monomer in the 
asymmetric unit in which full occupancies of PPNP and ADO are clearly observed in the active 
site (Fig. 3.4.3A). The crystal structure of S114A in the P22121 space group shows two 
monomers in the asymmetric unit with the gating loop in different conformations. One 
monomer shows the active site occupied by PPNP (occupancy 0.5) and ADO (occupancy 0.75) 
neighbouring with the well-ordered, closed gating loop, while the other active site is empty 
showing the ordered, visible gating loop in the open conformation (Fig. 3.4.3B). This is the 
first time that the main part of the gating loop (residues 113-125) is clearly visible in its open 
conformation of the human MAT enzyme family (Fig. 3.4.3B and D). Additionally, the similar 
behaviour was found in the archaeal MAT that showed structural rearrangement of its gating 
(flexible) loop (residues 139-156) in apo- and holo-states. The open conformation of the gating 
loop found in Thermococcus kodakarensis MAT (apo-state) showed the movement of the 
gating loop domain (residues 144-155) from its closed conformation (residues 142-142), which 
was reported in another thermophilic archaeal MAT, Sulfolobus solfataricus [14, 48] (Fig. 
3.4.3E, 3.4.3F).  
The presence of enzyme intermediates (PPNP and ADO) observed in the S114A structure (Fig. 
3.4.3C) indicates that the early step of the reaction (ATP cleavage: ADO and PPNP) has taken 
place, but the S114A mutant fails to provide the nucleophilic attack of methionine’s sulphur 
atom against C’5 atom of AMP-PNP, thus unable to produce SAMe. These observations are 
consistent with the suggestion that C-O bond breaking occurs prior to C-S bond formation at 
the catalytic transition state of human wtMATα2 [146]. The previous high-resolution structure 
of SAMe+ADO+MET+PPNP bound wtMATα2 (PDB: 5A1I) showed that Ser114 is the only 
residue in the gating loop that interacted with AMP-PNP via a water molecule. The functional 
group (-OH) of Ser114 side chain cooperates with the water molecule in positioning AMP-
PNP or ATP via its adenine ring and facilitates SAMe production. Ser114 also interacts with 
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the neighbouring gating loop residues (Asp116, Ile117 and Ala118) and stabilises the helix 
conformation of the ordered gating loop.  
The S114A structure shows that the gating loop becomes more ordered in the closed 
conformation as observed by comparing helical initiation and termination residues of the closed 
(Pro115-His122) to the open (Ile117-Val121) conformation (Fig. 3.4.3B). In the wtMATα2 
(PDB: 5A1I), two active sites are identical, occupied by substrates or products with the gating 
loop in the closed conformation blocking reactive intermediates from escaping into solution. 
In contrast, in both S114A and Q113A mutants (see below), only one active site is occupied 
by substrate or product indicating that the gating loop is unable to rearrange itself properly to 
the closed conformation during the substrate binding step, therefore the reactive intermediates 
might be able to leave the enzyme. Two loop conformations showing in the S114A structure 
suggest that the loop has ability to adopt different conformations when SAMe formation does 
not occur.  
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Fig. 3.4.3 The structure of S114A MATα2 mutant. (A) The S114A mutant structure (I222 
space group) contains PPNP and ADO in the active site showing the closed gating loop (red). 
(B) The S114A mutant structure (P22121 space group) contains PPNP and ADO in the active 
site of one subunit showing a closed gating loop (red), while the other subunit is empty having 
an ordered, visible gating loop in the open conformation. (C) The mutation site and 
intermediates (PPNP and ADO) are shown with omit maps. (D) The ordered, open gating loop 
(residues 113-125) is shown with omit maps. (C, D) Fo-Fc omit maps (green) are contoured at 
the 3 σ level (sigma or noise level) allowing only electron density regions above the noise value 
to be calculated. (E) The structures of archaeal MAT in an apo-state with the gating loop in the 
open conformation (PDB: 4L4Q, grey) and a holo-state with the closed gating loop (PDB: 
4L7I, cyan) are aligned to compare the movement of gating loops in the different 
conformations. The gating loops are represented in red ribbons and all active site ligands 
(SAMe and Pi) are shown as sticks. (F) Structural alignment of the apo human MATα2 (PDB: 
6FAJ, grey) and the holo form with the closed gating loop (PDB: 5A1I, cyan) is shown. SAMe 
and PPNP are shown as sticks.  
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The Q113A crystal structure was obtained in the P22121 space group showing two MATα2 
monomers in the asymmetric unit (Fig. 3.4.4A). One subunit shows the closed, well-ordered 
gating loop with SAMe and PPNP (full occupancy) binding in the active site (Fig. 3.4.4B). The 
active site of the second subunit is empty with the open conformation of gating loop. Most of 
residues of the open gating loop (residues 117-131) are disordered, and electron density is not 
observed in the structure (Fig. 3.4.4A). In the wtMATα2, Met (N and O atom) forms H-bonds 
with MAT enzyme at Glu70 (OE1 atom) and Gln113 (NE2 atom) of one subunit. Met (N atom) 
also interacts with Asp258 (OD1 atom) that belongs to the partner subunit. Gln113 to Ala113 
mutation shows no effect on the binding of Met or SAMe to the active site. SAMe can bind to 
MAT enzymes by various interactions. It (N atom) forms H-bonds with OE1 atom of Glu70 
(2.6 Å) and OD1 atom of Asp258 (2.5 Å), while its oxygen atom (O3 atom) interacts with OD2 
atom of Asp258 (3.0 Å). These interactions maintain the position of SAMe in the active site 
(Fig. 3.4.4C). A loss of the interaction of Met’s main chain with Gln113 arising from the 
mutation to Ala113 is likely to be responsible for the less efficiency of SAMe production (75 
% compared to wtMATα2). In addition, the possible role of Gln113 is to sense the substrate 
entry and stabilises the closed gating loop through its interaction with Met, while the entire 
orientation of Met or SAMe position is maintained by other residues in the active site as 
observed from the crystal structure.  
The different conformations of the gating loop observed in the mutant structures (Q113A and 
S114A) clearly show the importance of these two residues in regulating the gating loop 
rearrangement to different conformations. These residues sense the presence of substrate Met 
and ATP in the active site via the interaction of Gln113 with Met and Ser114 with an adenine 
ring of ADO or ATP (Fig. 3.4.4D). These important interactions of the gating loop with the 
substrates drive the rearrangement of the gating loop to its closed conformation.  
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Fig. 3.4.4 Q113A mutant and wild-type structure. (A) The closed and the open conformation 
of the gating loop are shown in red. One subunit contains product SAMe and PPNP in the 
active site neighbouring with the closed gating loop. The other subunit has no ligand in the 
active site showing the disordered, open gating loop. (B) Close view of the Q113A structure 
showing the omit map contoured around Ala113 is illustrated. An intermediate PPNP or a 
product SAMeare shown as sticks. Fo-Fc omit maps are contoured at the 3 σ level (noise value) 
and coloured in green. Only electron density regions above the noise value are drawn. (C) 
Close view of SAMe in the active site of Q113A mutant is displayed. (D) The interactions of 
Gln113 and Ser114 with Met and ADO found in the structure of wtMATα2 (PDB: 5A1I) is 
demonstrated. Water is shown as a red sphere. 
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The crystal structure of the P115G mutant shows a full occupancy of SAMe and PPNP in the 
active site (Fig. 3.4.5A-B) with the closed, well-ordered gating loop. Pro115 is not associated 
with the substrate or the product interaction as observed in the wild-type structure (Fig. 3.4.5C). 
This mutation has no effect on the overall arrangement of the gating loop. The identical 
subunits with the gating loops in their closed conformation are found in this mutant structure, 
the same as observed in the wild-type structure.  
 
 
Figure 3.4.5 P115G MATα2 mutant structure (A) The I222 crystal form displays the closed 
conformation of the well-ordered gating loop (red) with SAMe and PPNP in the active site. (B) 
The omit maps of P115G mutation site and products (SAMe, PPNP) are exhibited with the 
closed gating loop. Fo-Fc omit maps are coloured in green and contoured at the 3 σ level (noise 
level). Only electron density regions above the noise value are shown. (C) Close view of SAMe 
in the active site of the P115G mutant structure and its interacting residues is displayed.  
The wtMATα2 structure in an apo state (PDB: 6FAJ) was crystallised in the P22121 crystal 
form. The active sites of both subunits are empty anchoring with the gating loop in the open 
conformation. Interestingly, one subunit has the ordered, visible gating loop with the clear 
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electron density as found in the S114A (P22121) structure (Fig. 3.4.6A). The dilation along with 
the dimer interface is found in one active site because of the gating loop, adjacent loop (residues 
245-264) and residues 320-328 being oriented outwardly to the substrate binding cleft, while 
the other subunit active site shows a disordered open gating loop with less dilated binding cleft 
(Fig. 3.4.6B). Structural alignment of the wtMATα2 (apo form) with the ligand-bound (holo 
form) wtMATα2 or the MATα2 (S114A) mutant reveals that apart from the movement in the 
gating loop region itself, the adjacent loop and residues 320-328 that contribute to substrate/ 
product binding pocket (Fig 3.4.6A, B) of wtMATα2 (holo form) line inward to the active site 
pocket. In contrast, the substrate binding clefts of wtMATα2 (apo form) are oriented outwardly 
from the active site which also found in the S114A structure. This finding suggests the 
importance of Ser114 interaction to the substrate binding during the rearrangement of the 
gating loop into its closed conformation. The interaction of the gating loop and the substrates 
prevent the substrate binding pocket residues from moving apart from the active site, which 
fails in the S114A mutant. Most residues that are involved in SAMe formation including 
Ser247, Arg249 have a similar conformation in apo- and holo-wtMATα2, except for Phe250 
and Asp258. These two residues move from their original positions in the apo-wtMATα2 as 
shown in Fig. 3.4.6C. In holo-state of wtMATα2, Ser247 (OG atom), Arg249 (O atom) and 
Asp258 (OD1 and OD2 atom) interact with the N1 (2.81 Å), N6 (2.90 Å), N (2.76 Å), and O3 
atom (2.70 Å) of SAMe, respectively, while Phe250 forms the π-π stacking with the SAMe 
adenine ring (Fig. 3.4.6C). The position of other residues (His29, Lys181, Lys265, Lys285, 
Lys289 and Asp291) that were previously reported to be involved in SAMe formation are 
preserved in both the apo and the holo-wtMATα2 structure. The dilation of the substrate 
binding pocket found in the MAT(α2)4(βV2)2 complex is identical to the dilated active site 
found in the present apo-wtMATα2 structure, suggesting that this dilation is not the unique 
property of the MATαβ complex.  
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Fig. 3.4.6 The structure of apo wtMATα2 and its conformational changes upon substrate 
binding (A) The crystal structure of wtMATα2 (blue) shows two subunits with the different 
gating loop conformations (red ribbons). The substrate/ product binding pocket are shown in 
yellow (an adjacent loop, residues 245-264) and orange (residues 320-328) loops. The 
interactions of the key residues Gln113, Ser114, Pro115 and Arg264 are shown with the local 
surrounding. (B) The surface view of substrate binding clefts is shown with the gating loop 
(red), adjacent loop (245-264, yellow) and residues 320-328 (orange). (C) Structural 
comparison of the holo (pink sticks) and the apo (blue sticks) of the wtMATα2 structure reveals 
SAMe interacting residues including Ser247, Arg249, Phe250 and Asp258 of their positions in 
the apo state. 
The overall active site conformation of the S114A mutant are similar to the wild type with 0.2 
Å differences of residues 250-286 being oriented away from the dimer interface. The apo 
S114A mutant structure is similar to the apo-wtMATα2 structure which shows the wider open 
active cleft than that found in the holo-wtMATα2 structure, while in the MATα2β complex this 
cleft takes intermediate position (between apo and holo state). The less dilated substrate 
binding pocket of MATα2β is a result of MATβ interaction. The local changes in the complex 
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suggest that MATβ insertion modulates the tightness of the dimer interface (residues 250-286) 
that comprising substrate binding pocket for the S114A mutant which could result in different 
degrees of the activity recovery.  
3.5 Conclusion. 
The gating loop features different conformations during substrate binding, SAMe formation 
and product release, suggesting that it facilitates the enzyme reaction. Functional analysis and 
crystallographic structures are used to investigate the role of the gating loop where the single 
residue, Ser114, is found to involve with SAMe formation and structural movement of the 
gating loop. Ser114 coordinates the adenine ring of the substrate ATP via a water molecule and 
it also stabilises a rigid helix conformation of the closed gating loop. The finding of the visible, 
ordered gating loop in the open conformation for the first time in human MATs provides an 
understanding of how this loop undergoes structural changes upon substrate binding and 
product release as evidenced by the different conformations found in the mutant structures 
(Q113A and S114A). The gating loop interacts with substrates and drives the rearrangement to 
its closed conformation. SAMe formation and phosphatase activity are indeed regulated by a 
different part of the enzyme as no alteration of the PPPi hydrolysis is observed in the mutant 
that exhibits the loss of SAMe formation. In addition, the ligated structure of human MATa2 
reported in this study shows that ADO and PPNP tightly bind to MAT enzyme at the transition 
state of the enzyme reaction, indicating that these intermediates could be a potential model for 
designing enzyme inhibitor which competitively binds to the active site. The catalytic reaction 
of SAMe formation combined with structural movements (e.g. gating loop) at each step is 
proposed in Fig. 3.4.7.  
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Table 3.4.3a Crystallographic data collection and refinement statistics for wtMATα2 and its mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                Q113A                              P115A                      wtMATα2 (Apo)                     wtMATα2 (Holo) 
Data collection 
   Space group                          P22121                                   I222                            P22121                                            I222 
Cell dimensions 
    a, b, c (Å)                  63.63, 103.93, 109.79 66.33, 94.87, 117.37      62.18, 103.23, 108.36             67.63, 94.00, 116.69 
   α, β, ϒ (Å)                      90, 90, 90                               90, 90, 90                        90, 90, 90                                      90, 90, 90 
Resolution  (Å)               103.93-2.70                              54.36-2.70                     74.74-1.95                                    73.20-1.35 
(last shell)   (Å)                (2.83-2.70)                              (2.83-2.70)                    (2.00-1.95)                                     1.37-1.35 
No. of  reflections         20580       8945                51446                                            80461 
Rmerge (%)                       14.3 (77.6)                    16.2 (56.4)                    18.1 (38.7)                                     8.6 (57.5) 
I/ϬI           10.6 (2.1)       5.2 (2.0)               4.7 (2.1)                                         8.5 (2.1) 
Completeness (%)                99.5 (100)                    85.0  (89.6)                    99.6 (99.8)                                    98.7 (97.1) 
Redundancy          5.6 (5.9)                    4.4 (4.3)                         3.5 (3.6)                                        5.0 (4.2) 
Wilson B factor ( Å2 )                  44.90                             51.10                             9.94                                              11.10 
Refinement 
    Rwork/Rfree**             17.89/ 19.02       19.19/ 23.41                18.96/ 22.39                                13.73/ 16.19 
No. of atoms 
    Protein          5711                     2977                 5711                                             3089 
     Ligand                        77         50                              31                                                 74 
    Waters          87                      3                 302                                               430 
Average B-factors  ( Å2 ) 
    Protein                                47.05                                  49.89                             14.66                                             12.93 
    Ligand                                54.28                                  54.83                             31.43                                              24.14 
    Water                                 33.85                                   41.80                             20.66                                             28.16 
R.m.s. deviations 
    Bond lengths (Å)        0.012        0.012  0.013                                             0.012 
    Bond angles (ο)        1.552        1.587                           1.666                                              1.690 
PDB Code                                6FBN                                 6FCB                            6FAJ                                              6G6R 
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Table 3.4.3b Crystallographic data collection and refinement statistics for wtMATα2 and its mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutants                                                    S114A                                                         S114A                                      
Data collection 
   Space group                                            P22121                                            I222       
Cell dimensions 
    a, b, c (Å)                                    62.09, 102.87, 108.17                             66.62, 94.68, 116.55       
   α, β, ϒ (Å)                                            90, 90, 90                                                   90, 90, 90                    
Resolution  (Å)                                        54.08-1.65                                                58.28-1.80                       
(last shell)   (Å)                                        (1.68-1.65)                                               (1.84-1.80)                       
No. of  reflections                        81704                                              34507                               
Rmerge (%)                                      10.8 (56.6)                                               17.0 (76.6)               
I/ϬI                          8.0 (1.9)                                              5.80 (2.0)                 
Completeness (%)                          97.2 (98.4)                                               99.8 (100.0)   
Redundancy            5.3 (5.3)                                 5.3 (5.4)                 
Wilson B factor ( Å2 )                                14.90                                                        17.10                               
Refinement           
    Rwork/Rfree**                         16.32/ 19.46                                             15.10/ 17.44                    
No. of atoms 
    Protein            5902                                               3005              
     Ligand                                       78                                               79    
    Waters                    499                                 224                 
  
Average B-factors  ( Å2 ) 
    Protein                                                    21.72                                                       15.30                               
    Ligand                                                    27.77                                                       32.78                               
    Water                                                      27.77                                                      24.81                               
R.m.s. deviations 
    Bond lengths (Å)             0.015                                0.014                   
    Bond angles (ο)                          1.760                                1.670                  
  
PDB Code                                                   6FBP                                                     6FBO                                                        
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Fig. 3.4.7 The proposed MAT catalytic cycle. The functional active site is formed between the monomer interface (cyan and grey), and the gating 
loop (red) is located beside the active site of MAT enzymes. The entrance of the active site is accessible when the gating loop is in the open 
conformation which substrates and products can bind or release from the active site. The first step Met and ATP binds to the active site following 
by the cleavage of the C-O bond of the ATP and C-S bond formation of ATP and Met to produce SAMe. During enzyme reaction the gating loop 
is in the closed conformation. At the transition state ADO and tripolyphosphate (PPPi or PPNP) are formed. After the production of SAMe, it exits 
from the active site before the hydrolysis of tripolyphosphate. The enzyme is ready for the next reaction cycle after Pi and PPi are released from 
the active site.
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Chapter IV 
The functional and structural study of a disease related residue Arg264 in 
hypermethioninemia 
 
4.1 Background and objective 
MAT deficiency (OMIM 250850) is characterized by isolated persistent hypermethioninemia 
(IPH). This condition is associated with mutations in the MAT1A gene encoding MATal (the 
major hepatic MAT). IPH is detected as an inborn error of methionine metabolism. MAT 
enzymes are found in almost all living organisms [1]. SAMe formation and its level in cellular 
tissues is crucial for normal cell functions which are derived from its versatile roles (Fig. 4.1.1) 
[3-5, 23], while its level is found to be relatively low when Met level is high in patients with 
IPH [147]. 
Case reports with MATa1 deficiency were identified through new born screening programmes 
when the activity of MATa2 in erythrocytes, fibroblasts and lymphocytes was normal [148, 
149]. Hepatic MAT deficiency is mostly transmitted by an autosomal recessive inheritance [15, 
150-152] or the exceptional Arg264His (R264H) autosomal dominant mutations [152-156]. 
Neurological problems including demyelination, abnormal mental development and cognitive 
impairment have been reported in severe cases of autosomal recessive IPH patients, while the 
majority of patients with mild to moderate condition present no clinical manifestations [15, 
150, 157-160]. R264H is the most prevalent mutation associated with IPH observed in new 
born screening programmes, as previously reported in USA (3 of 13), Spain (15 of 18), Japan 
(14 of 24), Portugal (all 12 cases) and Taiwan (3 of 16) [153, 155, 156, 161, 162]. Patients with 
IPH related with R264H mutation is usually clinically benign at the early stage of life [155, 
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161], however a report of the 3-year-old girl developing demyelination and severe vascular 
diseases found in some cases associated with R264H mutation suggest that clinical monitoring 
should be taken [156].  
In the central region of the MATa1 and MATa2 dimer, the dimeric subunit interacts through 
a few polar interactions involving a salt bridge between Arg264 of one subunit and Glu57 of 
the other (Fig. 4.1.2). These two residues, Arg264 and Glu57, are conserved in both MATa1 
and MATa2. Their interactions were reported to be essential for subunit dimerization, 
facilitating the active site formation [17, 163].  
To understand the structure and function relationship of the dominant effect of the R264H 
mutation in the hepatic MAT enzyme (MATa1), Arg264 was mutated to His264 in MATa1. 
The oligomeric forms of R264H mutant were characterised in solution and crystal structures. 
In addition, to investigate the role of Arg264 side chain, Arg264 was mutated to Ala264 in both 
MATa1 and MATa2. All mutants were generated by site-directed mutagenesis and were 
confirmed by DNA sequencing (Fig. 4.1.3). Full DNA sequencing results are shown in Table 
4.1.  
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Fig. 4.1.1 Simplified synthesis and metabolic pathways of SAMe. SAMe is synthesized from 
methionine and ATP by MAT enzymes and can participate three pathways; (i) methylation; 
(ii) transsulfuration; (iii) aminopropylation. (i) The methyl group of SAMe is transferred to 
methyl acceptors and SAMe is converted to SAH. SAH is then hydrolysed by SAH hydrolase 
to adenosine and Hcy. (ii) Hcy has two alternative pathways; Hcy can be methylated to 
methionine which can re-enter the trans-methylation cycle or it can undergo the trans-
sulfuration process for the biological compound synthesis e.g. Cys or GSH (glutathione, a 
major cellular antioxidant). (iii) SAMe is able to participate the decarboxylation pathway and 
acts as the propylamine donor for the polyamine biosynthesis. Polyamines are important for 
many cellular functions including cell growth and differentiation. In this pathway SAMe is 
catalysed by SAMe decarboxylase for the removal of its carboxyl group. The figure was 
modified from [164]. 
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Fig. 4.1.2 Salt bridge interaction of Arg264 and Glu57 at the dimer interface. Arg264 of 
one subunit interacts with Glu57 of its partner subunit through the H-bonds and electrostatic 
interactions (ionic boding) aiding the dimer formation. The model was derived from the native 
state (apo form) of the wild-type MATa2 structure (PDB: 6FAJ). 
 
Fig. 4.1.3 DNA sequencing results for Arg264 mutation variants. DNA sequences of 
MATa2 (Arg264Ala) and MATa1 (Arg264Ala and Arg264His) mutants were aligned to the 
wild-type DNA using SnapGene. The mutation sites are highlighted in red boxes.  
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Table 4.1 DNA sequences of Arg264His (MAT1A), Arg264Ala (MAT1A) and 
Arg264Ala (MAT2A) mutants 
Mutants DNA sequences 
Arg264His 
(MAT1A) 
GGAGTCTTCATGTTCACATCGGAGTCTGTGGGAGAGGGACAC
CCGGATAAGATCTGTGACCAGATCAGTGATGCAGTGCTGGAT
GCCCATCTCAAGCAAGACCCCAATGCCAAGGTGGCCTGTGAG
ACAGTGTGCAAGACCGGCATGGTGCTGCTGTGTGGTGAGATC
ACCTCAATGGCCATGGTGGACTACCAGCGGGTGGTGAGGGAC
ACCATCAAGCACATCGGCTACGATGACTCAGCCAAGGGCTTT
GACTTCAAGACTTGCAACGTGCTGGTGGCTTTGGAGCAGCAA
TCCCCAGATATTGCCCAGTGCGTCCATCTGGACAGAAATGAG
GAGGATGTGGGGGCAGGAGATCAGGGTTTGATGTTCGGCTAT
GCCACCGACGAGACAGAGGAGTGCATGCCCCTCACCATCATC
CTTGCTCACAAGCTCAACGCCCGGATGGCAGACCTCAGGCGC
TCCGGCCTCCTCCCCTGGCTGCGGCCTGACTCTAAGACTCAG
GTGACAGTTCAGTACATGCAGGACAATGGCGCAGTCATCCCT
GTGCGCATCCACACCATCGTCATCTCTGTGCAGCACAACGAA
GACATCACGCTGGAGGAGATGCGCAGGGCCCTGAAGGagCAA
GTCATCAGGGCCGTGGTGCCGGCCAAGTACCTGGACGAAGAC
ACCGTCTACCACCTGCAGCCCAGTGGGCGGTTTGTCATCGGA
GGTCCCCAGGGGGATGCGGGTGTCACTGGCCATAagATTATTG
TGGACACCTATGGCGGCTGGGGGgCTCATGgTGGTGGGGCCTT
CTCTGggAAGGACTACACCAAGGTGGACCGCTCAGCCGCTTAT
GCTGCCCGCTGGGTGGCCAAGTCTCTGGTGAAAGCAgggnTCT
GCCggaanGTGCTTGTCcaGgTTTCCTATGCCATTggtgtggccnnanCc
GCTGtccATTtCCATCttcaccTacGgaac 
Arg264Ala 
(MAT1A) 
GGAGTCTTCATGTTCACATCGgAGTCTGTGGGAGAGGGACAC
CCGGATAAGATCTGTGACCAGATCAGTGATGCAGTGCTGGAT
GCCCATCTCAAGCAAGACCCCAATGCCAAGGTGGCCTGTGAG
ACAGTGTGCAAGACCGGCATGGTGCTGCTGTGTGGTGAGATC
ACCTCAATGGCCATGGTGGACTACCAGCGGGTGGTGAGGGAC
ACCATCAAGCACATCGGCTACGATGACTCAGCCAAGGGCTTT
GACTTCAAGACTTGCAACGTGCTGGTGGCTTTGGAGCAGCAA
TCCCCAGATATTGCCCAGTGCGTCCATCTGGACAGAAATGAG
GAGGATGTGGGGGCAGGAGATCAGGGTTTGATGTTCGGCTAT
GCCACCGACGAGACAGAGGAGTGCATGCCCCTCACCATCATC
CTTGCTCACAAGCTCAACGCCCGGATGGCAGACCTCAGGCGC
TCCGGCCTCCTCCCCTGGCTGCGGCCTGACTCTAAGACTCAG
GTGACAGTTCAGTACATGCAGGACAATGGCGCAGTCATCCCT
GTGCGCATCCACACCATCGTCATCTCTGTGCAGCACAACGAA
GACATCACGCTGGAGGAgaTGCGCAGGGCCCTGAAGGAGCAA
GTCATCAGGGCCGTGGTGCCGGCCAAGTACCTGGACGAAGAC
ACCGTCTACCACCTGCAGCCCAGTGGGCGGTTTGTCATCGGA
GGTCCCCAGGGGgATGCGGGTGTCACTGGCGCTAAGATTATT
GTGGACACCTATGGCGGCTGGGGGGCTCATGGTGGTGGggCC
TTCTCTGGGAAGGACTACACCAAGGTGGACCGCTCagCcGCTT
ATGCTGCCCGCTGGgTGGCCAAGTCTCTGGTgAanGCAGGGCT
CTGCCggaangTGCTTGTCCAGGTTTCCTATGCCATtggnggnGgCC
GanccnGCTGtccAtTtnCCATCTtcacctnACGGAanc 
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Mutants DNA sequences 
Arg264Ala 
(MAT2A) 
CATGAACGGACAGCTCAACGGCTTCCATGAGGCGTTCATCGA
GGAGGGCACATTCCTTTTCACCTCAGAGTCGGTCGGGGAAGG
CCACCCAGATAAGATTTGTGACCAAATCAGTGATGCTGTCCT
TGATGCCCACCTTCAGCAGGATCCTGATGCCAAAGTAGCTTG
TGAAACTGTTGCTAAAACTGGAATGATCCTTCTTGCTGGGGA
AATTACATCCAGAGCTGCTGTTGACTACCAGAAAGTGGTTCG
TGAAGCTGTTAAACACATTGGATATGATGATTCTTCCAAAGG
TTTTGACTACAAGACTTGTAACGTGCTGGTAGCCTTGGAGCA
ACAGTCACCAGATATTGCTCAAGGTGTTCATCTTGACAGAAA
TGAAGAAGACATTGGTGCTGGAGACCAGGGCTTAATGTTTGG
CTATGCCACTGATGAAACTGAGGAGTGTATGCCTTTAACCAT
TGTCTTGGCACACAAGCTAAATGCCAAACTGGCAGAACTACG
CCGTAATGGCACTTTGCCTTGGTTACGCCCTGATTCTAAAACT
CAAGTTACTGTGCAGTATATGCAGGATCGAGGTGCTGTGCTT
CCCATCAGAGTCCACACAATTGTTATATCTGTTCAGCATGATG
AAGAGGTTTGTCTTGATGAAATGAGGGATGCCCTAAAGGAGA
AAGTCATCAAAGCAGTTGTGCCTGCGAAATACCTTGATGAGG
ATACAATCTACCACCTACAGCCAAGTGGCAGATTTGTTATTG
GTGGGCCTCAGGGTGATGCTGGTTTGACTGGAGCGAAAATCA
TTGTGGACACTTATGGCG 
 
4.2 Production of MATα2 (R264A) mutant 
The mutant was purified by three different columns (nickel affinity, anion-exchange and gel 
filtration chromatography). Protein purity of the MATα2 (R264A) mutant was assessed by 
SDS-PAGE (Fig. 4.2.1). The high purity was observed after proteins had been purified by the 
last step (size-exclusion chromatography). The estimated molecular weight of the MATα2 
subunit is about 45 kDa. The precipitation of the protein during a dialysis and a concentrating 
procedure was removed by centrifugation. The remaining soluble protein aggregates were 
separated by the gel filtration column and were discarded. Protein yield of the MATα2 (R264A) 
mutant was about 5 mg/L. This amount was sufficient to produce protein crystals and to 
perform functional experiments. The purity of the mutant was also enough for producing good 
quality diffracting crystals. 
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Fig. 4.2.1 MATα2 (R264A) mutant purification. (A) SDS-PAGE of the mutant from Ni-
affinity purification is shown. (B) SDS-PAGE of the protein from anion-exchange purification 
with 0.05-1 M NaCl gradient is displayed. (C) The gel filtration profile is shown by the 
absorbance at 280 nm. The main peak indicated that the majority of protein was eluted at 62.5-
72.5 mL. The crystals were produced from the eluted peak at 62.5-72.5 mL. (D) SDS-PAGE 
of fractions containing MATα2 (R264A) proteins is shown. The eluted fractions containing 
proteins at 45.0, 65.0 and 80.0 mL were an aggregation, a tetramer and a dimer, respectively. 
Sam, FT, lysis, WB and E indicate protein sample, flow through, flow through of lysis buffer, 
wash buffer and elution fraction, respectively. 
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4.3 Production of MATα1 (wild type, R264A and R264H mutants) 
MATα1 was purified in the same manner as MATα2 (section 2.7, chapter 2). SDS-PAGE 
analysis was performed in each step of purification to check protein purity and production (Fig. 
4.3.1-4.3.3). Protein precipitation occurred during the dialysis and the concentrating procedure 
was removed by centrifugation before proceeding to the next step of purification. The 
remaining soluble aggregated protein could be separated from the protein samples by size-
exclusion chromatography and it was firstly eluted at the void volume of the column. Protein 
yield of MATα1 and its mutants ranged from 2-4 mg/L. This amount was sufficient for 
producing protein crystals and performing activity measurements. The purity of all purified 
proteins was high enough to produce protein crystals. However, MATα1 protein crystals 
generally gave lower resolution crystals compared to those of the MATα2. The wild-type 
MATα1 crystal structure was obtained at 2.35 Å, and its mutants (R264H and R264A) were 
diffracted at 2.85 and 3.1 Å, respectively. In contrast, the MATα2 (R264A) mutant crystal 
structure was obtained at 1.6 Å.  
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Fig. 4.3.1 wtMATa1 purification (A) SDS-PAGE of the protein from Ni-affinity purification 
is shown. (B) SDS-PAGE of the protein from anion-exchange purification with 0.05-1.0 M 
NaCl gradient is exhibited. (C) The gel filtration profile is shown by the absorbance at 280 nm. 
The first peak indicated that the majority of protein was aggregated in a soluble form (7.0-10.0 
mL). SDS-PAGE of the fractions containing wtMATa1 (no aggregation) was shown at 11.5-
13.5 mL. SAM, FT, lysis, WB and E represent protein sample, flow through, flow through of 
lysis buffer, wash buffer and elution fraction, respectively. The protein crystals of wtMATa1 
(needle form) are shown. 
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Fig. 4.3.2 MATa1 (R264H) mutant purification. (A) SDS-PAGE shows the proteins from 
Ni-affinity purification. (B) SDS-PAGE of proteins from anion-exchange purification is 
shown. (C) The gel filtration profile (the absorbance at 280 nm) showed that proteins were 
largely eluted at 12.5 mL and 15.5 mL corresponding to a tetramer and a dimer, respectively. 
SDS-PAGE of the proteins from the fractions eluted at 12.5 mL and 15.5 mL is shown. Crystals 
obtained from the tetrameric and the dimeric fractions were displayed. SAM, FT, lysis, WB 
and E stand for protein sample, flow through, flow through of lysis buffer, wash buffer and 
elution fraction, respectively. 
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Fig. 4.3.3 MATa1 (R264A) mutant purification. (A) SDS-PAGE of proteins from Ni-
affinity purification is shown. (B) The gel filtration profile is shown by the absorbance at 280 
nm. SDS-PAGE showed the protein bands corresponding to a fraction of 85.0 mL. Crystals 
were obtained in needle forms. SAM, FT, lysis, WB and E are protein sample, flow through, 
flow through of lysis buffer, wash buffer and elution fraction, respectively. 
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4.4 The structural and functional analysis of Arg264 mutation in human MAT enzyme 
4.4.1 The SAMe synthetic and phosphatase activity of Arg264 mutants: Arg264Ala 
(MATa2) and Arg264His (MATa1) 
A number of mutations causing IPH were identified in human MATα1 which resulted in lower 
enzymatic activity and decreased SAMe production, while Met is accumulated in blood 
plasma. In some cases, patients show developmental delay or neurological problems [165]. 
Some mutations causing IPH were reported at the dimer interface (e.g. Arg249Trp, Ala259Val 
and Arg264Cys/His) and these residues are conserved in both catalytic isoforms of MAT 
enzymes (MATα1 and MATα2). In particular, Arg264 is involved in the salt-bridge formation 
with the dimeric partner, Glu57. Arg264 mutation to Cys264 or His264 caused a loss of SAMe 
synthetic activity. The activity reduction was hypothesized to be the result of the inability to 
form a dimer [163, 166]. The study in the hepatic rMAT showed that the substitution of the 
homologous Arg265 by His265 (Arg265His) only produced a monomeric species with 0.4 % 
of SAMe production [166]. 
The present study of human MAT mutants found that both MATα1 (R264H) and MATα2 
(R264A) mutants can form the oligomeric states in solution. Using size-exclusion 
chromatography (SEC), the MATα1 (R264H) mutant showed two peaks, corresponding to a 
tetramer and a dimer, respectively, while the wtMATα1 and the MATα2 (R264A) mutant 
eluted primarily as a tetramer (Fig. 4.4.1A). The equivalent mutants (Arg244Leu and 
Arg244His) of eMAT were reported to form a tetramer in solution [167]. In addition, both 
MATα1 (R264H) and MATα2 (R264A) mutants can form the hetero-oligomeric complex with 
the MATβ subunit as shown by the analytical SEC for MATα2 (R264A): MATβ (Fig 4.4.1B) 
and the native/ SDS-PAGE analysis (Fig. 4.4.1C). To confirm the oligomeric state of the 
MATα2 (R264A) mutant in solution, the SEC-SAXS experiment of the purified MATα2 
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(R264A) was performed. The data exhibit that the dominant species of the MATα2 (R264A) 
mutant forms a tetramer in solution (Fig. 4.4.1D). The native-PAGE/SDS-PAGE analysis of a 
dimer and a tetramer of the MATα1 (R264H) mutant is provided in Fig. 4.4.2. 
 
Fig. 4.4.1 The oligomeric state analysis of MATα2 (R264A) and MATα1 (R264H) mutant 
(A) Gel filtration profiles of wtMATα1 compared to MATα1 (R264H) and MATα2 (R264A) 
mutants. (B) Gel filtration profiles of MATα2:MATβV1 (wild type) and MATα2 
(R264A):MATβV1 complexes compared to wtMATα2 alone. (A, B) a, ferritin (440 kDa); b, 
aldolase (158 kDa); c, conalbumin (75 kDa); d, ovalbumin (43 kDa); e, ribonuclease (13.7 
kDa). (C) Native and SDS-PAGE analysis of the complexes (MATα1/2 variants:MATβV1) 
compared to each protein on its own are shown. (D) The SAXS profile (upper panel) was 
calculated from the crystal structure (model) and was fitted to the obtained scattering data of 
the MATα2 (R264A) mutant (black dots). The calculated SAXS profile of the tetrameric crystal 
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model (PDB: 5UGH) is shown by a red line; χ = 1.65, C1 = 1.01, C2 = 3.65, Rg = 36.55, while 
the dimeric crystal model (PDB: 1QM4) is shown by a blue line; χ = 27.38, C1 = 1.05, C2 = 
4.00, Rg = 24.73. The experimental scattering data of the mutant better fit to the tetrameric 
crystal model. The Chi (χ) value of 1.65 suggests a tetrameric state compared to the χ value of 
27.38 of a dimeric form. Retention time of the tetrameric MATα2 (R264A) elution peak that 
used for the oligomeric state analysis was 7.24 min (lower panel). 
 
Fig. 4.4.2 Native and SDS-PAGE analysis of the MATa1 (R264H) mutant. The dimer and 
the tetramer of R264H are shown with the estimated molecular weight. One monomer contains 
395 amino acids and the estimated molecular weight is 45 kDa. 
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MATa1 is the liver specific enzyme and it is found to work as a homotetramer or homodimer, 
while MATa2 functions as a hetero-oligomer forming complexes with its regulatory subunit 
MATbV1 or MATbV2 [13]. MATbV1 contains 20 N-terminal amino acids longer than those 
found in MATbV2, while the remaining amino acids are identical [10]. An in vitro study has 
suggested that MATa1 can also form the hetero-complex with MATbV1, but to a lesser extent 
with MATbV2 [13]. In the present study, both MATbV1 and MATbV2 are incubated with the 
MATa1 (R264H) mutant, only MATbV1 was found to form the heterocomplex with R264H 
mutant (Fig. 4.4.1C). 
Although these MATα1 and MATα2 mutants are multimeric in solution, a substantial decrease 
in SAMe production is found without MATβV1 or MATβV2 subunits. The activity loss caused 
by Arg264 mutation can be recovered to the wtMATα1/2 levels when the mutants form the 
hetero oligomer with MATβV1/V2 (Fig. 4.4.3A). However, the regulatory subunits are 
normally not co-expressed with MATα1 in the healthy adult liver. Additionally, PPPi 
hydrolysis rates of these mutants are relatively similar to the wild-type enzyme (Fig. 4.4.3B). 
Arg264 was suggested to be involved with the PPPi C-O bond cleavage of ATP during SAMe 
formation and also associated with stabilising PPPi orientation in the active site. Arg264 is less 
related to the subsequent PPPi hydrolysis [167]. Perez Mato I, et al., 2001 also found that the 
monomer of the Arg265His mutant (rMAT) showed the normal activity of PPPi hydrolysis. 
The results of the equivalent Arg264 mutation studies carried out in eMAT and rMAT are 
consistent with the present study showing that the PPPi hydrolytic reaction is less affected by 
this Arg mutation compared to the SAMe synthetic activity [166, 167]. 
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Fig. 4.4.3 SAMe synthetic and phosphatase activity of wild-type and mutant enzymes. (A) 
SAMe formation of wtMATα1 and MATa2 compared to their mutant enzymes. (B) 
Phosphatase activity of wild-type enzymes and complexes compared to the mutants. ‘**’ and 
‘***’ indicate statistical significance at p < 0.01 and p < 0.001, respectively, when compared 
with the wild type (MATα1 or MATα2). ‘###’ corresponds to statistical difference at p < 0.001 
compared to the MATα2 (R264A) mutant. ‘&&’ corresponds to statistical difference at p < 
0.01 compared to the MATα1 (R264H) mutant. Data are mean of three independent 
experiments ± SEM (n=3). All experiments were performed using protein samples from the 
same batch of protein purification (different aliquots). 
4.4.2 The structural study of disease related residue Arg264 in hypermethioninemia 
Data collection and refinement statistics of wtMATa1 and Arg264 mutants (Arg264His 
MATa1, Arg264Ala MATa1 and Arg264Ala MATa2: R264H MATa1, R264A MATa1 
and R264A MATa2, respectively) are shown in Table 4.4.  
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4.4.2.1 The crystal structure of the tetrameric wild-type MATa1: an apo form 
Numerous MAT structures are available in the protein data bank ranging from archaeal 
bacteria, E. coli to human MAT structures with the ligand or un-liganded form. However, the 
native form of human MATa1 (apo form) is not yet available. The crystal structure of the 
tetrameric form of human MATa1 was obtained at 2.3 Å. The crystal was crystallised in the 
C2 space group containing the cell solvent content of 45.29 %. The asymmetric unit contains 
two dimers of four subunits (Fig. 4.4.4A). A dimer constitutes two equivalent active sites 
forming at the dimer interface. Each MATa1 subunit has 395 residues mostly visible in the 
structure. However, there are two main regions that are typically invisible in electron density 
maps of MAT enzymes. The first region is the N-terminal Met1-Glu15 which is found to be 
missing in most reported MAT structures due to its flexibility. The second region is the gating 
loop region, Asp116-Glu127, which was also found to be flexible in an E. coli MAT, a rat liver 
MAT and a human MATa1/ MATa2 structure. This loop regulates the access to active site by 
undergoing conformational changes in the open or closed conformation. The previous reported 
structure of SAMe bound MATa1 showed the closed formation of the gating loop and SAMe 
binding was partially stabilised by this loop. The gating loop is disordered and invisible in 
unliganded structure (apo form), and this open conformation allows the active site to be 
solvent-accessible [43]. These two regions (Met1-Glu15 and Asp116-Glu127) are missing in 
all subunits (Chain A-D) of the present MATa1 structure. The last absent region is Phe250-
Ala259 which contains the methionine binding site and is located at the dimer interface in 
which active sites reside. This region has been reported to show high flexibility in the rMAT 
structure [53], while it was clearly seen in the apo structure of the human MATa2 despite the 
similarity of their sequences to MATa1 [47]. Once a substrate binding to the active site, the 
gating loop adopts the reorientation to its closed conformation and SAMe binding stabilises 
Phe250-Ala259 making it visible in the SAMe-bound structures [13, 30, 36, 43]. In addition, 
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the Asp94-Phe99 region that is usually found in MAT structures is absent in Chain A and Chain 
D of the current apo MATa1 structure. This region is located at the surface where the two 
domains of the a-helix (Tyr79-Ile90) and the b-sheet (Lys53-Thr72 and Asn105-Gln112) are 
connected.  
Each subunit of the dimer largely interacts via b-sheets in an inverse contact generating two 
active sites per dimer at the dimer interface (Fig. 4.4.4B). Only few polar interactions are found 
at the dimer interface and Arg264 is the most studied residue at the dimer interface of MAT 
enzymes [17, 150, 152, 163, 167]. Arg264 forms salt bridges with Glu57 of the partner subunit 
at the dimeric centre (Fig. 4.4.4C). Beyond its role in dimer stabilisation, mutation of this 
residue to histidine can cause IPH for which less than 30 % of the activity was observed in this 
mutant [163]. However, the structural study of this mutant has not been available, while 
prediction of IPH clinical manifestations caused by this mutation are usually variable from 
genotype to phenotype. In order to address these questions, the crystal structure of R264H 
mutant of the human hepatic MAT is solved and provides structural understanding of this 
disease’s causing residue (section 4.4.2.2).  
Structural comparison of the SAMe-bound structure (PDB: 2OBV) and the present apo 
structure of MATa1 at the active site residues reveals that an aromatic ring of Phe250 in the 
apo structure is located in the SAMe binding site, while it forms the p-p stacking with adenine 
moiety of SAMe in the SAMe-bound structure (Fig 4.4.4D) [43]. In addition, O atom of 
Ser247, OE1 atom of Glu70 and OD1 atom of Asp258 in the apo structure show to move by 
3.9, 6.5 and 3.9 Å, respectively, from their positions in the SAMe-bound structure (Fig 4.4.4D-
E). According to the conformational change of the gating loop upon substrate binding and 
SAMe production, Gln113 which directly bind to SAMe and is also a part of the gating loop 
shows 8.1 Å movement of its position in the apo structure (Fig 4.4.4E). 
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Fig. 4.4.4 The structure of apo wtMATa1. (A) Each subunit of a tetrameric wtMATa1 
tetramer is shown in grey, cyan, yellow and blue. The tetramer is composed by the self-
assembly of two dimers (4 subunits of wtMATa1). (B) One dimer is shown in blue and yellow. 
The gating loop and residues 250-259 are shown in red and pink, respectively. A central part 
of the dimer interface is shown in a black square. (C) Arg264 and Glu57 of each partner subunit 
forms a salt bridge and stabilise the dimer formation. (D, E) The active site residues that interact 
with SAMe of the apo structure (current study) and the SAMe-bound structure (PDB: 2OBV) 
are shown in blue and pink sticks, respectively. H-bonds are represented by black dots. 
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Table 4.4 Data collection and refinement statistics for wtMATa1, R264H MATa1, 
R264A MATa1 and R264A MATa2 structure 
Data collection wtMATa1 R264H MATa1 R264A    
MATa1 
R264A 
MATa2 
Wavelength (Å) 0.9795 0.97624 0.9785 0.9785 
Space group                                          C2 C2 C2  I222   
    a, b, c (Å) 218.68, 61, 
119.76 
108.56, 83.62, 
87.56 
217.82, 
61.38, 119.51 
67.14, 94.23, 
116.82      
   a, b, g (Å)  90.00, 90.55, 
90.00 
90.00, 107.99, 
90.00 
90.00, 90.47, 
90.00 
90.00, 90.00, 
90.00                   
Resolution (Å) 58.76-2.35 
(2.41-2.35) 
51.62-2.85 (3.00-
2.85) 
46.87-3.10 
(3.29-3.10) 
58.41-1.70    
(1.73-1.70)                  
No. of reflections 66266 17484 27923 40576 
Rmerge (%)               10.8 (50.2) 17.7 (85.8) 16.1 (71.9) 12.4 (51.3)      
I/s(I) 6.4 (1.9) 5.1 (1.5) 5.6 (1.5)     5.9 (1.9)    
CC (1/2) 0.991(0.762) 0.974 (0.755) 0.977 (0.618) 0.985 (0.619) 
Completeness (%) 100.0 (99.9) 99.3 (97.9) 97.2 (96.1) 98.7 (99.8) 
Redundancy 3.4 (3.4) 5.1 (5.2)   2.8 (2.6) 4.3 (4.1) 
Wilson B factor (Å)2 29.3 55.5 53.8 12.4 
Refinement     
Rwork / Rfree 18.38/ 23.73 24.10/ 29.38 21.64/ 25.89 16.00/ 18.42 
No. atoms     
    Protein 11211 5683 11242 2963 
    Ligand/ion  62 - - 66 
    Water 408 3 5 284 
Average B-factor 
(Å)2 
    
   Protein 36.88 58.95 60.97 15.3 
   Ligand 46.76 - - 21.77 
   Water 31.92 50.34 19.78 29.36 
Ramachandran 
statistics 
    
 
    Residues in 
preferred regions  
1395 709 1375 372 
    Residues in 
allowed regions 
29 21 56 6 
    Outlier 11 5 12 0 
R.m.s deviations     
    Bond lengths (Å) 0.014 0.010 0.011 0.015 
    Bond angles (°) 1.638 1.363 1.638 1.695 
PDB Code        6SW5                   6SW6         6FCD 
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4.4.2.2 The crystal structure of the dimeric R264H: an apo form  
The crystal structure of MATa1 (R264H) mutant was solved at 2.85 Å. The crystal belongs to 
the C2 space group containing the cell solvent content of 42.2 %. The asymmetric unit 
containing a dimer of 2 subunits (Chain A-B). R264H mutation sites are shown in the Fo-Fc 
omit map (Fig. 4.4.5A). Three regions are invisible in this mutant structure including an N-
terminus (Met1-Glu15), gating loop (Asp116-Glu127) and Phe250-Gly257 region. Only Chain 
B that contains all of these three invisible regions, while Chain A shows electron density maps 
of the gating loop and the Phe250-Gly257 region.  
The R265H mutant (corresponding to Arg264 in human) of rMAT and human MATa1 
(R264H) were reported to fail in dimerization [163, 166], whereas the analogous eMAT R244H 
mutant remained as a tetramer [167]. The crystal structure of MATa1 (R264H) mutant shows 
a huge difference of the dimeric interface orientation due to Arg264 substitution by His264. 
His264 forms stronger H-bonds with Glu57 (2.7 and 2.9 Å) than those found in the wild type 
(Arg264) due to the shorter side chain of histidine rendering the displacement of the residues 
that are located at the dimer interface (Fig. 4.4.5B). At the mutation site, the distance between 
His264 of each subunit is 7.38 Å, about 2.06 Å difference to the wild type (Fig. 4.4.6A). 
Residues that line the dimer interface are found to be displaced along this mutation site causing 
difference in the dimerization forces (Fig. 4.4.6A-B). The upper part of the interface (Thr262-
Gly263) that neighbours the mutation site (Arg264His) becomes generally tighter along the 
dimer interface, while the mutation site itself loosens up. Distance displacement caused by 
R264H mutation compared to wtMATa1 is shown in Table 4.5.  
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Fig. 4.4.5 The structure of apo MATa1 (R264H) mutant. (A) Each subunit of the mutant’s 
dimer is shown in yellow and blue ribbons. The dimer is composed by self-assembly of the 
MATa1 (R264H) monomer (chain A and chain B). The Arg264His mutation site is shown in 
the Fo-Fc omit map contoured at the 3 σ level (green). The gating loop and residues 250-259 
are shown in red and pink, respectively. (B) His264 and Glu57 of each subunit forms H-bonds 
at 2.7 and 2.9 Å stabilising dimer formation.  
Table 4.5 Ca to Ca measurements of the residues (Val262-Ile267) along the mutation site 
of each subunit in comparison to wild type. 
Residue Ca-Ca (Wild Type, Å) Ca-Ca (R264H, Å) 
Thr262 12.01 10.23 
Gly263 10.14 7.75 
Arg264/ His264 5.47 7.53 
Lys265 11.37 12.73 
Ile266 9.22 9.63 
Ile267 10.58 10.88 
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Fig. 4.4.6 The structural comparison of the wtMATa1 and MATa1 (R264H) mutant. The 
wtMATa1 and the MATa1 (R264H) mutant are shown in pink and blue ribbons, respectively 
with alignment of chain A to chain A of each protein. (A) The dimer interface is represented 
by dash line and a Ca to Ca distance at Arg264 and the mutation site (His264) are illustrated. 
Ca atoms are marked by yellow circles. (B) The distance displacement causing by R264H 
mutation is shown by Ca to Ca measurements of these residues (Val261-Ile267) of each 
subunit compared to the wild type. Thr262-Ile266 main chains are shown in dark pink (wild 
type) and blue (R264H) sticks. Ca atoms are marked by yellow circles. (C) Normalised 
fluorescence curves used for Tm determination of the wild type and the mutant are shown.  
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The MATa1 (R264H) mutant is statistically less stable than the wild-type enzyme, its Tm 
being 47.50 ± 0.15 (p < 0.001), 47.27 ± 0.37 oC (p < 0.001) of a tetramer and a dimer, 
respectively, compared to 50.30 ± 0.10 oC of the wild type (Fig. 4.4.6C). The crystal structure 
of R264H mutant in an apo form was obtained, although R264H proteins were mixed with their 
substrates (Met and AMP-PNP) before crystallisation. The loss of enzymatic activity caused 
by this mutation may thus originate from its inability to bind the substrates in the first place 
which may arise from the change in position of residues at dimer interface. This results in the 
lower affinity for a tetrameric assembly and greater propensity of a dimeric assembly.  
4.4.2.3 Dimer-dimer interface: the structural comparison of the apo form of the 
wtMATa1 (tetramer) and the R264H mutant (dimer) 
The subunit interactions in the dimer may play a crucial role in contribution of forming the 
tetramer as described in Fig. 4.4.7A-C. The tetrameric form of wtMATa1 structure reveals a 
dimer to a dimer contact surface which consists of only few polar interactions including Thr62 
(chain A, B) to Asn105 (Chain C, D) and Arg84 (chain A, B) to Glu111 (Chain C, D) (Fig. 
4.4.7B). Also, no disulphide bond is observed in both dimer and tetramer subunit interactions. 
The R264H mutation causes residues at the dimer interface to be displaced from their original 
position in the wild type.  Accordingly, overall protein architectures are changed, despite that 
the secondary structures are preserved. As a consequence of mutation effect, Thr62 and Arg84 
which participate in dimer to dimer contact are relocated 8.6 and 9.8 Å compared to the wild-
type structure (Fig. 4.4.7C), resulting in the instability of forming the tetramer.  
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Fig. 4.4.7 The structural comparison of wtMATa1 and MATa1 (R264H) mutant. (A) The 
wtMATa1 and MATa1 (R264H) mutant are shown in pink and blue ribbons, respectively with 
alignment of chain A to chain A of each protein. The dimer to dimer interface of wtMATa1 is 
shown in red color (chain C and chain D). (B) The polar interactions at dimer to dimer 
interfaces found in the wild type are illustrated at chain A to chain C and chain B to chain D. 
The residues of chain A and B are shown in pink sticks, while the residues of chain C and D 
are shown in red sticks. (C) The wtMATa1 and MATa1 (R264H) mutant are shown in pink 
and blue, respectively with alignment of chain A to chain A of each protein. The distance 
displacement of Thr62 and Arg84 caused by the R264H mutation is shown compared to the 
wild type. Thr62 and Arg84 are presented by pink and red sticks for the wild type and blue 
sticks for the R264H mutant. Thr262-Ile266 main chains are shown in dark pink (wild type) 
and blue sticks (R264H) to mark the mutation regions. 
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4.4.2.4 The crystal structure of the tetrameric MATa1 (R264A) mutant: an apo form 
The crystal structure of the MATa1 (R264A) mutant was solved at 3.1 Å. The crystal was 
crystallised in the C2 space group containing the cell solvent content of 45.29 %. The 
asymmetric unit shows two dimers (Chain A-D), the same as found in the wild-type structure 
(Fig. 4.4.8A). R264A mutation sites are shown in Fo-Fc omit maps confirming positive peaks 
for alanine in the model (Fig. 4.4.8B). Three regions are invisible in this mutant structure 
including the N-terminus (Met1-Glu15), gating loop (Asp116-Glu127) and substrate binding 
region (Phe250-Asp258) indicating their flexibility. At the mutation site, the distance between 
Ala264 of each subunit is 6.80 Å (Fig. 4.4.8B), while R264H mutant showed 7.53 Å compared 
to wtMATa1 (5.47 Å). In contrast to R264H MATa1, there is no prominent displacement in 
positions of the residues that line the dimeric interface along this mutation site when compared 
to the wild-type structure (Fig. 4.4.8C). Only a small difference is observed by structural 
alignment of the wtMATa1 and the R264A mutant, RMSD of 0.340 Å.  
As relatively lower resolution was usually obtained from the MATa1 mutant crystal, the 
R264H and R264A mutant structures were solved at 2.85 Å and 3.1 Å, respectively. In addition, 
the mutation of Arg264 to His264 in MATa1 caused a substantial change at the dimeric 
interface which could lead to an inability to bind the substrates of the mutant. MATa2 has 
sequence similarity of 84 % to MATa1 and Arg264 is conserved among these two proteins. 
The equivalent mutation in MATa2 (Arg264Ala: R264A) was designed in order to produce 
the substrate-bound crystal form, allowing to understand the functional role of Arg264’s side 
chain in the active site. Therefore, the MATa2 (R264A) mutant was generated and 
characterised both structurally and functionally (see below, section 4.4.2.5).  
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Fig. 4.4.8 The structure of apo R264A MATa1 mutant. (A) Each subunit (chain A-D) of 
R264A MATa1 tetramer is shown in blue, green, yellow and pink ribbons. The tetramer is 
composed by self-assembly of two dimers. (B) A dimer is shown in blue and green robbons. 
The gating loop and residues 250-259 are shown in red and pink, respectively. The Arg264Ala 
mutation site is shown in the Fo-Fc omit map contoured at the 3 σ level (grey colour). The 
substitution of Arg264 to Ala264 changes the Ca to Ca distance between this residue of each 
subunit to 6.80 Å (wild type: 5.47 Å). (C) The wtMATa1 and the MATa1 (R264A) mutant 
are shown in pink and blue, respectively, with the structural alignment of chain A to chain A 
of each protein (left panel). The structural comparison of the wtMATa1 and the MATa1 
(R264A) mutant is shown at the dimer interface (right panel).  
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4.4.2.5 The crystal structure of the MATα2 (R264A) mutant: a holo form  
The R264A MATα1 and R264H MATα1 crystals diffracted at the resolution of 3.1 Å and 2.85 
Å, respectively. Only apo form is obtained when the R264H MATα1 protein was co-
crystallised with methionine and ATP analogue. It is likely that substitution of Arg to His 
causes a huge change to the orientation of the enzyme’s dimeric interface that also affects 
diffraction-quality, therefore Arg264Ala (R264A) mutant in MATα2 was used as the model to 
study the functional role of Arg264 in MAT active sites. The crystal structure of MATα2 
(R264A) mutant was obtained at 1.7 Å and it was in complex with an enzyme intermediate. 
Arg264 side chain is involved in tripolyphosphate interaction during enzyme reaction, while 
the dimer interface of the R264A mutant and the wild-type MATα2 is in similar orientation 
and no significant movement has been observed. In contrast, the R264H crystal structure of 
MATa1 shows a huge difference of the dimeric interface orientation at the central part where 
His264 was substituted to Arg264 (Fig. 4.4.5B), resulting in the disordered active site.  
R264A MATα2 protein was co-crystallised with Met and AMP-PNP and its structure contains 
enzyme intermediates that are well-defined in the active sites. The crystal structure of R264A 
MATα2 does not contain SAMe in the active site, but the full occupancy of ADO and 
Pyrophosphate (PPi) is observed (Fig. 4.4.9A-B). In the wild type, Arg264 stabilises the Pγ of 
the tripolyphosphate (PPPi or PPNP) via its NH2 and NE atoms (Fig. 4.4.9C). Therefore, the 
Pγ of PPNP is invisible in the R264A mutant structure, suggesting the important role of Arg264 
in stabilising the PPPi conformation for ATP cleavage. The loss of the Arg264-Glu57 salt 
bridges of the mutant results in a decrease of thermal stability of the enzyme. The Tm of the 
R264A mutant is significantly decreased to 42.50 ± 0.06 οC (p<0.001), compared to 47.10 ± 
0.10 οC of the wtMATα2. The normalised fluorescence curves used to determine the Tm of 
each protein are shown in Fig. 4.4.9D.  
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Fig. 4.4.9 The structural comparison of the R264A MATα2 mutant and the wild-type 
structure. (A) The crystal structure of R264A MATa2 is shown with fully symmetrical 
crystallographic dimer (yellow and pink) with the closed gating loop (red). (B) The active site 
of the R264A mutant is shown with the omit map contoured around Ala264 and enzyme 
intermediates (ADO and PPi). The Fo-Fc omit map is contoured at the 3 σ level (green). (C) 
Arg264 forms a salt bridge with its dimeric Glu57. Arg264 interacts with PPNP at O2G and 
O3G atoms via its NE and NH2 atom. The figure is derived from the wtMATα2 structure (PDB: 
5A1I). H-bonds are represented by black dots. (D) Normalised fluorescence curves used for 
Tm determination of each protein are shown. 
  
 130 
4.5 The conservation sequence analysis and insight from structural analysis of MAT 
enzymes 
The multiple sequence alignment of MAT homologous proteins in all living organisms have 
been performed using 2,963 amino acid sequences (Fig. 4.5.1). The residues involve in SAMe 
formation including 5 acidic (Asp31, Glu57, Glu70, Asp258 and Asp291), 6 basic (His29, 
Lys181, Arg264, Lys265, Lys285 and Lys289) and 1 neutral amino acid (Gln113) (Fig. 
4.5.2A). These catalytic residues are highly conserved through organisms (Fig. 4.5.1). Three 
of these catalytic residues including Asp258, Arg264 and Lys289 play direct roles in the 
substrate binding and have been reported to cause IPH when the MAT1A gene has genetic 
mutations at these residues: Asp258Gly, Arg264His/Cys and Lys289Asn [144, 150, 153, 168]. 
All mutation points of MAT1A gene causing IPH reported to date are illustrated in Fig. 4.5.1 
and 4.5.2B. MAT1A gene sequences where the missense mutations mostly take place are the 
fully conserved amino acid residues: Ser22Leu, Ser38Asn, Ala55Asp, Gly69Ser, Tyr92His, 
Pro255Ser, Tyr271Cys, Gly280Val, Arg292Cys, Arg299His/Cys, Ile322Val/Met, Val361Phe, 
Gly378Ser and Gly381Arg [15, 144, 150, 152, 153, 159, 160, 169] (Fig. 4.5.1).  
In addition to Arg264His, the functional role of Arg299 was aimed to investigate using the 
Arg299His mutant which causes IPH in patients. Though it was successful in producing 
Arg299His mutant, the majority of this mutant protein formed aggregate in solution, so the 
functional oligomeric form could not be obtained. Arg299 is located at the middle of the solvent 
inaccessible a-helix domain. The Arg299’s side chain forms H-bond with Tyr141 of the 
underlining b-sheet domain and also Glu148, Cys149 and Glu388 of the connecting loop (Fig. 
4.5.2C), suggesting its importance in protein folding and overall structural stability. Some of 
the IPH causing mutants arise from highly conserved amino acid residues: Leu42Pro, 
Arg177Trp, Arg199Cys, Arg249Trp, Ile252Thr, Gly257Arg, Ala259Val, Ala297Asp, 
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Gly336Arg, Arg356Trp/Pro/Gln, and Pro357Leu [15, 144, 150, 152, 153, 160, 169, 170] (Fig. 
4.5.1). The Arg356Trp mutant was generated, but its purification exhibited the problem similar 
to that observed in the Arg299His mutant. The protein was highly aggregated in solution and 
eluted at the void volume of a gel filtration column. Arg356 is located at the surface of the 
solvent accessible a-helix domain and it forms several H-bonds with Glu128, Asp129 of the 
gating loop and Asp354 of the neighbouring connecting loop (Fig. 4.5.2D), suggesting its 
important role in overall protein architecture. Only few mutations causing IPH have been found 
with poorly conserved amino acids (Leu305Pro and Glu344Ala and Val361Phe) (Fig. 4.5.1) 
[150, 152, 170]. In addition, Arg356His and Glu344Ala were reported to cause the increase of 
susceptibility to a thoracic aortic aneurysms when mutations occur in the MAT2A gene, 
suggesting their importance in enzyme stability and function [171].   
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Fig. 4.5.1 Amino acid conservation of MATa1 with catalytic residues and mutation sites 
causing hypermethioninemia. Different colour is used to show amino acid hydrophobicity 
(blue: hydrophilic, green: neutral and black: hydrophobic). Catalytic residues are marked by 
green squares. Residues reported to have mutations which cause hypermethioninemia are 
marked with yellow squares. Red marks represent residues involved in both SAMe formation 
and missense mutations causing IPH.  
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Fig. 4.5.2 Catalytic residues and mutation sites causing IPH of MATa1 (A) Two active 
sites of MATa2 are shown with SAMe and PPNP highlighted with orange colour. Residues 
involved in SAMe formation are shown in green spheres. Missense mutations causing 
hypermethioninemia are shown with yellow spheres. Red spheres are represented residues that 
involved in both catalysis and mutations causing hypermethioninemia. (B) The mutations 
causing hypermethioninemia are shown with yellow spheres. The two subunits are shown by 
dark and light blue using the MATa2 structure as a model (PDB: 5A1I). (C) Arg299 interaction 
sites are illustrated. Black dots indicate H-bonds and the interacting residues are shown as 
sticks. (D) Arg356 interaction sites are presented. H-bonds are shown in black dots and the 
interacting residues are shown as sticks. 
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4.6 Conclusion  
This study provides the structural basis of the R264H mutation at the MATa1 dimer interface. 
This mutation changes the position of residues that constitute the dimer interface where the 
active sites are located. This results in an inability to bind the substrate which causes a loss in 
activity. The changes at the dimeric interface also give rise to the lower affinity for a tetrameric 
assembly and greater propensity of a dimeric assembly. Arg264 is also involved in providing 
enzyme stability by forming a salt bridge with Glu57, so mutation to histidine causes the lower 
thermal stability of the enzyme as observed by the decreased melting temperatures of the 
mutants.  
The data show that the MATa1 (R264H) mutant is able to assemble as a dimer or a tetramer 
in solution and exists as a dimeric form in the crystal structure. However, the R264H mutation 
causes a substantial loss in activity, suggesting that Arg264 may be overrated for subunit 
dimerization but it is indeed crucial for the optimal enzyme reaction. The crystal structure of 
the MATa1 (R264H) mutant is obtained in apo form with no Met or SAMe bound, although 
the mutant protein was co-crystallised with the substrate Met and AMP-PNP, consistent with 
a reduction in enzyme activity. The functional impairment is also related to the residue’s role 
in the interaction with the tripolyphosphate as shown in the R264A MATa2 mutant structure. 
Also, the R264H mutation causes a disordered active site which results from a disorganised 
dimer interface. This change of the dimer interface attenuates the ability of the mutant enzyme 
to bind with substrates. In addition, the incubation of the R264A MATa2 mutant and the 
R264H MATa1 mutant with the regulatory subunits, MATbV1/V2, shows activity restoration 
of these mutants. This observation opens up an opportunity of modifying enzyme defect in the 
disease-causing mutants by small molecules to mimic the effect of the binding of the regulatory 
subunits. 
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Chapter V 
The regulation of human MAT enzymes by quinolone-based compounds 
 
5.1 Background and objective 
A decrease in SAMe formation is varying from a partial loss in the Q113A mutant to a 
substantial loss in the S114A mutant or the R264A/R264H mutant. Forming complexes with 
MATβV1 or MATβV2 can restore the activity of MATα2 mutants. Only the regulatory subunit, 
MATbV1, can form the complex with the MATα1 (R264H) mutant and has the recovery effect 
on the mutant activity, while this mutant is unable to form the complex with MATbV2. This 
observation suggests that modifying enzyme defect that cause a disease by using the protein-
protein interacting surface (e.g. MATαβ binding interface) by small molecules either designed 
for restoring or inhibiting enzyme function could be a promising approach for therapeutic 
treatment. The idea is not limited to the restoring of disease’s causing enzyme, but it could be 
extended to other aspects including designing the inhibitor for MATa2, e.g. anticancer 
therapeutics. Structural data on MAT enzymes bound with Met, ADO and PPNP are in 
agreement with the hypothesis that MAT catalyses SAMe via the asymmetrical reaction of SN2 
nucleophilic substitution mechanism [146]. The C-O bond of ATP is broken to the 
intermediates (ADO and PPNP) and is suggested to occur prior to the formation of the C-S 
bond between C atom of ADO and S atom of Met at the transition state [146]. The chemical 
form in the transition state differs to those found in the substrate or product [172] and the 
reactive intermediate is formed in this state (i.e. C-S bond formation between ADO and Met, 
which will be further converted to SAMe). Although, the transition state cannot be directly 
studied by X-ray crystallography using crystal structures, a number of the reported ligand-
bound structures of human MATa2 can shed some light on what is happening at the transition 
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state and are also useful for structural-based drug design (Table 5.1). For instance, ADO and 
PPNP tightly bind to the active site (prior to SAMe formation), indicating that these 
intermediates could be a potential model for designing enzyme inhibitors which competitively 
bind to the active site.  
The PF-9366 (1-[2-(dimethylamino) ethyl] quinoline benzodiazepine derivative) was found to 
regulate MATa2 by binding at the same interacting interface reported to form MATα2β 
complexes (Fig. 5.1.1A). [145]. The PF-9366 bound structure of MATa2 showed that two 
molecules of PF-9366 interacted with one MAT dimer (Fig. 5.1.1B) and inhibited MATa2 
activity. PF-9366 is a 1,2,4-triazolo[4,3-a]-class inhibitor and its main scaffold is similar to the 
4(1H) quinolone. Coincidentally, a number of quinolone-based compounds (SCR0911, 
SCR0915, CK267 and WDH1U4) are available for testing their effect on MAT activity. The 
possible binding sites of the compounds on MAT enzymes were preliminary predicted by 
molecular docking using SwissDock (Table 5.2). The binding energies of these quinolone-
based compounds are shown in comparison with the PF-9366 compound using the wtMATα2 
as the target model. The results show that PF-9366 is the most favourable compound to bind 
with the wtMATα2 as indicated by its lowest binding energies (Gibbs free energy (∆G) of -
8.53 kcal/mol and FullFitness of -3146.97 kcal/mol). The most energetically favourable ligand 
binding site of these quinolone-based compounds is predicted to be the compound, SCR0915, 
which show comparable binding energies to PF-9366 (∆G of -8.40 kcal/mol and FullFitness of 
-3055.58 kcal/mol). The potential binding energies of other compounds used in this study 
(WDH1U4, CK267 and SCR0911) are shown in Table 5.2. The compound, SCR0911, is the 
most energetically unfavourable ligand showing highest energies for binding to the wtMATα2 
(∆G of -7.62 kcal/mol and FullFitness of -3045.93 kcal/mol), when compared to other 
compounds reported here (Table 5.2). Interestingly, the predicted binding sites of all quinolone-
based compounds on MATα2 are similar to the protein-protein interacting surface where PF-
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9366 and MATβ have been reported to bind at. Therefore, the effect of these compounds on 
MAT activity has been further investigated. An attempt to obtain the compound-bound 
structure of MAT enzymes by co-crystallisation technique has been done using a variety of 
available commercial screens. The quinolone-based compound structures used in this study are 
shown in Fig. 5.1.2. 
Table 5.1 Human MATa2 structures with ligands in the active site 
hMATa2 Resolution (Å) PDB Active site ligands Reference   
Wild type 1.09 5A1I SAMe+ADO+MET+PPNP [30] 
Wild type 2.34 5A19 PPNP [30] 
Q113A 2.70 6FBN SAMe+PPNP [47] 
S114A 
(P22121) 1.65 6FBP PPNP+ADO [47] 
S114A 
(I222) 1.80 6FBO PPNP+ADO [47] 
P115G 2.70 6FCB SAMe+PPNP [47] 
R264A 1.70 6FCD PPi+ADO [47] 
MATa2b 2.34 4NDN SAMe+PPNP [13] 
MATa2b 2.59 4KTT SAMe+Pi [13] 
 
Table 5.2. The binding energy of compounds predicted by SwissDock. wtMATa2 (PDB: 
5A1I) was used as the model.  
Compounds Delta Gibbs free energy 
(kcal/mol) 
FullFitness score 
(kcal/mol) 
PF-9366 -8.53 -3146.97 
SCR0911 -7.62 -3045.93 
SCR0915 -8.40 -3055.58 
CK267 -8.08 -3054.34 
WDH1U4 -8.26 -3043.29 
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Fig. 5.1.1 The structural comparison of MAT(a2)4(MAT(bV2)2 complex and the PF-9366 
bound MATa2 structure. (A) MAT(a2)4MAT(bV2)2 complex (PDB: 4NDN, blue and 
green) and the PF-9366 bound MATa2 structure (PDB: 5UGH, yellow) are aligned. PF-9366 
compounds are shown in pink sticks. (B) Two molecules of PF-9366 bind to MATa2 showing 
the same binding site of MATbV2. 
 
Fig. 5.1.2 Quinolone-based compound structures. The PF-9366 structure is shown in 
comparison with the quinolone-based compounds used in this study. 
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5.2 The regulation of human MAT enzymes by quinolone-based compounds 
The effect of quinolone-based compounds on MAT activity has been tested for wtMATα1, 
R264H MATα1, wtMATα2, S114A MATα2 and R264A MATα2. The final concentration of 
DMSO in protein samples was less than 1 %. The effect of DMSO on enzyme activity and 
melting temperature has been examined at 2 % which shows no effect on both SAMe formation 
and thermal stability of enzymes. The mutants of MATα2 that their mutations cause a reduction 
of enzyme activity show the recovery of SAMe formation by these quinolone-based 
compounds, whereas the wtMATα2 activity is inhibited by these compounds (Fig. 5.2.1A). 
Each mutant responds differently to the tested compounds. SCR0911 and WDH1U4 
compounds can recover the MATa2 (S114A) mutant, while they have no effect on the MATa2 
(R264A) mutant. The R264A MATa2 can produce SAMe of about 50 % compared to the wild-
type activity when it is incubated with CK267 or SCR0915 compounds (Fig. 5.2.1A). 
Additionally, the compounds have no effect on the phosphatase activity of the enzyme and its 
mutants (Fig. 5.2.1B). 
The compound, SCR0915, is selected as the model to study the effect of these quinolone-based 
compounds on MATα2 activity. This compound inhibits the wild-type activity (Fig. 5.2.2A), 
while it recovers SAMe formation of the MATα2 (R264A) mutant (Fig.5.2.2B). The 
determination of SCR0915 IC50 using an inhibition curve of wtMATα2 is shown in Fig. 5.2.2C. 
SCR0915 also slightly increases the thermal stability of wtMATα2 to 48.17 ± 0.23 οC (p < 
0.01) when compared to the Tm of an untreated wtMATα2 (47.20 ± 0.15 οC). The thermal 
stability of the MATα2 (R264A) mutant significantly increases to 41.48 ± 0.06 οC (p < 0.001) 
when compared to the Tm of an untreated R264A mutant (39.2 ± 0.07 οC). The fluorescence 
curves used to determine the Tm of each protein are shown in Fig. 5.2.2D. The compound 
treatments show the different effect on wtMATα2 and its mutant. It is likely that the compound 
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can render the MATα2 to be more sensitive to SAMe inhibition. Therefore, this results in a 
reduction of SAMe formation found in the wild type, while the compound can increase SAMe 
formation in the MATα2 (R264A) mutant just only to 41.2 ± 1.4 % relative to the wild type 
(Fig. 5.2.1A).  
 
Fig. 5.2.1 Effect of quinolone-based compounds on wild-type and mutant MAT enzymes 
(A) 10 µM of the compound was incubated with Met and ATP before SAMe formation was 
measured by ELISA kit (Cell biolabs). (B) The compounds show no effect on the PPPi 
hydrolysis. (‘*’, ‘**’ and ‘***’ indicates statistical significance at p < 0.05, p <0.01 and p 
<0.001, respectively, compared to the untreated enzymes). Data are mean of three independent 
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experiments ± SEM (n=3). All experiments were performed using protein samples from the 
same batch of protein purification (different aliquots).  
In contrast to wtMATα2, the incubation of wtMATα1 with the compound SCR0911 or 
WDH1U4 shows the increase in SAMe production as shown in Fig. 5.2.1A. Therefore, 
SCR0911 has been selected to investigate its effect on the activity of the MATa1 (R264H) 
mutant. The results show that the R264H mutant treated with SCR0911 is able to restore its 
function to the similar level compared to the wild type (Fig. 5.2.2E). However, pre-incubation 
with the compound SCR0911 does not prevent the hetero-complex (R264H-MATbV1) 
formation (Fig. 5.2.2F). The addition of SCR0911 to R264H-MATbV1 complex does not give 
the synergistic effect, suggesting that SCR0911 competes with MATbV1 for binding at the 
same dimeric interface and MATbV1 binding prevent SCR0911 to interact with the mutant 
protein (Fig. 5.2.2E-F). These compounds show different effects on MATα1 and MATα2 
activity which may be related to the different kinetic properties of these two isoforms. MATα1 
has higher Km for Met (23 µM-1 mM) compared to MATα2 (4-10 µM) and MATα1 is not 
very sensitive to SAMe inhibition compared to MATα2 [41, 72]. The compounds may lower 
Km for Met of MATα1 which results in the observed higher SAMe formation. The kinetic 
study of the compounds on MAT enzymes needs further investigation to understand how these 
compounds indeed regulate MAT activity.  
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Fig. 5.2.2 The effect of SCR0915 and SCR0911 compound on MAT activity (A) The effect 
of SCR0915 on the wild-type MATα2 is exhibited. (B) The effect of SCR0915 on the MATα2 
(R264A) mutant is shown. ‘***’ corresponds to the statistical difference at p <0.001 when 
compared to the untreated enzyme (0 µM). (C) The SCR0915 IC50 (half-maximal inhibitory 
concentration) are shown with the inhibition curve. The IC50 was calculated from a 
log([SCR0915]) versus normalised response curve fit using GraphPad Prism version 5.00. (D) 
The fluorescence curves used to determine the thermal stability of each protein are shown. (E) 
The effect of regulatory subunits (MATb) and SCR0911 on the MATa1 (R264H) activity are 
shown by measuring SAMe formation. ‘***’, ‘&&&’ and ‘###’ denote statistical significance 
at p < 0.001 compared with R264H (tetramer), R264H (dimer) and both oligomeric forms of 
R264H, respectively. (F) Gel filtration profiles of R264HbV1 with or without SCR0911 pre-
incubation are shown by the absorbance at A280. (A-B, E) Data are mean of three independent 
experiments ± SEM (n=3). All experiments were performed using protein samples from the 
same batch of protein purification (different aliquots).  
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5.3 Compound screening: co-crystallisation of R264A MATa2 and SCR0915 
In order to obtain the crystallisation conditions for producing SCR0915-bound crystals, fifteen 
commercial screens (96 conditions each) were tested by co-crystallisation of the R264A 
MATa2 with the SCR0915. All screening trays were kept at room temperature (18 °C) and for 
each condition 200 nL of protein was mixed with 200 nL of precipitant (200:200 nL) (protein: 
precipitant). Crystals appeared in some of the commercial screens (JCSG plus, SALTRx and 
PACT premier screens). The screening conditions that promote crystal growth are provided in 
Table 5.3.1-5.3.3. Some screening solutions showed protein precipitation which was scored 
from 1 to 5 depending on the levels of observed precipitations (5 indicated a highly aggregated 
state). Blank cells in the table correspond to the clear drop, while good hit is shown with H (i.e. 
crystal is growing). If the reservoir condition was suitable for growing protein crystals, the 
crystal would normally appear in 3-4 days. 
The crystals from these three screens were tested with X-ray beam but diffracted to only 8-10 
Å. Despite the low-resolution, the diffraction patterns were originated from protein crystals 
(Fig. 5.3). Therefore, further optimisation is necessary (section 6.2.2, chapter 6). 
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Table 5.3.1 JCSG plus screening of the R264A MATa2 co-crystallised with SCR0915 
 
Screening conditions: 
Protein: R264A MATα2 (5mg/ml) + SCR0915 200:200 nL 
E11 0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate pH 6.5, 14.4 % w/v PEG 
8000 and 20 % v/v glycerol: F1 0.05M Cesium chloride, 0.1 M MES pH 6.5 and 30 % v/v 
Jeffamine® M-600. 
Table 5.3.2 SALTRx screening of the R264A MATa2 co-crystallised with SCR0915 
 
Screening conditions: 
Protein: R264A MATα2 (5mg/ ml) + SCR0915 200:200 nL 
E9 1.8 M Sodium phosphate monobasic monohydrate and Potassium phosphate dibasic pH 
6.9: E12 1.0 M Succinic acid pH 7.0 and 0.1 M BIS-TRIS propane pH 7.0. 
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Table 5.3.3 PACT premier screening of the R264A MATa2 co-crystallised with 
SCR0915 
 
Screening conditions: 
Protein: R264A MATα2 (5mg/ml) + SCR0911 200:200 nL 
B3 0.1M MIB (Malonic acid, Imidazole and Boric acid) pH 6.0 and  25 % w/v PEG 1500: C7 
0.2 M Sodium chloride, 0.1 M HEPES pH 7.0  and 20 % w/v PEG 6000: C7 0.2 M Sodium 
chloride, 0.1 M HEPES pH 7.0 and 20 % w/v PEG 6000: C9 0.2 M Lithium chloride, 0.1 M 
HEPES pH 7.0 and 20 % w/v PEG 6000: D3 0.1 M MMT (Malic acid, MES and Tris) pH 6.0 
and 25 % w/v PEG 1500: F10 0.02 M Sodium/potassium phosphate, 0.1M Bis-Tris propane 
pH 6.5 and 20 % w/v PEG 3350. 
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Fig. 5.3 Crystal diffraction test at Diamond Light Source (DLS). Numerous crystals from 
the screens were sent to test at DLS (I24 beamtime). All tested crystals were protein crystals 
and diffracted at only 8-10 Å resolution. 
5.4 The molecular modelling of SCR0915 and SCR0911 binding site on MAT enzymes 
The prediction of SCR0915 binding sites was performed using SwissDock (blind docking) and 
Autodock Vina (local docking). The wild type and MATα2 (R264A) mutant were used as the 
target proteins. The best binding position are selected based on the Gibbs free energy (∆G) and 
FullFitness score. Both SwissDock and Autodock Vina predicted the most favourable binding 
position at the same binding interface where PF-9366 and MATβ were reported to bind to 
MATα2 [13, 145]. The SCR0915 binding position predicted by Autodock vina using the wild-
type structure as the model (PDB: 5A1I) shows ∆G of -11.4 kcal/mol, while ∆G of -7.8 
kcal/mol and FullFitness of -3486.08 kcal/mol are predicted by SwissDock (Fig. 5.4.1 A-C).  
The SCR0915 binding position predicted by Autodock Vina using the MATα2 (R264A) 
structure as the model (PDB: 6FCD) exhibits ∆G of -10.2 kcal/mol, whereas ∆G of -8.1 
kcal/mol and FullFitness of - 3111.79 kcal/mol are predicted by SwissDock (Fig. 5.4.1D-F). 
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The predicted SCR0915 binding site of both the wild type and R264A MATα2 is found to be 
at the same binding interface as the reported PF-9366 compound (Fig. 5.4.1G). Pre-incubation 
of the compound SCR0915 with MATα2 partially prevents MATβV1 to form the complex with 
MATα2 (Fig. 5.4.1I), confirming the similar binding interface. In contrast to SCR0915, 
SCR0911 cannot prevent the binding of MATβV1 on the MATα1 (R264H) mutant (Fig. 
5.2.2F). 
MATb could alter MATa2 activity, while the residues in the catalytic site of MATa2 was 
preserved in the presence of MATb [13, 146], indicating that the increase in activity might be 
modulated by an allosteric regulation rather than the direct binding in the active site. The 
activity restoration of the MATa1 (R264H) mutant by MATbV1 or SCR0911 suggests a 
similar binding interface. The best binding position of SCR0911 on MATa1 (R264H) mutant 
is predicted by blind docking using SwissDock (FullFitness = -3475.04 kcal/mol, and ΔG = -
7.76 kcal/mol) and the interaction profiles are shown in Fig 5.4.2A-B. The predicted site is at 
the same dimeric-interface pocket of MATa2 where SCR0915, MATβ and PF-9366 compound 
are shown to bind to [13, 145]. Efforts to obtain crystallographic structure with the compounds 
have not been successful suggesting some flexibility, heterogeneity and/or weaker binding 
compared to MATb, consistent with the inability of SCR0911 to compete with MATb in 
restoring SAMe activity of the MATa1 (R264H) mutant.  
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Fig. 5.4.1 The molecular modelling of ligand binding sites using Autodock Vina and 
SwissDock (A) The best binding positions of SCR0915 were predicted by Autodock Vina and 
SwissDock. SCR0915 is shown in a green stick (Autodock Vina) and a magenta stick 
(SwissDock) (B, C) The SCR0915 binding interaction profiles on wtMATα2 were predicted 
by Autodock Vina and SwissDock, respectively. (D) The SCR0915 best binding poses on 
R264A MATα2 were shown. (E, F) The interaction profiles of SCR0915 and MATα2 (R264A) 
mutant were obtained from Autodock Vina and SwissDock, respectively. H-bonds are shown 
in black dashed lines. Halogen bonds and electrostatic interaction are shown in blue and orange 
dashed lines. The π-π stacking is shown in pink dashed lines. (G) The MATα2 structure in 
complex with PF-9366 (PDB: 5UGH) is shown. The binding site of SCR0915 is similar to the 
PF-9366 binding interface. (H) Close view of PF-9366 and SCR0915 binding site is exhibited. 
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(I) The MATαβV1 formation (with or without SCR0915 (10 µM)) are shown by the absorbance 
at A280.  
 
 
Fig. 5.4.2 The molecular docking of SCR0911 binding site on the MATa1 (R264H) mutant 
(A) The SCR0911 binding site of the MATa1 (R264H) mutant (grey) is aligned with MATαβ 
complex. MATa2 and MATbV2 are shown with yellow and pink, respectively. SCR0911 is 
shown in the blue stick. (B) SCR0911 and R264H interaction profiles obtained from 
SwissDock are illustrated using DS visualiser. Protein ligand interactions are shown in blue, 
pink and orange dashed lines corresponding to halogen bonds, π-π stacking, electrostatic 
interactions, respectively. 
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Chapter VI 
Conclusion and future direction of the project 
6.1 Conclusion 
The functional and structural role of the gating loop have been studied by site-directed 
mutagenesis at the conserved residues Gln113, Ser114 and Pro115. The results show that 
Ser114 (OG atom) coordinates the adenine ring of the substrate ATP (N6 and N7 atom) via a 
water molecule. This coordination of Ser114, water and adenine moiety of ATP or SAMe is 
preserved in the structures of both MATa1 and MATa2, while mutation of this residue results 
in the loss of SAMe formation. Ser114 also stabilises a rigid helix conformation of the closed 
gating loop with the neighbouring gating residues (Asp116, Ile117 and Ala118). The ordered 
open conformation of the gating loop is firstly observed in the crystal structure of human MAT 
providing evidence that the gating loop rearranges to different conformations in each step of 
enzyme reaction. The conformational changes of the gating loop are driven by the substrate/ 
product interaction. Gln113Ala mutation results in about 25 % decrease in SAMe production 
compared to the wild type, while SAMe formation of Pro115Gly is normal. Although Gln113 
directly interacts with the oxygen atom of Met or SAMe via its side chain nitrogen atom, 
mutation of this residue does not completely prevent Met to bind at the active site. In addition, 
the Gln113Ala and the Ser114Ala mutant structures show asymmetrical active sites; one is 
empty, while the other is bound with substrates/products. In contrast to Pro115Gly mutant, its 
structure shows symmetrical active sites which both are fully occupied by substrates or 
products as found in the wild-type structure.   
The loss in activity of Arg264 mutant found in hypermethioninemia patients is not due to an 
inability to form a dimer or a tetramer in solution. The data show that the Arg264His MATa1 
mutant is able to assemble as a dimer or a tetramer, and Arg264Ala MATa2 is also tetrameric 
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in solution. These Arg264 mutants also exist as the dimeric form in crystal structures. The loss 
in activity is more likely to be related to the residue’s role in interacting with the 
tripolyphosphate as shown in the Arg264Ala (MATa2) structure. In addition, the Arg264His 
(MATa1) mutant structure shows the disordered active site due to the changes at the dimer 
interface caused by Arg264His mutation. Therefore, the ability of the enzyme to bind to 
substrates may be attenuated, resulting in the loss in activity.  
The current results suggest that the phosphatase activity and SAMe production are catalysed in 
distinct parts of the active site as PPPi hydrolysis is not affected by mutations which cause a 
decrease in SAMe production. Forming complexes with the regulatory subunit MATβ show 
the restoration of the mutant activity. This observation has been exploited for using small 
molecules that may interact with this protein interacting interface and can regulate MAT 
enzyme activity (Fig. 6.1).  
The effects of quinolone-based compounds on MAT activity have been tested and compared 
to the regulatory subunit MATβ. The compound binding sites are predicted to be at the same 
interacting interface of MATβ. However, it is likely that MATβ can bind with the catalytic 
subunits tightly than these quinolone compounds. Pre-incubation of the compound with 
MATa1/2 prior to MATβ cannot or partially prevent the MATaβ complex formation. The 
crystals produced by the compound co-crystallisation are obtained but do not diffract at the 
high resolution, thus the ligand-protein interaction profiles are obtained by using molecular 
docking tools (SwissDock and AutoDock Vina). The aromatic ring of Phe333 plays an 
important role in p-p stacking with the compound heterocyclic rings as predicted by both 
docking programs. Two molecules of PF-9366 compounds also interact with Phe333 and Phe18 
of each MAT subunit via its triazoloquinoline core.    
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Fig. 6.1 The effect of regulatory subunits and small compounds on MAT activity. 
MATa2βV2 complex structure is illustrated (PDB: 4NDN) showing protein-protein interacting 
interface (yellow boxes). Small molecules designed to interact with MATa2 at the similar 
MATb binding site can regulate MAT activity responding to Met or SAMe concentrations. 
SAMe levels control biological function of an organism mainly via methylation processes of 
numerous biomolecules (DNA, histones, polypeptide, etc.).  
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6.2 Future direction of the project 
6.2.1 Mutant MATa2-MATb complex formation 
The crystal of mutant MATa2b complexes could not be reproduced following the published 
wild-type condition [13]. To get the complex structure, extensive re-screening of crystallisation 
conditions might be a way to get a suitable condition by using a crystallisation robot system. 
This system allows the experiment to be performed in an array of crystallisation’s conditions 
and needs only small amount of proteins. Seeding techniques may be used to facilitate 
crystallisation by using any existent MATa2 crystals as a nucleation point. There are several 
ways of seeding that can be performed (e.g. macro-seeding, micro-seeding, streak-seeding, 
cross-seeding, etc).  
6.2.2 Compound-bound crystal optimisation 
Although Arg264Ala crystals co-crystallised with SCR0915 compound were obtained, the 
crystals did not diffract at the high resolution. Further optimisation may be able to improve the 
quality of crystals. There are a number of factors that can affect crystal quality which can be 
varied during crystallisation (e.g. pH, additives, temperature, precipitant concentrations, etc). 
Using the condition obtained from the robot screening can be used as a starting point for a 
larger batch of crystal production. Varying different kinds of cryoprotectants and also 
concentration or duration of soaking when freezing crystals can promote crystals to diffract at 
a higher resolution. 
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6.2.3 A structural study of MATβV1/V2 and GIT1 interaction 
MATα2 and MATβV1/V2 have been reported to be involved in several cellular pathways that 
trigger cancer cell growth. Besides their role as the regulatory subunits of MATα2, 
MATβV1/V2 can interact with several proteins related to a cellular survival pathway e.g. ERK 
and PI3-K pathway [41, 173-175]. The two isoforms of MATβV1/V2 were related to cancer 
development which involved in their interaction with GIT1 (G-protein-coupled receptor kinase 
interacting protein 1). GIT1 and MATβ formed a scaffold to recruit and activate MEK1/2 and 
ERK1/2 (Fig. 6.2.1A) [173]. GIT1 and MATβ were found to be overexpressed in human HCC 
and colon cancer. This promoted cell growth and tumorigenesis, while cellular apoptosis 
occurred when GIT1 and MATβ were knocked down [174]. In addition, both variants (V1 and 
V2) of MATb are necessary for forming complex with MEK1/2 and GIT1 [173]. The full-
length GIT protein contains 5 domains including an N-terminal ARF-GAP (ARF-GTPase 
activating) domain, three ANK (ankyrin) repeats, a SHD (Spa2-homology) domain, a CC 
(coiled-coil) domain necessary for dimerization, and a PBS (paxillin-binding site) domain (Fig. 
6.2.1B). The truncated GIT1 protein containing 3 domains (lacking the CC domain and C-
terminal paxillin binding domain) was reported to lose their ability to interact with both variants 
of the MATβ proteins, therefore full-length GIT1 would be necessary for forming complex 
with MATβ [176]. Structural studies of this complex can be performed by forming full-length 
GIT1 and MATβ complex using SEC analysis or ITC (isothermal titration calorimetry) to 
identify the complex formation, prior to crystallisation screening or grid preparation for 
cryoEM (cryogenic electron microscopy) experiments.  
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Fig. 6.2.1 The illustration of the GIT1-MATb scaffold and the GIT1 encoding genes (A) 
Overexpression of GIT1 and MATbV1/V2 during human HCC and colon cancer promotes the 
recruitment of GIT1, MEK and ERK which results in the increased ERK phosphorylation. (B) 
The full-length GIT1 protein contains 5 domains including an N-terminal ARF-GTPase 
activating domain, three ankyrin repeats, a Spa2-homology domain, a coiled-coil domain, and 
a paxillin-binding site domain. The figure (B) was modified from [177]. 
6.2.4 Phosphatase activity study of MAT enzymes based on the structural study 
The tripolyphosphate binding site is conserved from eMATs to human MATs as seen by the 
AMP-PNP, Met+PPNP+SAMe+ADO and PPNP-bound structure (Fig. 6.2.2A). There are six 
residues that involve in PPPi interaction including the three of lysine (Lys181, Lys265 and 
Lys285), His29, Arg264 and Asp291. Once the conformation of tripolyphosphate changes, as 
observed in the Met+PPNP+ADO+SAMe and the PPNP-bound structure of MATa2 (Fig. 
6.2.2A-B), the positions of these six residues are preserved. Comparison of the PPNP-bound 
structure to the apo-structure (Fig. 6.2.2C) shows that only Lys181 is in different conformation 
to the apo state.  
From the present study, the phosphatase activity is not affected by the mutations in Ser114 and 
Arg264, whereas the SAMe production is enormously decreased. In order to investigate the 
key residues that separately participate in SAMe formation and PPPi hydrolysis-specific site, 
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mutational analysis of a single amino acid involved in PPPi interaction can be designed using 
the rational structural basis. Once the purified proteins of mutants are obtained, they can be 
studied in both functional and structural relevance. Crystallisation can be done with a variety 
of substrates (e.g. AMP-PNP, ATP, PO43-, etc.) in comparison with the apo-state of its own and 
the wild type. PPPi hydrolysis rate and SAMe production can be tested to investigate whether 
these residues are either solely involved in phosphatase activity or SAMe formation or in both 
of them. It will be explained which step depend on each other, since some mutants in the current 
study show a reduction in SAMe formation, while the PPPi hydrolysis rate is unchanged. 
 
Fig. 6.2.2 The illustration of the tripolyphosphate interacting residues. (A) The human 
Met+PPNP+SAMe+ADO bound MAT structure (PDB: 5A1I, green sticks) and the E. coli 
AMP-PNP bound MAT structure (PDB: 1P7L, white sticks) are aligned. (B) PPNP-bound 
structure (blue sticks) of MATa2 is shown with the different PPNP conformation in 
comparison with the Met+PPNP+SAMe+ADO bound structure. (C) The PPNP-bound (blue 
sticks) and apo-structure (pink sticks) are aligned.  
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